<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95453</article-id><article-id pub-id-type="doi">10.7554/eLife.95453</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.95453.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Proteogenomic analysis of air-pollution-associated lung cancer reveals prevention and therapeutic opportunities</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Honglei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5522-8120</contrib-id><email>hlzhang2014@163.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Liu</surname><given-names>Chao</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Shuting</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Qing</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Xu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Huawei</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Chao</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lu</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Hou</surname><given-names>Fei</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Minjun</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Zhiyong</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund11"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Heng</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Yong</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0513-8941</contrib-id><email>nankai1989@foxmail.com</email><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Su</surname><given-names>Xiaosan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6163-2429</contrib-id><email>suxs163@163.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Gaofeng</given-names></name><email>ligaofeng@kmmu.edu.cn</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04zap7912</institution-id><institution>Center for Scientific Research, Yunnan University of Chinese Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/038c3w259</institution-id><institution>Department of Nuclear Medicine, Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/038c3w259</institution-id><institution>Department of Thoracic Surgery II, Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution>Department of Oncology, Qujing First People’s Hospital</institution><addr-line><named-content content-type="city">Kuming</named-content></addr-line><country>China</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00c639s42</institution-id><institution>Department of Ophthalmology, Second People's Hospital of Yunnan Province</institution></institution-wrap><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff><aff id="aff6"><label>6</label><institution>Department of Family Medicine, Community Health Service Center</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/011ashp19</institution-id><institution>Department of Nephrology, Institutes for Systems Genetics, Frontiers Science Center for Disease Related Molecular Network, West China Hospital, Sichuan University</institution></institution-wrap><addr-line><named-content content-type="city">Chengdu</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sobol</surname><given-names>Robert W</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05gq02987</institution-id><institution>Brown University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>El-Deiry</surname><given-names>Wafik S</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05gq02987</institution-id><institution>Brown University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>21</day><month>10</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP95453</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-03-07"><day>07</day><month>03</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-03-13"><day>13</day><month>03</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.03.11.24304129"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-05-31"><day>31</day><month>05</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95453.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-10-02"><day>02</day><month>10</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.95453.2"/></event></pub-history><permissions><copyright-statement>© 2024, Zhang, Liu, Wang et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Zhang, Liu, Wang et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-95453-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-95453-figures-v1.pdf"/><abstract><p>Air pollution significantly impacts lung cancer progression, but there is a lack of a comprehensive molecular characterization of clinical samples associated with air pollution. Here, we performed a proteogenomic analysis of lung adenocarcinoma (LUAD) in 169 female never-smokers from the Xuanwei area (XWLC cohort), where coal smoke is the primary contributor to the high lung cancer incidence. Genomic mutation analysis revealed XWLC as a distinct subtype of LUAD separate from cases associated with smoking or endogenous factors. Mutational signature analysis suggested that Benzo[a]pyrene (BaP) is the major risk factor in XWLC. The BaP-induced mutation hotspot, EGFR-G719X, was present in 20% of XWLC which endowed XWLC with elevated MAPK pathway activations and worse outcomes compared to common <italic>EGFR</italic> mutations. Multi-omics clustering of XWLC identified four clinically relevant subtypes. These subgroups exhibited distinct features in biological processes, genetic alterations, metabolism demands, immune landscape, and radiomic features. Finally, <italic>MAD1 and TPRN</italic> were identified as novel potential therapeutic targets in XWLC. Our study provides a valuable resource for researchers and clinicians to explore prevention and treatment strategies for air-pollution-associated lung cancers.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>lung cancer</kwd><kwd>tumor tissue</kwd><kwd>cell line</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82273501</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Honglei</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82360613</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Honglei</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82160343</award-id><principal-award-recipient><name><surname>Deng</surname><given-names>Zhiyong</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82060519</award-id><principal-award-recipient><name><surname>Su</surname><given-names>Xiaosan</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Yunnan Basic Research Program</institution></institution-wrap></funding-source><award-id>202101AZ070001-002</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Honglei</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Yunnan Basic Research Program</institution></institution-wrap></funding-source><award-id>202401AS070070</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Honglei</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>Yunnan Basic Research Program</institution></institution-wrap></funding-source><award-id>202301AY070001-106</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Chao</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Yunnan Young and Middle-aged Academic and Technical Leaders Reserve Talents Project</institution></institution-wrap></funding-source><award-id>202005AC160048</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Honglei</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Yunnan Provincial Department of Education Science Research Fund Project</institution></institution-wrap></funding-source><award-id>2024J0246</award-id><principal-award-recipient><name><surname>Wang</surname><given-names>Shuting</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution>&quot;Famous Doctor&quot; Special Project of Ten Thousand People Plan of Yunnan Province</institution></institution-wrap></funding-source><award-id>CZ0096</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Gaofeng</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution>&quot;Famous Doctor&quot; Special Project of Ten Thousand People Plan of Yunnan Province</institution></institution-wrap></funding-source><award-id>YNWR-MY-2020-095</award-id><principal-award-recipient><name><surname>Deng</surname><given-names>Zhiyong</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution>Medical Leading Talents Training Program of Yunnan Provincal Health Commission</institution></institution-wrap></funding-source><award-id>L-2019028</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Gaofeng</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value><italic>MAD1 and TPRN</italic> were identified as novel potential therapeutic targets of lung adenocarcinoma in female never-smokers from the Xuanwei area.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Lung cancer is the leading cause of cancer deaths globally (<xref ref-type="bibr" rid="bib7">Bray et al., 2018</xref>). Though the most common cause of lung cancer is tobacco smoking, studies estimate that approximately 25% of lung cancers worldwide occur in individuals who have never smoked (<xref ref-type="bibr" rid="bib57">Parkin et al., 2005</xref>). Recently, lung cancer in never smokers (LCINS) were molecular profiled and new genomic features were revealed (<xref ref-type="bibr" rid="bib16">Chen et al., 2020b</xref>; <xref ref-type="bibr" rid="bib31">Govindan et al., 2012</xref>; <xref ref-type="bibr" rid="bib15">Chen et al., 2020a</xref>; <xref ref-type="bibr" rid="bib95">Zhang et al., 2021a</xref>; <xref ref-type="bibr" rid="bib94">Zhang et al., 2019</xref>; <xref ref-type="bibr" rid="bib88">Xu et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Gillette et al., 2020</xref>). For now, further stratification of LCINS based on different risk factors would be helpful to reveal the oncogenic mechanisms and develop more targeted therapies. Air pollutants, which can directly affect the pulmonary airway, play crucial roles in promoting lung adenocarcinoma (<xref ref-type="bibr" rid="bib38">Hill et al., 2023</xref>; <xref ref-type="bibr" rid="bib72">Turner, 2020</xref>; <xref ref-type="bibr" rid="bib24">Fajersztajn et al., 2013</xref>). More than 20 environmental and occupational agents are lung carcinogens (<xref ref-type="bibr" rid="bib21">Cogliano et al., 2011</xref>; <xref ref-type="bibr" rid="bib41">IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010</xref>) and amount of studies have been made to investigate molecular mechanisms in tumor progression of air pollution chemicals or components using cell lines or mouse/rat models (<xref ref-type="bibr" rid="bib66">Shi et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">Saravanakumar et al., 2022</xref>; <xref ref-type="bibr" rid="bib1">Abd El-Fattah and Abdelhamid, 2021</xref>). However, a comprehensive molecular characterization of clinical lung cancer samples associated with air pollution is still lacking.</p><p>The Xuanwei area has the highest rate of lung cancer in China, and extensive research has established a strong link between lung cancer and exposure to domestic coal smoke (<xref ref-type="bibr" rid="bib55">Mumford et al., 1987</xref>; <xref ref-type="bibr" rid="bib5">Barone-Adesi et al., 2012</xref>; <xref ref-type="bibr" rid="bib13">Chapman et al., 2005</xref>; <xref ref-type="bibr" rid="bib49">Lin et al., 2015</xref>; <xref ref-type="bibr" rid="bib93">Zhang et al., 2016</xref>; <xref ref-type="bibr" rid="bib47">Lan et al., 2002</xref>). Specifically, the etiologic link between smoky coal burning and cancer was epidemiologically established <xref ref-type="bibr" rid="bib55">Mumford et al., 1987</xref>; <xref ref-type="bibr" rid="bib5">Barone-Adesi et al., 2012</xref>, and an association between household stove improvement and lower risk of lung cancer was observed (<xref ref-type="bibr" rid="bib47">Lan et al., 2002</xref>). Moreover, genomic evidence of lung carcinogenesis associated with coal smoke in Xuanwei area, China was provided in our previous study (<xref ref-type="bibr" rid="bib93">Zhang et al., 2016</xref>). Thus, lung cancer in Xuanwei areas exemplifies the ideal disease to study characteristics of lung cancers associated with air pollution. In recent years, the molecular features of Xuanwei lung cancer have been gradually revealed (<xref ref-type="bibr" rid="bib39">Hosgood et al., 2013</xref>; <xref ref-type="bibr" rid="bib80">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib78">Wang et al., 2017a</xref>; <xref ref-type="bibr" rid="bib96">Zhang et al., 2021b</xref>). A large sample size with multi-comic molecular profiling is urgently needed to explicit the air pollution chemicals and furthermore propose more targeted therapies.</p><p>To better understand the molecular mechanisms and heterogeneity of XWLC and to advance precision medicine, we expanded the sample size of our next-generation sequencing dataset to 169 sample size and performed proteomic and phosphoproteomic profiling on 112 samples. Furthermore, we integrated 107 radiomic features derived from X-ray computed tomography (CT) scans into 115 samples to non-invasively distinguish molecular subtypes. This allowed us to identify potential major risk factors, distinguish the genomic features, and establish clinically relevant molecular subtypes. Our study provides an exceptional resource for future biological, diagnostic, and drug discovery efforts in the study of lung cancer related to air pollution.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>To investigate unique biological features of LUAD associated with air pollution, three previous LUAD datasets related to different carcinogens were used for comparison (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). CNLC is the subset of lung adenocarcinoma from non-smoking patients in Chinese Human Proteome Project (CNHPP project)(<xref ref-type="bibr" rid="bib88">Xu et al., 2020</xref>) (n=77). TSLC is the subset of lung adenocarcinoma from smoking females in the TCGA-LUAD project (<xref ref-type="bibr" rid="bib9">Cancer Genome Atlas Research, 2014</xref>) (n=168). TNLC is the subset of lung adenocarcinoma from non-smoking females in TCGA-LUAD project (<xref ref-type="bibr" rid="bib9">Cancer Genome Atlas Research, 2014</xref>) (n=102). The clinicopathological characteristics of patients from CNLC, TSLC, and TNLC cohorts were supplied in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a and b</xref>.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Proteogenomic profiling and mutational signatures in Xuanwei lung cancer (XWLC).</title><p>(<bold>a</bold>) Four cohort datasets used in this study: XWLC (Lung adenocarcinoma from non-smoking females in Xuanwei area), CNLC (subset of lung adenocarcinoma from non-smoking patients in Chinese Human Proteome Project), TSLC (subset of lung adenocarcinoma from smoking females in TCGA-LUAD project), TNLC (subset of lung adenocarcinoma from non-smoking females in TCGA-LUAD project); (<bold>b</bold>) Age distribution of patients at the time of operation in the four cohorts; (<bold>c</bold>) Distribution of tumor stages across the cohorts; (<bold>d</bold>) Data availability for the XWLC datasets. Each bar represents a sample, with orange bars indicating data availability and gray bars indicating data unavailability. T, tumor sample. N, Normal tissue; (<bold>e</bold>) Summary of data generated from the XWLC cohort; (<bold>f–i</bold>) Mutational signatures were identified in XWLC (<bold>f</bold>), TSLC (<bold>g</bold>), TNLC (<bold>h</bold>), and CNLC (<bold>i</bold>) cohorts. Cosine similarity analysis of the signatures compared to well-established COMIC signatures (in green) and Kucab et al. signatures (in red). Contribution of signatures in each cohort is provided on the right; (<bold>j–k</bold>) Protein abundance of CYP1A1 (<bold>j</bold>) and AhR (<bold>k</bold>) in tumor and normal samples within the XWLC cohort; Two-tailed Wilcoxon rank sum test used to calculate p-values in (<bold>j–k</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Experimental workflow and data quality metrics.</title><p>(<bold>a</bold>) Schematic representation showing sample processing steps. Tumors and their matched normal-adjacent tissues (NATs) were divided for genomics and proteomics analyses; (<bold>b</bold>) Schematic representation of the workflows used for proteome and phosphoproteome analyses. MS-based label-free quantification was used to determine the relative amount of proteins or phosphoproteins; (<bold>c–d</bold>) Bar plot showing consistent numbers of identified and quantified proteins (<bold>c</bold>) and phosphosites (<bold>d</bold>) in 102 tumors and 20 NATs; (<bold>e</bold>) Correlation matrix of 102 tumor proteomes (Pearson’s correlation coefficients).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Identification and profile of de novo mutational signatures in each cohort.</title><p>(<bold>a–d</bold>) Left, residual sum of square (RSS) and percentage of variance explained of different signature number selections in each cohort. Number of signatures was determined by choosing the reflection point in the curves of the residual sum of squares (RSS) and explained variance. Right, mutation signatures detected in each cohort.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig1-figsupp2-v1.tif"/></fig></fig-group><sec id="s2-1"><title>Proteogenomic landscape in Xuanwei lung cancer (XWLC)</title><p>The present study prospectively collected primary samples of LUAD from 169 never-smoking women from the Xuanwei area in China (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref>). The XWLC cohort had a median age of 56 years (<xref ref-type="fig" rid="fig1">Figure 1b</xref>), and the majority of tissue samples were in the early stages of the disease (145 were stage I/II, and 24 were stage III/IV, <xref ref-type="fig" rid="fig1">Figure 1c</xref>). A total of 135, 136, 102, and 102 tumor samples were profiled with whole-exome sequencing (WES), RNA-seq, label-free protein quantification, and label-free phosphorylation quantification, respectively (<xref ref-type="fig" rid="fig1">Figure 1d–e</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a and b</xref>). Analysis of the WES data from the paired tumor and normal tissue samples revealed 37,149 somatic mutations, including 1797 InDels, 32,972 missense mutations, 2345 nonsense mutations, and 35 nonstop mutations (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Copy number analysis showed 140,396 gene-level amplifications and 67,605 deletions across 40 cytobands (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>). The mRNA-seq data characterized the transcription profiles of 19,182 genes (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). The label-free global proteomics identified 9152 proteins (encoded by 6864 genes) with an average of 6457 proteins per sample (<xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). The label-free phosphoproteomics identified 24,990 highly reliable phosphosites from 5832 genes with an average of 10,478 phosphosites per sample (<xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). The quality and reproducibility of the mass spectrometry data were maintained throughout the study (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1c–e</xref>).</p></sec><sec id="s2-2"><title>The air pollutant Benzo[a]pyrene (BaP) primarily contributes to the mutation landscape of XWLC</title><p>To infer the primary risk factor responsible for the progression of XWLC, we used SomaticSignatures <xref ref-type="bibr" rid="bib29">Gehring et al., 2015</xref> to identify mutational signatures from single nucleotide variants. Mutational signatures were identified in each cohort and a cosine similarity analysis was performed against mutational signatures in COSMIC mutational signatures <xref ref-type="bibr" rid="bib3">Alexandrov et al., 2013b</xref>; <xref ref-type="bibr" rid="bib2">Alexandrov et al., 2013a</xref> and environmental agents mutational sigantures (<xref ref-type="bibr" rid="bib45">Kucab et al., 2019</xref>) allowing for inference of the underlying causes (<xref ref-type="fig" rid="fig1">Figure 1f–i</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Generally, exposure to tobacco smoking carcinogens (COSMIC signature 4) and chemicals such as BaP (Kucab signatures 49 and 20) were identified as the most significant contributing factors in both the XWLC and TSLC cohorts (<xref ref-type="fig" rid="fig1">Figure 1f and g</xref>). In contrast, defective DNA mismatch repair (COSMIC signature ID: SBS6) was identified as the major contributor in both the TNLC and CNLC cohorts (<xref ref-type="fig" rid="fig1">Figure 1h and i</xref>), with no potential chemicals identified based on signature similarities. Therefore, the XWLC and TSLC cohorts appear to be more explicitly associated with environmental carcinogens, while the TNLC and CNLC cohorts may be more associated with defective DNA mismatch repair processes. BaP, a representative compound of polycyclic aromatic hydrocarbons (PAHs), is found in both cigarette smoke and coal smoke and is recognized as a major environmental risk factor for lung cancer (<xref ref-type="bibr" rid="bib58">Petit et al., 2019</xref>; <xref ref-type="bibr" rid="bib83">Widziewicz et al., 2017</xref>; <xref ref-type="bibr" rid="bib51">Mangal et al., 2009</xref>). Upon metabolism, BaP forms the carcinogenic metabolite 7β,8α-dihydroxy-9α,10α-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BPDE), which creates DNA adducts leading to mutations and malignant transformations. This process involves two key regulators: <italic>CYP1A1</italic> and <italic>AhR</italic>. CYP1A1 plays a crucial role in BaP epoxidation at the 7,8 positions, which is the most critical step in BPDE formation (<xref ref-type="bibr" rid="bib20">Chung et al., 2007</xref>). AhR is a ligand-activated transcription factor that responds to various chemicals, including chemical carcinogens, and is activated by BaP (<xref ref-type="bibr" rid="bib37">Hidaka et al., 2019</xref>). Accordingly, our results demonstrated significantly higher protein expression of CYP1A1 in tumor samples compared to normal samples (<xref ref-type="fig" rid="fig1">Figure 1j</xref>). AhR showed higher mRNA expression in tumor samples, with no difference in protein level expression (<xref ref-type="fig" rid="fig1">Figure 1k</xref>). All these results suggested the involvement of BaP and its metabolite in the development of lung cancer.</p><p>Though coal-smoke-related lung cancer (XWLC cohort) and cigarette-smoke-related lung cancer (TSLC cohort) showed similar environmental carcinogens, we found that downstream pathway activation and therapeutic targeted potential showed distinctive features. First, the correlation of genomic mutations between XWLC and TSLC was found to be low (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). Second, there was a remarkable difference in the fraction of samples affected by pathway mutations between the two cohorts (<xref ref-type="fig" rid="fig2">Figure 2b</xref>). Notably, the TSLC cohort exhibited a higher fraction of samples affected by oncogenic pathways comparing to XWLC cohort. Third, mutation frequencies of top mutated genes (<xref ref-type="bibr" rid="bib96">Zhang et al., 2021b</xref>), such as <italic>EGFR</italic>, <italic>TP53</italic>, <italic>RBM10</italic>, and <italic>KRAS</italic> (<xref ref-type="fig" rid="fig2">Figure 2c</xref>), as well as the distribution of amino acid changes in <italic>EGFR</italic> and <italic>TP53</italic>, showed noticeable differences between the XWLC and other cohorts (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). Specifically, the XWLC cohort exhibited a higher mutation rate in G719C/A/D/S within the <italic>EGFR</italic> gene compared to the other three cohorts. For the <italic>TP53</italic> gene, frame shift mutations including D9Gfs*3 (n=1), S15Ifs*28 (n=1), D22Efs*61 (n=1), and V34Wfs*49 (n=2) were exclusively detected in the XWLC cohort, whereas tetramer domain mutations were only found in the other three cohorts (<xref ref-type="fig" rid="fig2">Figure 2d</xref>). Finally, there was a noticeable disparity in the percentage of samples with actionable targets among the cohorts. (<xref ref-type="fig" rid="fig2">Figure 2e</xref>). Actionable targets in the XWLC cohort were mainly focused on <italic>EGFR</italic> mutations including pG719S, pG719C, pG719A, and pL858R, whereas the TSLC cohort had more actionable targets in CHEK2 p.K373E, KRAS p.G12V/D/C/A (<xref ref-type="fig" rid="fig2">Figure 2e</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Genomic and genetic features in the Xuanwei lung cancer (XWLC) cohort.</title><p>(<bold>a</bold>) Correlation of genomic mutations among cohorts, determined using the Pearson correlation coefficient; (<bold>b</bold>) Comparison of oncogenic pathways affected by mutations in each cohort; (<bold>c</bold>) Comparison of mutation frequency of four key genes across cohorts; (<bold>d</bold>) Lollipop plot illustrating differences in mutational sites within EGFR (left) and TP53 (right) across XWLC/CNLC, XWLC/TSLC, and XWLC/TNLC pairs; (<bold>e</bold>) Analysis of the percentage of samples with actionable alterations, with a focus on significant variations between XWLC and TSLC cohorts, highlighted by black boxes.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig2-v1.tif"/></fig><p>Taken together, we found that the XWLC and TSLC cohorts, which are smoke-related lung adenoma groups, demonstrated distinct etiology compared to the TNLC and CNLC cohorts which may be influenced by endogenous risk factors to a greater extent. Additionally, significant disparities were observed between XWLC and TSLC in terms of downstream pathway activations and specific oncogene loci. Consequently, we conclude that air pollution-associated lung cancer represents a distinct subtype within LUAD.</p></sec><sec id="s2-3"><title>The EGFR-G719X mutation, which is a hotspot associated with BaP exposure, possesses distinctive biological features</title><p>Notably, the XWLC cohort displayed a distinguishable mutation pattern in specific <italic>EGFR</italic> mutation sites compared to the other cohorts (<xref ref-type="fig" rid="fig3">Figure 3a</xref> and <xref ref-type="fig" rid="fig2">Figure 2d</xref>). In particular, the G719C/A/D/S (G719X) mutation was the most prevalent <italic>EGFR</italic> mutation in the XWLC cohort (20%), while it was rarely found in the other three cohorts (CNLC: 1.9%; TSLC: 1.9%; TNLC: 0) (<xref ref-type="fig" rid="fig3">Figure 3b</xref>). Notably, we found it was a hot spot associated with BaP exposure (<xref ref-type="fig" rid="fig3">Figure 3c and d</xref>). Specifically, <bold>GG</bold>C is the 719 codon, the first G can be converted to T (pG719C, n=13) or A (pG719S, n=5), the second G can be converted to A (pG719D, n=1) or C (pG719C, n=8). Thus, pG719C was the most detected mutation type (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). G&gt;T/C&gt;A transversion can be induced by several compounds such as BaP or dibenz(a,h)anthracene (DBA), unlike other compounds, the tallest peak induced by BaP occurs at GpGpG, reflecting how their DNA adducts are formed principally at N<sup>2</sup>-guanine (<xref ref-type="bibr" rid="bib45">Kucab et al., 2019</xref>). Our result showed that the most frequently detected pG719C AAchange corresponded to G<bold>G</bold>GC&gt;G<bold>T</bold>GC transversion (<xref ref-type="fig" rid="fig3">Figure 3d</xref>). Thus, pG719C is a hot spot associated with BaP exposure.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>EGFR-G719X in the Xuanwei lung cancer (XWLC) cohort.</title><p>(<bold>a</bold>) Distribution of different EGFR mutation statuses across the four cohorts; (<bold>b</bold>) Comparison of the fraction of G719X mutations across the four cohorts. Two-sided Fisher’s test was used to calculate p-values; (<bold>c</bold>) Detailed information on pG719X (pG719/A/D/C/S) mutations in the XWLC cohort. The number of each mutation type is labeled; (<bold>d</bold>) Distribution of nucleotide pairs surrounding the most common G&gt;T transversion site in the XWLC cohort. The x-axis represents the immediate bases surrounding the mutated base. For Benzo[a]pyrene (BaP), the tallest G&gt;T peak occurs at GpGpG; (<bold>e–h</bold>) Comparison of activation levels of key components in the MAPK pathway across different EGFR mutation statuses in the XWLC cohor. N, number of tumor samples containing corresponding EGFR mutation; (<bold>i</bold>) Comparison of patient ages across different EGFR mutation statuses in the XWLC cohort, N, number of tumor samples containing corresponding EGFR mutation; (<bold>j–k</bold>) Presentation of overall survival (OS), (<bold>j</bold>) and progression-free interval (PFI), (<bold>k</bold>) analysis across different EGFR mutation statuses in the TCGA-LUAD cohort, Logrank test was used to calculate p-values; (<bold>l</bold>) Evaluation of kinase activities by KSEA in tumors across different EGFR mutation statuses in the XWLC cohort. The two-tailed Wilcoxon rank sum test was used to calculate p-values in panels (<bold>e–i</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Comparison of hallmark capability, immune cell infiltration, and mutation burden across different EGFR mutation status.</title><p>(<bold>a</bold>) Hallmark capabilities; (<bold>b</bold>) Immune cell infiltration; (<bold>c</bold>) Mutation burden and neoantigens; (<bold>d</bold>) FDA-approved drugs targeting activated kinases in tumors with G719X mutation.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig3-figsupp1-v1.tif"/></fig></fig-group><p>We conducted further investigations into the biological characteristics of samples carrying the G719X mutations. Notably, we observed a moderate to high expression of MAPK signaling components, MAP2K2 (MEK), and MAPK3 (ERK1), in tumors harboring the EGFR-G719X mutation compared to other EGFR statuses (<xref ref-type="fig" rid="fig3">Figure 3e–h</xref>). Utilizing hallmark capability analysis and RNA-seq-based estimation of immune cell infiltration, we found that tumors with G719X mutations exhibited similarities to those with L858R mutations (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1a–b</xref>). However, patients with G719X mutations were notably younger than those with L858R mutations, indicating a higher occurrence rate of G719X in younger female patients (<xref ref-type="fig" rid="fig3">Figure 3i</xref>). Analysis of overall survival and progression-free interval (PFI) revealed that patients with the G719X mutation had worse outcomes compared to other EGFR mutation subtypes (<xref ref-type="fig" rid="fig3">Figure 3j and k</xref>) which was consistent with a previous study (<xref ref-type="bibr" rid="bib82">Watanabe et al., 2014</xref>). Furthermore, there were no significant differences in mutation burden or the number of neoantigens between tumors with G719X mutations and tumors with other <italic>EGFR</italic> mutation statuses (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1c</xref>).</p><p>To explore the heterogeneity of signaling pathways activated by different <italic>EGFR</italic> mutation statuses, we conducted a Kinase-Substrate Enrichment Analysis (KSEA) <xref ref-type="bibr" rid="bib85">Wiredja et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Casado et al., 2013</xref> based on the XWLC phosphoproteomics dataset. Our analysis of the phosphoproteome across various <italic>EGFR</italic> mutation types revealed distinct activation patterns of kinases. Specifically, the G719X mutation was associated with the activation of PRKCZ, CDK2, AURKB, CSNK1A1, CDK4, and HIPK2. The L858R mutation showed activation of PRKCZ, MAPK7, MAPK12, HIPK2, and CSNK2A1. The Exon19del mutation exhibited activation of CHUK, TTK, PRKCZ, PLK1, NEK2, MAP2K2, CDK2, PRKDC, and MAP2K6. Other EGFR mutations were associated with the activation of AURKB, NEK2, TTK, PLK1, PRKACB, and PRKACG. EGFR-WT mutations showed activation of CSNK1E, PRKCZ, AURKB, CDK2, AURKC, CDK1, CSNK1A1, PRKDC, and CSNK2A1 (<xref ref-type="fig" rid="fig3">Figure 3l</xref>). In <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1d</xref>, we provide a list of FDA-approved drugs that target the activated kinases in tumors harboring the G719X mutation. Currently, afatinib is widely regarded as a first-line therapy for patients with the G719X mutation (<xref ref-type="bibr" rid="bib23">Ettinger et al., 2022</xref>; <xref ref-type="bibr" rid="bib42">Janning et al., 2022</xref>; <xref ref-type="bibr" rid="bib92">Yang et al., 2020</xref>; <xref ref-type="bibr" rid="bib19">Cho et al., 2020</xref>). However, reports indicate that 80% of patients with this mutation may develop resistance to afatinib, even in the absence of T790M (<xref ref-type="bibr" rid="bib36">Harada et al., 2019</xref>), underscoring the need for a deeper understanding of the downstream pathways associated with the G719X mutation. Therefore, a promising approach to overcome resistance in tumors with this mutation could involve combining afatinib, which targets activated EGFR, with FDA-approved drugs that specifically target the activated kinases associated with G719X. Therefore, we propose a potential approach to overcoming resistance in tumors with this mutation, which could involve combining afatinib, targeting activated EGFR, with FDA-approved drugs that specifically target the activated kinases associated with G719X.</p></sec><sec id="s2-4"><title>Clinically relevant subtyping in XWLC</title><p>To uncover the inherent subgroups within air-pollution-associated tumors, we employed unsupervised Consensus Clustering <xref ref-type="bibr" rid="bib84">Wilkerson and Hayes, 2010</xref> on integrated RNA, protein, and phosphoprotein profiles of XWLC tumor samples. This analysis led to the identification of four distinct intrinsic clusters, denoted as MC-I, II, III, and IV (<xref ref-type="fig" rid="fig4">Figure 4a</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a</xref> and Methods). Further survival analysis demonstrated that patients belonging to the MC-IV group exhibited the poorest overall survival compared to the other three subgroups, thus indicating the prognostic potential of multi-omic clustering (<xref ref-type="fig" rid="fig4">Figure 4b</xref>). Notably, there were no significant differences in clinical features such as age and stage observed among the four subgroups (<xref ref-type="fig" rid="fig4">Figure 4a</xref>). As CYP1A1 is a key regulator involved in BaP metabolism and has been proven to be highly expressed in tumor samples (<xref ref-type="fig" rid="fig1">Figure 1j</xref>), we next examined the expression of CYP1A1 among the four subgroups to evaluate their associations with air pollution. Our findings revealed that the MC-II subtype exhibited higher expression of CYP1A1 (<xref ref-type="fig" rid="fig4">Figure 4c</xref>). Moreover, the MC-II possessed more G719X mutations (MC-1:0.39, MC-II:0.42, MC-III: 0.20, MC-IV: 0.08). Notably, there was a significant correlation between CYP1A1 and EGFR expression (<xref ref-type="fig" rid="fig4">Figure 4e</xref>), with EGFR being more highly expressed in the MC-II subtype (<xref ref-type="fig" rid="fig4">Figure 4e</xref>). Collectively, these results indicated that MC-II was more associated with air-pollution.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Subtyping of Xuanwei lung cancer (XWLC).</title><p>(<bold>a</bold>) Integrative classification of tumor samples into four ConsensusClusterPlus-derived clusters (MC-I to MC-IV). The heatmap displays the top 50 features, including mRNA transcripts, proteins, and phosphoproteins, for each multi-omic cluster. The features are annotated with representative pathways or genes. If a cluster has fewer than 50 features, all features are shown. If no significant GO biological processes are associated with cluster features, all features are displayed; (<bold>b</bold>) Comparison of overall survival between MC-IV and the other three subtypes; (<bold>c</bold>) Protein abundance comparison of CYCP1A1 across subtypes; (<bold>d</bold>) Protein-level correlation between CYCP1A1 and EGFR; (<bold>e</bold>) Protein-level comparison of EGFR across subtypes; (<bold>f</bold>) Evaluation of kinase activities by Kinase-Substrate Enrichment Analysis (KSEA) in tumors across subtypes in the XWLC cohort. The two-tailed Wilcoxon rank sum test was used to calculate p-values in panels (<bold>c</bold>) and (<bold>e</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>ConsensusClusterPlus clustering in Xuanwei lung cancer (XWLC).</title><p>(<bold>a</bold>) Delta area plot showing the relative change in area under the CDF curve comparing k and k-1. This plot allows to determine the relative increase in consensus and determine k at which there is no appreciable increase. (<bold>b</bold>) Consensus cumulative distribution function (CDF) Plot shows the cumulative distribution functions of the consensus matrix for each k (indicated by colors), estimated by a histogram of 100 bins. This figure allows to determine at what number of clusters, k, the CDF reaches an approximate maximum, thus consensus and cluster confidence is at a maximum at this k. (<bold>c</bold>) Heatmaps of the consensus matrices for k=4.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig4-figsupp1-v1.tif"/></fig></fig-group><p>Through KSEA of the phosphoproteome in tumor samples compared to normal adjacent tissues (NATs), we identified specific kinase activations within the four subgroups. In MC-I samples, kinase activations included PRKDC, PRKCZ, CSNK1A1, NEK2, GSK3A, and ROCK1. MC-II samples showed activations of CDK2, CDK1, AURKA, TTK, CDK6, and CHUK. MC-III samples exhibited activations of AKT1, AKT3, RPS6KB1, CSNK2A1, and PAK2. Finally, CDK2 and ROCK1 were activated in MC-IV samples (<xref ref-type="fig" rid="fig4">Figure 4f</xref>). Particularly noteworthy is the enrichment of CDK1/2/6 kinases, which regulate cell cycle checkpoints, in the MC-II subtype, indicating its high proliferation capabilities. These findings imply that distinct kinase pathways are activated within each subgroup, suggesting the presence of specific therapeutic targets for each subgroup. Consequently, we proceeded to explore therapeutic strategies for each subgroup as outlined below:</p><p>The <bold>MC-IV</bold> subtype exhibited the poorest overall survival compared to the other three subtypes (<xref ref-type="fig" rid="fig4">Figure 4b</xref>). Given the crucial role of epithelial-mesenchymal transition (EMT) in malignant progression, our first evaluation focused on the EMT process across the four subtypes. We observed higher expression levels of mesenchymal markers such as <italic>VIM</italic>, <italic>FN1</italic>, <italic>TWIST2</italic>, <italic>SNAI2</italic>, <italic>ZEB1</italic>, <italic>ZEB2</italic>, and others in the MC-IV subtype (<xref ref-type="fig" rid="fig5">Figure 5a</xref>). To comprehensively assess the EMT capability of the MC-IV subtype, we calculated EMT scores using the ssGSEA enrichment method based on protein levels and GSEA hallmark gene set (M5930) (<xref ref-type="bibr" rid="bib48">Liberzon et al., 2015</xref>). The results confirmed the elevated EMT capability of the MC-IV subtype at the protein level (<xref ref-type="fig" rid="fig5">Figure 5b</xref>). Furthermore, Fibronectin (FN1), an EMT marker that promotes the dissociation, migration, and invasion of epithelial cells, was found to be highly expressed in the MC-IV subtype at the protein level (<xref ref-type="fig" rid="fig5">Figure 5c</xref>). Additionally, β-Catenin, a key regulator in initiating EMT, was highly expressed in the MC-IV subtype at the protein level (<xref ref-type="fig" rid="fig5">Figure 5d</xref>). Collectively, our findings demonstrate that the MC-IV subtype is associated with enhanced EMT capability, which may contribute to the high malignancy observed in this subtype.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Biological and immune features across MC subtypes.</title><p>(<bold>a</bold>) Relative expression of epithelial-mesenchymal transition (EMT) markers across subtypes; (<bold>b</bold>) EMT scores across subtypes using a gene set derived from MsigDB (M5930); (<bold>c–d</bold>) Protein abundance comparison of FN1 (<bold>c</bold>) and β-Catenin (<bold>d</bold>) across subtypes; (<bold>e</bold>) Protein and phosphoprotein levels of key cell cycle kinases across subtypes; (<bold>f</bold>) Expression of mRNA and protein levels of glycolysis-associated enzymes; (<bold>g</bold>) mRNA expression of VEGFA across subtypes; (<bold>h</bold>) Phosphoprotein abundance of VEGFR1 across subtypes; (<bold>i</bold>) Angiogenesis score across subtypes using a gene set derived from MsigDB (Systematic name M5944); (<bold>j</bold>) Expression comparison of key regulators of the Notch pathway across subtypes; (<bold>k</bold>) Metabolism-associated hallmarks across subtypes. Gene sets for oxidative phosphorylation, peroxisome, adipogenesis, fatty acid metabolism, and xenobiotic metabolism were derived from MsigDB hallmark gene sets; (<bold>l</bold>) Expression of PD-1 signaling-associated genes across subtypes. PD-1 signaling-associated genes were derived from MsigDB (Systematic name M18810); (<bold>m</bold>) Immune cell infiltration across subtypes. Gene sets for each immune cell type were derived from a previous study (<xref ref-type="bibr" rid="bib14">Charoentong et al., 2017</xref>); (<bold>n</bold>) Expression of anti-tumor/pro-tumor lymphocyte receptors and ligands across subtypes. The two-tailed Wilcoxon rank sum test was used to calculate p-values in panels b, c, d, g, h, i, and m.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>KEGG pathview showing the difference across MC subtypes.</title><p>KEGG pathview showing the protein change between tumor vs normal in MC-I subtype (<bold>a</bold>) and therapeutic strategies for each subtype (<bold>b</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig5-figsupp1-v1.tif"/></fig></fig-group><p>The <bold>MC-II</bold> subtype demonstrated the second-worst outcome and was found to be more strongly associated with air pollution (<xref ref-type="fig" rid="fig4">Figure 4</xref>). This subtype exhibited dysregulation of cell cycle processes, including cell division, glycolysis, and cell cycle biological processes (<xref ref-type="fig" rid="fig4">Figure 4a</xref>). The KSEA analysis revealed that the CDK1 and CDK2 pathways, which are closely linked to cell cycle regulation, were predominantly activated in the MC-II subtype (<xref ref-type="fig" rid="fig5">Figure 5e</xref>). Consistently, we observed higher expression levels of CDK1 and CDK2 at both the protein and phosphoprotein levels in the MC-II subtype, indicating specific elevation of the G2M phase in the cell cycle (<xref ref-type="fig" rid="fig5">Figure 5e</xref>). The cell cycle and glycolysis processes are tightly coordinated, allowing cells to synchronize their metabolic state and energy requirements with cell cycle progression to ensure proper cell growth and division (<xref ref-type="bibr" rid="bib74">Vander Heiden et al., 2009</xref>; <xref ref-type="bibr" rid="bib22">DeBerardinis and Thompson, 2012</xref>; <xref ref-type="bibr" rid="bib8">Cairns et al., 2011</xref>). In line with this, we found that key enzymes involved in glycolysis regulation, such as Hexokinase 1 (HK1), Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and Glyceraldehyde-3-phosphate dehydrogenase-like protein (GPL), were highly expressed in the MC-II subtype (<xref ref-type="fig" rid="fig5">Figure 5f</xref>). Additionally, the MC-II subtype was enriched with EGFR mutations (MC-II vs. others: 18/24 vs. 51/110; Fisher’s exact p=0.013) and TP53 mutations (MC-II vs. others: 14/24 vs. 35/110; Fisher’s exact p=0.019), consistent with the characteristic loss of control over cell proliferation. In summary, the MC-II subtype exhibited dysregulated cell cycle processes accompanied by an elevated glycolysis capability, indicating a distinct metabolic and proliferative phenotype.</p><p>The <bold>MC-I</bold> subtype exhibited enrichment in various biological processes including angiogenesis, the cAMP signaling pathway, complement and coagulation cascades, PDL1 expression, the PD-1 checkpoint pathway, leukocyte transendothelial migration, and actin cytoskeleton processes (<xref ref-type="fig" rid="fig4">Figure 4a</xref>). In-depth exploration of key components involved in angiogenesis revealed that vascular endothelial growth factor A (VEGFA), a growth factor crucial for both physiological and pathological angiogenesis, was highly expressed in the MC-I subtype (<xref ref-type="fig" rid="fig5">Figure 5g</xref>). Additionally, phosphorylation of vascular endothelial growth factor receptor 1 (VEGFR1), a receptor tyrosine kinase essential for angiogenesis and vasculogenesis, was also highly expressed in the MC-I subtype (<xref ref-type="fig" rid="fig5">Figure 5h</xref>). The angiogenesis scores, calculated using the ssGSEA method based on protein levels and the hallmark gene set (M5944), were relatively high in the MC-I and MC-IV subtypes (<xref ref-type="fig" rid="fig5">Figure 5i</xref>). Furthermore, the relationship between the Notch signaling pathway and angiogenesis is well-established (<xref ref-type="bibr" rid="bib10">Carmeliet, 2005</xref>). Notch signaling plays a role in multiple aspects of angiogenesis, including endothelial cell sprouting, vessel branching, and vessel maturation (<xref ref-type="bibr" rid="bib60">Pitulescu et al., 2017</xref>; <xref ref-type="bibr" rid="bib32">Gridley, 2007</xref>). In the MC-I subtype, the expression of Notch receptors (Notch1-4) and ligands (DLL1, DLL4, JAG1, and JAG2) was highly elevated, indicating increased activation of Notch signaling (<xref ref-type="fig" rid="fig5">Figure 5j</xref>). KEGG path view analysis demonstrated that key regulators of the VEGF signaling pathway were highly expressed in the MC-I subtype (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1a</xref>). Therefore, manipulating Notch signaling could potentially serve as a strategy to regulate angiogenesis and control pathological angiogenesis in the MC-I subtype.</p><p>The <bold>MC-III</bold> subtype is characterized by the upregulation of various metabolic processes, including oxidative phosphorylation, peroxisome function, adipogenesis, fatty acid metabolism, and xenobiotic metabolism-related processes (<xref ref-type="fig" rid="fig5">Figure 5k</xref>). Additionally, we conducted further investigations into the immune features across the subtypes. Interestingly, we observed higher expression of genes associated with PD-1 signaling (GSEA, SYSTEMATIC_NAME M18810) in the MC-III subtype (<xref ref-type="fig" rid="fig5">Figure 5l</xref>). Since PD-1 is primarily expressed on the surface of certain immune cells, particularly activated T cells, we inferred the immune cell infiltration using the ssGSEA method based on immune cell-specific gene sets. We found that activated CD8 + T cells exhibited higher infiltration levels in the MC-III subtype compared to the other three subtypes (<xref ref-type="fig" rid="fig5">Figure 5m</xref> and <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref>), which may explain the elevated PD-1 signaling in the MC-III subtype. Furthermore, we examined the expression of receptor-ligand pairs involved in both anti-tumor and pro-tumor lymphocyte recruitment. Remarkably, the MC-III subtype exhibited specific high expression of anti-tumor lymphocyte receptors and ligands, while the expression of pro-tumor lymphocyte receptors and ligands was relatively lower (<xref ref-type="fig" rid="fig5">Figure 5n</xref>). In general, the MC-I subtype showed the reverse expression trend in terms of anti-tumor and pro-tumor receptor-ligand pairs (<xref ref-type="fig" rid="fig5">Figure 5n</xref>).</p><p>In conclusion, our classification of lung adenocarcinoma associated with air pollution resulted in the identification of four subtypes, each exhibiting distinct biological pathway activation and immune features. The MC-I subtype demonstrated elevated angiogenesis processes, while the MC-II subtype showed a high capacity for cell division and glycolysis. The MC-III subtype exhibited a notable infiltration of CD8 + cells, and the MC-IV subtype was characterized by high EMT capability, which may contribute to its poor outcome. These findings have significant implications for the development of precision treatments for XWLC (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1b</xref>).</p></sec><sec id="s2-5"><title>Radiomic features across subtypes</title><p>Furthermore, we built a noninvasive method to distinguish MC subtypes with radiomics which entails the extensive quantification of tumor phenotypes by utilizing numerous quantitative image features. In the initial step, we defined 107 quantitative image features that describe various characteristics of tumor phenotypes, including tumor image intensity, size, shape, and texture. These features were derived from X-ray computed tomography (CT) scans of 155 patients with XWLC (Methods). The baseline characteristics of this cohort can be found in <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>. Firstly, all features were compared among the four subtypes, and notably, eight features showed significant differences between the MC-II subtype and the other three subtypes (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). Features such as median and mean reflect the average gray level intensity and Idmn and Gray Level Non-Uniformity measure the variability of gray-level intensity values in the image, with a higher value indicating greater heterogeneity in intensity values. These results suggest a denser and more heterogeneous image in the MC-II subtype. We further established a signature using a multivariate linear regression model with five image features to distinguish MC-II from the other three subgroups (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). The performance of the five-feature radiomic signature was validated using the AUC value, which is a generation of the area under the ROC curve. The radiomic signature had an AUC value of 0.94 in the training set and 0.83 in the validation set (<xref ref-type="fig" rid="fig6">Figure 6b</xref>). The confusion matrix revealed an overall accuracy of 0.875 for sample classification using the signature, indicating proficient performance. However, it exhibited suboptimal performance in terms of false-negative classification (<xref ref-type="fig" rid="fig6">Figure 6c</xref>). Taken together, we found that MC-II showed a dense image phenotype, which can be noninvasively distinguished using radiomic features.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Radiomic features across subtypes.</title><p>(<bold>a</bold>) Eight features showing significant differences between MC-II and the other three subtypes. The Wilcoxon rank sum test was used to calculate the p-values; (<bold>b</bold>) A receiver operating characteristic (ROC) curve was used to evaluate the performance of the radiomic signature in distinguishing MC-II from the other three subtypes; (<bold>c</bold>) Confusion matrix allows visualization of the performance of the algorithm in separating MC-II from other subtypes.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Determination of number of signature features.</title><p>(<bold>a</bold>) LASSO regression coefficient varies with change trend of tuning parameters (λ). The upper horizontal axis is the number of non-zero coefficients in the model. The dotted line is the λ value with the smallest mean squared error. (<bold>b</bold>) λ selected in the LASSO model applied tenfold cross-validation via the minimum criteria. The upper horizontal axis is the number of non-zero coefficients in the model. The left dotted line is the λ value with the smallest mean squared error; The right dotted line is the λ value when the mean squared error is the minimum mean square error plus 1 standard error.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig6-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Identification of novel targets based on mutation-informed protein-protein interface (PPI) analysis</title><p>The integration of genomics and interactomics has enabled the discovery of functional and biological consequences of disease mutations (<xref ref-type="bibr" rid="bib63">Sahni et al., 2015</xref>; <xref ref-type="bibr" rid="bib17">Cheng et al., 2021</xref>). To explore novel targets with the concept, we created PPI networks with structural resolution using missense mutations from the XWLC, CNLC, TSLC, and TNLC cohorts (<xref ref-type="fig" rid="fig7">Figure 7a</xref> and Methods). OncoPPIs, defined as a significant enrichment of interface mutations in either of the two protein-binding partners across individuals, were identified in each cohort and were provided in <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>. The OncoPPIs from the four cohorts are named XWLC_oncoPPIs, CNLC_oncoPPIs, TSLC_oncoPPIs, and TNLC_oncoPPIs, respectively (<xref ref-type="fig" rid="fig7">Figure 7b</xref> and <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1a–c</xref>). Initially, the nodes from these four OncoPPIs were subjected to biological process enrichment analysis (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1d</xref>). The analysis revealed that biological processes such as regulation of the mitotic cell cycle, TGF-beta signaling pathway, and immune system were predominantly enriched in the genes related to OncoPPIs. Moreover, the processes disrupted by interface mutations showed a relatively higher similarity between the XWLC and TSLC cohorts (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1d</xref>) suggesting convergent targets or pathways affected by smoke-induced mutations.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Identification of novel targets in Xuanwei lung cancer (XWLC).</title><p>(<bold>a</bold>) Flow chart showing the integration of mutation-informed PPI analysis, molecular dynamic simulation, and experiment validation to identify novel targets; (<bold>b</bold>) Network visualization of XWLC_oncoPPIs. Edge thickness represents the number of missense mutations at the protein-protein interaction (PPI) interface, while node size indicates connectivity; (<bold>c</bold>) MAD1-MAD2 interaction model and the p.Arg558His mutation at the interface (left). The complex model was generated using Zdock protein docking simulation. The right distribution showing root-mean-squared deviation (RMSD) during a 20 ns molecular dynamics simulation of MAD1 wild-type vs. MAD1 p.Arg558His in the complex; (<bold>d</bold>) Model showing the p.His550Gln alteration within the TPRN-PPP1CA complex (left). The right distribution showing root-mean-squared deviation (RMSD) during a 20 ns molecular dynamics simulation for TPRN wild-type vs. TPRN p.His550Gln (H550Q) in the complex; (<bold>e</bold>) Survival analysis of the TPRN mutation group and an unaltered group derived from cbioportal using TCGA-LUAD cohort (<ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org/">https://www.cbioportal.org/</ext-link>); (<bold>f</bold>) CCK8 assay for empty vector (EV), TPRN-WT, and TPRN-MT cell lines in A549 cells which was transfected by EV, TPRN-WT, and TPRN-MT, respectively. (<bold>g</bold>) Transwell assay for EV, TPRN-WT, and TPRN-MT after 24 hr and 36 hr in A549 cells. Magnification was set to 40 x; (<bold>h</bold>) Bar chart showing the statistical results of transwell assay; i. Cell colony assay for EV, TPRN-WT, and TPRN-MT in A549 and H1299 cell lines. All samples were run in triplicate; The two-tailed Wilcoxon rank sum test was used to calculate p-values in f and h. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Networks from oncoPPIs and energy distribution.</title><p>(<bold>a–c</bold>) Networks for CNLC_oncoPPIs (<bold>a</bold>), TNLC_oncoPPIs (<bold>b</bold>) and TSLC_oncoPPIs (<bold>c</bold>). Edge thickness is proportioned to the number of missense mutations at the PPIs interface. Node size is measured by connectivity; (<bold>d</bold>) Clustered heatmap showing the top 20 enriched terms derived from oncoPPIs across CNLC, TSLC, TNLC, and LCCS cohorts. Colors are scaled by p-values; (<bold>e–f</bold>) Distribution of binding affinity (ΔG) at amino acid residue for MAD1-MAD2 complex in mutant p.Arg558His (<bold>e</bold>) and wild-type (<bold>f</bold>) on MAD1; (<bold>g</bold>) Cancer driver genes detected in LCCS based on positional clustering (<xref ref-type="bibr" rid="bib69">Tamborero et al., 2013</xref>). Dot size is proportional to the number of clusters found in the gene. The x-axis shows the number of mutations (or fraction of mutations) observed in these clusters; (<bold>h</bold>) Lollipop plots for amino acid changes in TPRN in LCCS cohort; (<bold>i–j</bold>) Distribution of binding affinity (ΔG) at amino acid residue for TPRN-PPP1CA in p.His550Gln (<bold>i</bold>) and wild-type (<bold>j</bold>) on TPRN.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig7-figsupp1-v1.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>TPRN p.His550Gln promotes tumor progression in the H1299 cell line.</title><p>(<bold>a</bold>) CCK8 assay for TPRN-MT, TPRN-WT, and EV cell lines in H1299 cells. (<bold>b</bold>) Transwell assay for TPRN-MT, TPRN-WT, and EV after 24 hr and 36 hr in H1299 cells. Magnification was set to 40 x; (<bold>c</bold>) Bar chart showing the statistical results of transwell assay; All samples were run in triplicate; The two-tailed Wilcoxon rank sum test was used to calculate p-values in a and c. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-95453-fig7-figsupp2-v1.tif"/></fig></fig-group><p>To refine the novel targets from XWLC_oncoPPs, we performed molecular dynamics simulations to predict the binding affinity change by the interface-located mutations (Methods). Mitotic Arrest Deficient 1 Like 1 (MAD1), a crucial component of the mitotic spindle-assembly checkpoint (<xref ref-type="bibr" rid="bib79">Wang et al., 2017b</xref>; <xref ref-type="bibr" rid="bib71">Tsukasaki et al., 2001</xref>), forms a tight core complex with MAD2, facilitating the binding of MAD2 to CDC20 (<xref ref-type="bibr" rid="bib89">Yang et al., 2008</xref>), which plays a critical role in sister chromatid separation during the metaphase-anaphase transition (<xref ref-type="bibr" rid="bib67">Sironi et al., 2002</xref>). Specifically, MAD1 Arg558His has been identified as a susceptibility factor for lung cancer <xref ref-type="bibr" rid="bib34">Guo et al., 2010</xref> and colorectal cancer (<xref ref-type="bibr" rid="bib98">Zhong et al., 2015</xref>). Here, we found that MAD1 allele carrying a p.Arg558His substitution may disrupt the interaction between MAD1 and MAD2 (<xref ref-type="fig" rid="fig7">Figure 7c</xref>). To assess this, we performed molecular dynamics simulations and found that the binding affinity between Arg558His MAD1 and MAD2 was –195.091 kJ/mol and that of the wild-type was –442.712 kJ/mol (<xref ref-type="fig" rid="fig7">Figure 7c</xref>). Furthermore, on a per-residue basis, the predicted binding affinity (ΔΔG) of Arg558His (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1e</xref>) was projected to increase by 118.319 kJ/mol relative to the wild-type (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1f</xref>), indicating that the substitution of Arg558His in MAD1 perturbs the binding affinity. Thus, our findings suggest that the MAD1 Arg558His attributed to lung cancer progression by disrupting of the interaction between MAD1 and MAD2, which showed potential to be explored as a target.</p><p>Notably, we identified TPRN as a novel significantly mutated gene in the XWLC cohort (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1g and h</xref>) whose status was also associated with patients’ outcomes (<xref ref-type="fig" rid="fig7">Figure 7e</xref>). Previous studies have reported that TPRN interacts with PPP1CA (<xref ref-type="bibr" rid="bib26">Ferrar et al., 2012</xref>). Thus, we assessed the binding affinity of the TPRN-PPP1CA complex affected by the mutant variant His550Gln. Our result showed that the binding affinities of the complex were –694.372 kJ/mol and –877.570 kJ/mol in mutant and WT cases, respectively (<xref ref-type="fig" rid="fig7">Figure 7d</xref>). On a per-residue basis, the predicted ΔΔG of His550Gln compared to the wild-type exhibited an increase of 96.774 kJ/mol (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1i–j</xref>). All these results indicated that TPRN His550Gln increase the binding affinity of the TPRN-PPP1CA complex. To investigate the effect of TPRN His550Gln mutation on tumor progression, we examined proliferation and migration capabilities in both A549 and H1299 lung adenocarcinoma cell lines. CCK-8 assay showed significantly enhanced cell growth after transfection of the TPRN mutant allele in both A549 (<xref ref-type="fig" rid="fig7">Figure 7f</xref>) and H1299 cells (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2a</xref>). Moreover, the wound-healing assay showed that the TPRN mutant cell had achieved enhanced migration capacity (<xref ref-type="fig" rid="fig7">Figure 7g–h</xref> and <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2b–c</xref>). Finally, more cell clones in TPRN His550Gln mutation cells were observed in both TPRN-mutant A549 and H1299 cells (<xref ref-type="fig" rid="fig7">Figure 7i</xref>). All these results supported that TPRN His550Gln could be explored as a target in XWLC.</p><p>Taken together, our integrated analysis of oncoPPIs and molecular dynamics simulations showed the potential to explore novel therapeutic vulnerabilities.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we conducted proteogenomic and characterized air-pollution-related lung cancers. We found that Benzo[a]pyrene (BaP) influenced the mutation landscape, particularly the EGFR-G719X hotspot found in 20% of cases. This mutation correlated with elevated MAPK pathway activation, worse clinical outcomes, and younger patients. Multi-omics clustering identified four subtypes with unique biological pathways and immune cell patterns. Moreover, our analysis of protein-protein interfaces unveiled novel therapeutic targets. These findings have significant implications for preventing and developing precise treatments for air-pollution-associated lung cancers.</p><p>Previously considered uncommon, the EGFR-G719X mutation was detected in only 1–2% of CNLC or TCGA-LUAD cohort samples. Limited knowledge exists from G719X, mostly based on isolated case reports or small series studies (<xref ref-type="bibr" rid="bib18">Chiu et al., 2015</xref>; <xref ref-type="bibr" rid="bib46">Kunishige et al., 2023</xref>; <xref ref-type="bibr" rid="bib90">Yang et al., 2015</xref>; <xref ref-type="bibr" rid="bib52">Massarelli et al., 2013</xref>; <xref ref-type="bibr" rid="bib35">Han et al., 2005</xref>). In vitro experiments using G719X mutant cell lines and patient-derived xenografts (PDX) demonstrated that osimertinib effectively inhibits signaling pathways and cellular growth, leading to sustained tumor growth inhibition (<xref ref-type="bibr" rid="bib27">Floc’h et al., 2020</xref>). However, in silico protein structure analysis suggests that G719 alterations may confer osimertinib resistance due to reduced EGFR binding (<xref ref-type="bibr" rid="bib91">Yang et al., 2018</xref>). Presently, afatinib is proposed as the first-line therapy for G719X mutation patients (<xref ref-type="bibr" rid="bib23">Ettinger et al., 2022</xref>; <xref ref-type="bibr" rid="bib42">Janning et al., 2022</xref>; <xref ref-type="bibr" rid="bib92">Yang et al., 2020</xref>; <xref ref-type="bibr" rid="bib19">Cho et al., 2020</xref>). Unfortunately, 80% of G719X patients develop acquired resistance to afatinib without detecting the T790M mutation40. Hence, further mechanistic studies are warranted for G719X. Our study reveals that the G719X mutation is prevalent in the XWLC cohort, significantly impacting treatment selection. Additionally, the large number of G719X samples allowed us to uncover variations in biology and pathway activation, which may facilitate the development of more precise targeted therapies for these patients.</p><p>There is substantial evidence linking lung cancer in the Xuanwei area to coal smoke (<xref ref-type="bibr" rid="bib55">Mumford et al., 1987</xref>; <xref ref-type="bibr" rid="bib5">Barone-Adesi et al., 2012</xref>; <xref ref-type="bibr" rid="bib49">Lin et al., 2015</xref>; <xref ref-type="bibr" rid="bib96">Zhang et al., 2021b</xref>; <xref ref-type="bibr" rid="bib87">Wong et al., 2019</xref>; <xref ref-type="bibr" rid="bib77">Vermeulen et al., 2019</xref>). In addition, we conducted a rat model study that demonstrated the induction of lung cancer by local coal smoke exposure (<xref ref-type="bibr" rid="bib96">Zhang et al., 2021b</xref>). However, the specific chemical compound in coal smoke responsible for causing lung cancer remains largely unknown. Previous research has mainly focused on studying indoor concentrations of airborne particles and BaP (<xref ref-type="bibr" rid="bib55">Mumford et al., 1987</xref>; <xref ref-type="bibr" rid="bib5">Barone-Adesi et al., 2012</xref>; <xref ref-type="bibr" rid="bib49">Lin et al., 2015</xref>; <xref ref-type="bibr" rid="bib47">Lan et al., 2002</xref>; <xref ref-type="bibr" rid="bib44">Kim et al., 2014</xref>). For instance, studies have shown an association between the concentration of BaP and lung cancer rates across counties (<xref ref-type="bibr" rid="bib55">Mumford et al., 1987</xref>). Moreover, improvements in household stoves have led to reduced exposure to benzopyrene and particulate matter, benefiting people’s health (<xref ref-type="bibr" rid="bib47">Lan et al., 2002</xref>; <xref ref-type="bibr" rid="bib44">Kim et al., 2014</xref>). However, these studies primarily relied on epidemiological data, which may be influenced by confounding factors. Mechanistically, Qing Wang showed that BaP induces lung carcinogenesis, characterized by increased inflammatory cytokines, and cell proliferative markers, while decreasing antioxidant levels, and apoptotic protein expression (<xref ref-type="bibr" rid="bib81">Wang et al., 2020</xref>). In our study, we used clinical samples and linked the mutational signatures of XWLC to the chemical compound BaP, which advanced the etiology and mechanism of air-pollution-induced lung cancer. In our study, several limitations must be acknowledged. First, although our multi-omics approach provided a comprehensive analysis of the subtypes and their unique biological pathways, the sample size for each subtype was relatively small. This limitation may affect the robustness of the clustering results and the identified subtype-specific pathways. Larger cohort studies are necessary to confirm these findings and refine the subtype classifications. Second, although our study advanced the understanding of air-pollution-induced lung cancer by using clinical samples, the reliance on epidemiological data in previous studies introduces potential confounding factors. Our findings should be interpreted with caution, and further mechanistic studies are warranted to establish causal relationships more definitively. Third, our in silico analysis suggested a potential approach to drug resistance in G719X mutations. However, these predictions need to be validated through extensive in vitro and in vivo experiments. The reliance on computational models without experimental confirmation may limit the clinical applicability of these findings.</p><p>In summary, our proteogenomic analysis of clinical tumor samples provides insights into air-pollution-associated lung cancers, especially those induced by coal smoke, and offers an opportunity to expedite the translation of basic research to more precise diagnosis and treatment in the clinic.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Specimen acquisition</title><p>Female patients (n=169) from the Xuanwei area with treatment-naive LUAD were recruited from the Yunnan Cancer Hospital &amp; The Third Affiliated Hospital of Kunming Medical University with written informed consent, with an age range from 27 to 76 (mean = 56). All patients are never-smokers (less than 100 cigarettes in their lifetime which was self-reported smoking status) and also her spouse should be never-smokers if they live together. All tumor specimens were reviewed by pathologists to determine the histological subtype, histological grade, and TNM staging. Majority of the tumors analyzed were stage I or II (n=145) and the remainder were stage III or IV (n=24). Follow-up within this cohort of patients was completed in May 2021, and the median follow-up was conducted at 32 months. Fifteen patients died or experienced relapse or metastatic progression at the time of the last follow-up. Blood samples were also collected from the Yunnan Cancer Hospital &amp; The Third Affiliated Hospital of Kunming Medical University when the females from the Xuanwei area (n=219) or non-Xuanwei areas (n=216) came to the hospital for physical examination in the morning and the serum were kept in –80 °C. Xuanwei areas includes rural counties which high lung cancer incidence such as Laibin, Chang Long, Dai Hai, Shui Wan, Qiao Hong and Long Shuang etc. The study was approved by the ethical committees of Yunnan Cancer Hospital &amp; The Third Hospital of Kunming Medical University.</p><p>Methods for Sequencing sample preparation, Whole Exome Sequencing (WES) and quantification, WES library preparation and sequencing, WES data quality control, Reads mapping to the reference sequence, Somatic variant calling, Mutation annotation, Copy number calling, GISTIC and MutSig analysis, RNA sequencing and quantification, RNA library preparation for Transcriptome sequencing, RNA quality control, and Quantification of gene expression level please refer to the previous study (<xref ref-type="bibr" rid="bib96">Zhang et al., 2021b</xref>).</p></sec><sec id="s4-2"><title>Label-free mass spectrometry methods</title><p>The protocols below for total protein extraction, protein quality test, tryptic digestion, LC-MS/MS Analysis, phosphopeptide enrichment using immobilized metal affinity chromatography, and LC-MS/MS were performed as previously described in depth (<xref ref-type="bibr" rid="bib53">Mertins et al., 2018</xref>).</p></sec><sec id="s4-3"><title>Total protein extraction (<xref ref-type="bibr" rid="bib30">Gillette et al., 2020</xref>; <xref ref-type="bibr" rid="bib43">Kachuk et al., 2015</xref>; <xref ref-type="bibr" rid="bib86">Wiśniewski et al., 2009</xref>)</title><p>Sample was ground individually in liquid nitrogen and lysed with PASP lysis buffer (100 mM NH<sub>4</sub>HCO<sub>3</sub>, 8 M Urea, pH 8), followed by 5 min of ultrasonication on ice. The lysate was centrifuged at 12,000 <italic>g</italic> for 15 min at 4℃ and the supernatant was reduced with 10 mM DTT for 1 hr at 56℃, and subsequently alkylated with sufficient IAM for 1 hr at room temperature in the dark. Then samples were completely mixed with four times the volume of precooled acetone by vortexing and incubated at –20℃ for at least 2 hr. Samples were then centrifuged at 12,000 <italic>g</italic> for 15 min at 4℃ and the precipitation was collected. After washing with 1 mL cold acetone, the pellet was dissolved by dissolution buffer (8 M Urea, 100 mM TEAB, pH 8.5). For Phosphoproteome, the pellet was dissolved by dissolution buffer, which contained 0.1 M triethylammonium bicarbonate (TEAB, pH 8.5) and 6 M urea.</p></sec><sec id="s4-4"><title>Protein quality test</title><p>BSA standard protein solution was prepared according to the instructions of the Bradford protein quantitative kit, with gradient concentration ranged from 0 to 0.5 g/L. BSA standard protein solutions and sample solutions with different dilution multiples were added into 96-well plates to fill up the volume to 20 µL, respectively. Each gradient was repeated three times. The plate was added 180 μL G250 dye solution quickly and placed at room temperature for 5 min, the absorbance at 595 nm was detected. The standard curve was drawn with the absorbance of the standard protein solution and the protein concentration of the sample was calculated. 20 μg of the protein sample was loaded to 12% SDS-PAGE gel electrophoresis, wherein the concentrated gel was performed at 80 V for 20 min, and the separation gel was performed at 120 V for 90 min. The gel was stained by coomassie brilliant blue R-250 and decolored until the bands were visualized clearly.</p></sec><sec id="s4-5"><title>Trypsin treatment (<xref ref-type="bibr" rid="bib93">Zhang et al., 2016</xref>)</title><p>Each protein sample was taken and the volume was made up to 100 μL with DB lysis buffer (8 M Urea, 100 mM TEAB, pH 8.5), trypsin and 100 mM TEAB buffer were added, the sample was mixed and digested at 37 °C for 4 hr. Then trypsin and CaCl2 were added and digested overnight. Formic acid was mixed with the digested sample, adjusted pH under 3, and centrifuged at 12,000 <italic>g</italic> for 5 min at room temperature. The supernatant was slowly loaded to the C18 desalting column, washed with washing buffer (0.1% formic acid, 3% acetonitrile) three times, then added elution buffer (0.1% formic acid, 70% acetonitrile). The eluents of each sample were collected and lyophilized.</p></sec><sec id="s4-6"><title>Phosphopeptide enrichment using phos-select iron affinity gel for phosphoproteome only</title><p>Add binding buffer to dissolve the lyophilized powder, and centrifuge at 12,000 g at 4 °C for 5 min. The supernatant was loaded to the pretreated IMAC-Fe column and incubated at room temperature for 30 min. Then centrifuge at 2000 g for 30 s and wash with washing solution and water each once. Centrifuge at 2000 g for 30 s. Discard the tube, and replace it with a new, clean centrifuge tube. Elute with elution buffer and lyophilized.</p></sec><sec id="s4-7"><title>LC-MS/MS analysis for proteome only</title><p>Mobile phase A (100% water, 0.1% formic acid) and B solution (80% acetonitrile, 0.1% formic acid) were prepared. The lyophilized powder was dissolved in 10 μL of solution A, centrifuged at 14,000 <italic>g</italic> for 20 min at 4℃, and 1 μg of the supernatant was injected into a home-made C18 Nano-Trap column (4.5 cm ×75 μm, 3 μm). Peptides were separated in a home-made analytical column (15 cm ×150 μm, 1.9 μm), using a linear gradient elution as listed in <xref ref-type="table" rid="table1">Table 1</xref>. The separated peptides were analyzed by Q Exactive series mass spectrometer (Thermo Fisher), with an ion source of Nanospray Flex (ESI), spray voltage of 2.1 kV, and ion transport capillary temperature of 320°C. Full scan range from <italic>m/z</italic>350 to 1500 with resolution of 60,000 (at <italic>m/z</italic>200), an automatic gain control (AGC) target value was 3×10<sup>6</sup> and a maximum ion injection time was 20 ms. The top 40 precursors of the highest abundant in the full scan were selected and fragmented by higher energy collisional dissociation (HCD) and analyzed in MS/MS, where resolution was 15,000 (at <italic>m/z</italic>200), the automatic gain control (AGC) target value was 1×10<sup>5</sup>, the maximum ion injection time was 45 ms, a normalized collision energy was set as 27%, an intensity threshold was 2.2×10<sup>4</sup>, and the dynamic exclusion parameter was 20 s. The raw data of MS detection was named as ‘.raw.’</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Liquid chromatography elution gradient table.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Time (min)</th><th align="left" valign="bottom">Flow rate (nL/min)</th><th align="left" valign="bottom">Mobile phase A (%)</th><th align="left" valign="bottom">Mobile phase B (%)</th></tr></thead><tbody><tr><td align="left" valign="bottom">0</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">94</td><td align="left" valign="bottom">6</td></tr><tr><td align="left" valign="bottom">2</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">90</td><td align="left" valign="bottom">10</td></tr><tr><td align="left" valign="bottom">45</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">70</td><td align="left" valign="bottom">30</td></tr><tr><td align="left" valign="bottom">48</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">65</td><td align="left" valign="bottom">35</td></tr><tr><td align="left" valign="bottom">50</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">50</td><td align="left" valign="bottom">50</td></tr><tr><td align="left" valign="bottom">51</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">100</td></tr><tr><td align="left" valign="bottom">60.5</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">95</td><td align="left" valign="bottom">5</td></tr><tr><td align="left" valign="bottom">61.5</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">95</td><td align="left" valign="bottom">5</td></tr><tr><td align="left" valign="bottom">62</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">95</td></tr><tr><td align="left" valign="bottom">67</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">95</td></tr><tr><td align="left" valign="bottom">70</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">95</td><td align="left" valign="bottom">5</td></tr></tbody></table></table-wrap></sec><sec id="s4-8"><title>LC-MS/MS analysis for phosphoproteome only</title><p>Prepare mobile phase A (100% water, 0.1% formic acid) and B (80% acetonitrile, 0.1% formic acid). The lyophilized powder was dissolved in 10 μL solution A and centrifuged at 14,000 g for 20 min at room temperature. 1 μg supernatant was used for detection. Shotgun proteomics analyses were performed using an EASY-nLCTM 1200 UHPLC system (Thermo Fisher) coupled with a Q Exactive HF-X mass spectrometer (Thermo Fisher) operating in the data-dependent acquisition (DDA) mode. 1 μg sample was injected into a home-made C18 Nano-Trap column (2 cm ×75 μm, 3 μm). Peptides were separated in a home-made analytical column (15 cm ×150 μm, 1.9 μm), using a linear gradient elution as listed in <xref ref-type="table" rid="table2">Table 2</xref>. The separated peptides were analyzed by Q Exactive HF-X, with ion source of Nanospray Flex(ESI), spray voltage of 2.3 kV and ion transport capillary temperature of 320 °C. Full scan range from <italic>m/z</italic> 350–1500 with resolution of 120,000 (at <italic>m/z</italic> 200), an automatic gain control (AGC) target value was 3×10<sup>6</sup> and a maximum ion injection time was 80 ms. The 30 most abundant precursor ions from full scan were selected and fragmented by higher energy collisional dissociation (HCD) and analyzed in MS/MS, where resolution was 15,000 (at <italic>m/z</italic> 200), the automatic gain control (AGC) target value was 5×10<sup>4</sup> and the maximum ion injection time was 100 ms, a normalized collision energy was set as 27%, an intensity threshold was 5×10<sup>3</sup>, and the dynamic exclusion parameter was 30 s. The raw data of MS detection was named as ‘.raw’.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Liquid chromatography elution gradient table.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Time(min)</th><th align="left" valign="bottom">Flow rate (nL/min)</th><th align="left" valign="bottom">Mobile phase A (%)</th><th align="left" valign="bottom">Mobile phase B (%)</th></tr></thead><tbody><tr><td align="left" valign="bottom">0</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">95</td><td align="left" valign="bottom">5</td></tr><tr><td align="left" valign="bottom">2</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">90</td><td align="left" valign="bottom">10</td></tr><tr><td align="left" valign="bottom">112</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">70</td><td align="left" valign="bottom">30</td></tr><tr><td align="left" valign="bottom">117</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">50</td><td align="left" valign="bottom">50</td></tr><tr><td align="left" valign="bottom">118</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">95</td></tr><tr><td align="left" valign="bottom">123</td><td align="left" valign="bottom">600</td><td align="left" valign="bottom">5</td><td align="left" valign="bottom">95</td></tr></tbody></table></table-wrap></sec><sec id="s4-9"><title>The identification and quantitation of protein</title><p>The all resulting spectra were searched against the UniProt database by the search engines: Proteome Discoverer 2.2 (PD 2.2, Thermo). The search parameters are set as follows: mass tolerance for precursor ion was 10 ppm and mass tolerance for product ion was 0.02 Da. Carbamidomethyl was specified as fixed modifications, Oxidation of methionine (M) was specified as dynamic modification, and acetylation was specified as N-Terminal modification in PD 2.2. A maximum of two missed cleavage sites were allowed.</p><p>In order to improve the quality of analysis results, the software PD 2.2 further filtered the retrieval results: Peptide Spectrum Matches (PSMs) with a credibility of more than 99% was identified PSMs. The identified protein contains at least 1 unique peptide. The identified PSMs and protein were retained and performed with FDR no more than 1.0%. The protein quantitation results were statistically analyzed by t-test. The proteins whose quantitation was significantly different between experimental and control groups, (p&lt;0.05 and |log2FC|&gt;1), were defined as differentially expressed proteins (DEP).</p></sec><sec id="s4-10"><title>Mutational signature analysis</title><p>Based on the single nucleotide substitution and its’ adjacent bases pattern of samples, frequencies of 96 possible mutation types for each sample could be estimated. Non-negative matrix factorization (NMF) algorithm was used to estimate the minimal components that could explain the maximum variance among samples in the R package SomaticSignatures (v2.30.0). Number of signatures was determined by choosing the reflection point in the curves of explained variance and residual sum of squares (RSS). Then each component was compared to mutation patterns of 30 validated cancer signatures reported from the COSMIC database (<xref ref-type="bibr" rid="bib70">Tate et al., 2019</xref>) and of 53 carcinogen signatures reported from <xref ref-type="bibr" rid="bib45">Kucab et al., 2019</xref>. individually to identify cancer-related mutational signatures and carcinogen signatures. Cosine similarity analysis was used to measure the similarity between components and signatures, which ranged from 0 to 1, indicating maximal dissimilarity to maximal similarity. After decomposing the matrix of samples’ 96 substitution classes into signatures, the contribution of signatures in each sample could be estimated.</p></sec><sec id="s4-11"><title>Correlation of genomic mutations</title><p>To calculate the correlation of genomic mutations among four cohorts, all mutations in four cohorts were used and the percentage of mutated samples were correlated. The Pearson method was used.</p></sec><sec id="s4-12"><title>Actionable target analysis</title><p>Use vcf2maf software to re-annotate maf files. Run the maf2maf.pl file with the parameter + hgvs in the vep calling process to re-annotate HGVS information in the maf files. Use the MafAnnotator.py script from the oncokb-annotator annotation software provided by OncoKB (<xref ref-type="bibr" rid="bib12">Chakravarty et al., 2017</xref>) official to annotate the maf files, add ONCOGENIC information, filter the annotated ‘Oncogenic’ sites, and use ggplot2 to draw statistics.</p></sec><sec id="s4-13"><title>Estimating immune cell populations</title><p>RNAseq-derived infiltrating immune cell populations were estimated using the ssGSEA approach (<xref ref-type="bibr" rid="bib4">Barbie et al., 2009</xref>; <xref ref-type="bibr" rid="bib68">Subramanian et al., 2005</xref>). 28 subpopulations of TILs were estimated using prior immune signatures (<xref ref-type="bibr" rid="bib14">Charoentong et al., 2017</xref>). The immune cell populations were: Activated_CD4_T_cell, Activated_CD8_T_cell, Activated_dendritic_cell, CD56bright_natural_killer_cell, Central_memory_CD4_T_cell, Central_memory_CD8_T_cell, Effector_memeory_CD4_T_cell, Effector_memeory_CD8_T_cell, Natural_killer_cell, Natural_killer_T_cell, Type_1_T_helper_cell, Type_17_T_helper_cell, CD56dim_natural_killer_cell, Immature_dendritic_cell, Macrophage, MDSC, Neutrophil, Plasmacytoid_dendritic_cell, Regulatory_T_cell, Type_2_T_helper_cell, Activated_B_cell, Eosinophil, Gamma_delta_T_cell, Immature_B_cell, Mast_cell, Memory_B_cell, Monocyte, T_follicular_helper_cell.</p></sec><sec id="s4-14"><title>KSEA analysis</title><p>KSEA algorithm was used to estimate the kinase activities by using the ratios of all identified phosphosites between each EGFR mutation subtype and NAT (<xref ref-type="bibr" rid="bib85">Wiredja et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Casado et al., 2013</xref>) The kinase activity was predicted using the R package KSEAapp (v0.99.0). Annotations of kinase-substrate relationships were downloaded from the website (<ext-link ext-link-type="uri" xlink:href="https://github.com/casecpb/KSEA/">https://github.com/casecpb/KSEA/</ext-link>; <xref ref-type="bibr" rid="bib85">Wiredja et al., 2017</xref>; <xref ref-type="bibr" rid="bib11">Casado et al., 2013</xref>). NetworKIN predictions score was included and the minimum was set as 5. The minimum number of substrates a kinase must identify to be included was set as 5. p values less than 0.05 was used in this study.</p></sec><sec id="s4-15"><title>Subtyping</title><p>The top 2000 most variable features in each data level (RNA transcripts, proteins, phosphoproteins) were collected and subjected to clustering using ConsensusClusterPlus (<xref ref-type="bibr" rid="bib84">Wilkerson and Hayes, 2010</xref>). The top 6000 most variable features were measured by median absolute deviation. We selected 80% item resampling (pItem), 80% gene resampling (pFeature), a maximum evalulated k of 6 so that cluster counts of 2, 3, 4, 5, 6 are evaluated (maxK), 1000 resamplings (reps), and agglomerative hierarchical clustering algorithm (clusterAlg) upon 1- Pearson correlation distances (distance). We determined the number of clusters (k) based on the Consensus Cumulative Distribution Function (CDF) Plot and Delta Area Plot. Specifically, the number of k was determined when CDF reaches an approximate maximum and Delta Area Plot shows no appreciable increase (DOI:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1023/A">https://doi.org/10.1023/A</ext-link>:1023949509487).</p></sec><sec id="s4-16"><title>Isolation of signatures in each cluster</title><p>To isolate cluster specific highly expressed genes/proteins/phosphoproteins in each cluster, we applied DESeq2 <xref ref-type="bibr" rid="bib50">Love et al., 2014</xref> to calculate significantly up-regulated features by comparing the cluster samples to other cluster samples. FDR &lt;0.05 and fold change &gt;1.2 were used to determine significance.</p></sec><sec id="s4-17"><title>Pathway enrichment analysis for cluster signatures</title><p>Enriched GO biological processes were extracted from DAVID <xref ref-type="bibr" rid="bib40">Huang et al., 2009</xref> and FDR &lt;0.05 was used to determine the significance.</p></sec><sec id="s4-18"><title>Association of clusters to clinical features</title><p>To test the association of the resulting clusters to clinical variables we used Fisher’s exact test (R function fisher.test) to test for overrepresentation in the set of cluster samples. p&lt;0.05 was used to determine significance.</p></sec><sec id="s4-19"><title>Regions of interest (ROI) delineation and inter- and intra-observer reproducibility</title><p>All the patients underwent lung cancer examination before biopsy, and CT images were used for radiomics analysis in this study. ROIs were delineated semiautomatically using 3D Slicer software (<xref ref-type="bibr" rid="bib25">Fedorov et al., 2012</xref>). Two radiologists Zhi Li and Chao Liu with 4 and 7 years of experience in lung CT, respectively, were primarily responsible for evaluating the ROIs. The agreements of the ROIs between the radiologists and within the same radiologist represent inter- and intra-observer reproducibility, respectively. The inter- and intra-observer reproducibility of the ROIs and radiomic feature extraction were initially analyzed using the RIDER (<xref ref-type="bibr" rid="bib97">Zhao et al., 2009</xref>) data of 50 randomly selected patients in a blinded fashion by two radiologists. To ensure consistent ROI delineation, one radiologist repeated the ROI delineation twice with an interval of at least 1 month, while another radiologist independently drew the ROIs and generated radiomic features following the same procedure. Intraclass correlation coefficients (ICCs) were used to evaluate the intra- and interobserver agreement in terms of feature extraction. Inter- and intra-observer reproducibility and radiomic feature extraction achieved substantial agreement with ICC &gt;0.80 both among the ROIs from the two radiologists and between the ROIs from the same radiologist.</p></sec><sec id="s4-20"><title>Radiomics features</title><p>We defined 107 radiomic image features that describe tumour characteristics and can be extracted in an automated way. The features can be divided into three groups: (I) tumour intensity, (II) size and shape, and (III) texture features. The first group quantified tumour intensity characteristics using first-order statistics, calculated from the histogram of all tumour voxel intensity values. Group 2 consists of features based on the shape of the tumour. Group 3 consists of textual features that are used to quantify intratumour heterogeneity differences in the texture that is observable within the tumour volume. Specifically, they are First Order Statistics (18 features), shape-based (14 features), Gray Level Cooccurence Matrix (24 features), Gray Level Dependence Matrix (GLDM) Features (14 features), Gray Level Run Length Matrix (GLRLM) Features (16 features), Gray Level Size Zone Matrix (GLSZM) Features (16 features), Neighbouring Gray Tone Difference Matrix (NGTDM) Features (5 features). All feature algorithms were implemented with pyradiomics (3.0.1) (<xref ref-type="bibr" rid="bib75">van Griethuysen et al., 2017</xref>).</p></sec><sec id="s4-21"><title>Feature selection and radiomics model building</title><p>The LASSO method was used to select the most useful predictive features from the training cohort (glmnet R package) (<xref ref-type="bibr" rid="bib28">Friedman et al., 2010</xref>). Tuning parameter (λ) was selected in the LASSO model by cross-validation for distinguishing XWLC molecular subtypes. Radiomics scores were calculated for each patient using multivariate linear regression (glm R package). The abilities to distinguish XWLC molecular subtypes were assessed using the area under the curve (AUC) of the receiver operator characteristic curve (ROC) via the pROC R package (<xref ref-type="bibr" rid="bib62">Robin et al., 2011</xref>). Radiomics data from patients with multi-omic XWLC subtype and lung CT images were selected to build signatures for distinguishing molecular subtypes inside XWLC. Signature used t0 distinguish MC-II from other subtypes:<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mtable columnalign="left left" rowspacing="4pt" columnspacing="1em"><mml:mtr><mml:mtd><mml:mtext>Rad-score</mml:mtext><mml:mo>=</mml:mo></mml:mtd><mml:mtd><mml:mo>−</mml:mo><mml:mn>1.9203568703</mml:mn><mml:mspace width="thinmathspace"/><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mn>0.0010095229</mml:mn><mml:mo>∗</mml:mo><mml:mrow><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">m</mml:mi></mml:mrow><mml:mspace width="thinmathspace"/><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mo>−</mml:mo><mml:mn>0.0004598256</mml:mn><mml:mo>∗</mml:mo><mml:mrow><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">q</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mspace width="thinmathspace"/><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mn>7.4677789388</mml:mn><mml:mo>∗</mml:mo><mml:mrow><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">y</mml:mi></mml:mrow><mml:mspace width="thinmathspace"/><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mn>4.5385695277</mml:mn><mml:mo>∗</mml:mo><mml:mrow><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi mathvariant="normal">G</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mi mathvariant="normal">L</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">U</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">z</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mspace width="thinmathspace"/><mml:mo>+</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd><mml:mn>0.0234377968</mml:mn><mml:mo>∗</mml:mo><mml:mrow><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">_</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">y</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p></sec><sec id="s4-22"><title>Radiomics model validation</title><p>The radiomics prediction models were validated internally and externally. First, the trained classifiers were assessed by cross-validation via the glmnet R package (<xref ref-type="bibr" rid="bib28">Friedman et al., 2010</xref>). Next, the trained classifiers were further tested in the validation datasets in terms of the AUC of the ROC curve.</p></sec><sec id="s4-23"><title>Building mutation-associated protein-protein interactomes</title><p>To build structurally resolved mutation-associated protein-protein interaction (PPI) networks based on missense mutations from XWLC, CNLC, TNLC, and TSLC cohort, we downloaded genomic coordinates encoding PPI interfaces from Interactome INSIDER (v.2018.2) (<xref ref-type="bibr" rid="bib54">Meyer et al., 2018</xref>), in which PPI interfaces were compiled for all available 7,135 co-crystal structures and 5386 homology models and 184,605 computationally predicted interactions. We figured out those interfaces carrying missense mutations by mapping mutation sites to PPI interface genomic coordinates using bedtools (v2.25.0) (<xref ref-type="bibr" rid="bib61">Quinlan and Hall, 2010</xref>). Protein UniProt IDs were converted to their gene names based on the UniProt ID mapping tool (<xref ref-type="bibr" rid="bib6">Bateman et al., 2021</xref>). Those PPIs whose protein UniProt IDs conversion failed were discarded. The resulting mutation-associated PPI networks constructed in this way include 27270 PPIs (edges or links) connecting 8756 unique proteins (nodes) in the XWLC cohort, 10706 PPIs connecting 5759 unique proteins in the CNLC cohort, 14829 PPIs connecting 6455 unique proteins in the TNLC cohort and 32157 PPIs connecting 7157 unique proteins in TSLC cohort. All PPIs were experimentally validated PPIs derived from different types of experimental evidence, as described in the original study (<xref ref-type="bibr" rid="bib54">Meyer et al., 2018</xref>).</p></sec><sec id="s4-24"><title>Significance test of PPI interface mutations</title><p>An oncoPPI is defined as there is significant enrichment in interface mutations in one or the other of the two protein-binding partners across individuals. For each gene <inline-formula><mml:math id="inf1"><mml:mi>g</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> and its PPI interfaces, we assume that the observed number of cohort-associated mutations for a given interface follows a binomial distribution, binomial (<inline-formula><mml:math id="inf2"><mml:mi>n</mml:mi></mml:math></inline-formula>, <inline-formula><mml:math id="inf3"><mml:mi>p</mml:mi><mml:mi>g</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula>), in which <inline-formula><mml:math id="inf4"><mml:mi>n</mml:mi></mml:math></inline-formula> is the total number of cohort-associated mutations observed in one gene and <inline-formula><mml:math id="inf5"><mml:mi>p</mml:mi><mml:mi>g</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> is the estimated mutation rate for the interface region in one or the other of the two protein-binding partners of each PPI under the null hypothesis that the region was not recurrently mutated. Using M and N to represent the length of the interface and protein product of gene <inline-formula><mml:math id="inf6"><mml:mi>g</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula>, for each interface, we computed the p- value—the probability of observing &gt;k mutations around this interface out of n total mutations observed in this gene—using the following equation:<disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>X</mml:mi><mml:mo>≥</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>P</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>X</mml:mi><mml:mo>&lt;</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mi>n</mml:mi><mml:mi>x</mml:mi></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mi>p</mml:mi><mml:mi>g</mml:mi><mml:msup><mml:mi>i</mml:mi><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mi>g</mml:mi><mml:mi>i</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>−</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:mrow></mml:math></disp-formula></p><p>in which <inline-formula><mml:math id="inf7"><mml:mi>p</mml:mi><mml:mi>g</mml:mi><mml:mi>i</mml:mi></mml:math></inline-formula> = <inline-formula><mml:math id="inf8"><mml:mfrac><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula> . All p- values were adjusted for multiple testing using the FDR correction. FDR&lt;0.01 was set to determine the significance. In total, we identified 2139 XWLC_oncoPPIs, 1368 CNLC_oncoPPIs, 797 TNLC_oncoPPIs, and 3730 TSLC_oncoPPIs.</p></sec><sec id="s4-25"><title>Biological process enrichment in OncoPPI-related genes and term network construction</title><p>OncoPPI network was constructed using Cytoscape (v.3.9.1) <xref ref-type="bibr" rid="bib65">Shannon et al., 2003</xref> in four cohorts, respectively. Edge thickness is proportioned to the number of missense mutations at the PPIs interface. Node size is measured by connectivity. Biological process enrichment analysis was performed using Metascape (<xref ref-type="bibr" rid="bib99">Zhou et al., 2019</xref>) based on oncoPPI-related genes. Enrichment term network was built with Metascape (<xref ref-type="bibr" rid="bib99">Zhou et al., 2019</xref>) and major processes were outlined by manual revision.</p></sec><sec id="s4-26"><title>Molecular dynamic simulation</title><p>We conducted molecular dynamics simulation analysis using X-ray crystallography structures or, in cases where such structures were unavailable, AlphaFold Protein Structure (<xref ref-type="bibr" rid="bib76">Varadi et al., 2022</xref>) predictions. Protein-protein docking was accomplished by ZDOCK (<xref ref-type="bibr" rid="bib59">Pierce et al., 2014</xref>). Mutations were constructed, and incomplete internal sequences or absent terminal regions were modeled in using Swiss-PdbViewer (<xref ref-type="bibr" rid="bib33">Guex and Peitsch, 1997</xref>). Preparation of the system and molecular dynamics simulation were carried out using GROMACS (v.2021.3) <xref ref-type="bibr" rid="bib56">Páll et al., 2020</xref> on the Supercomputing Platform of the Kunming Institute of Zoology. Following a processing step, including the topology for the molecules processed by the pdb2gmx function using CHARMM36 all-atom force field and a water box using TIP3 water molecules with edges at least 10 Å from the protein was added. The system was neutralized to offset the charge on the protein. Energy minimizations of the systems were carried out using the steepest descent until the potential energy was on the order of 10<sup>5</sup>–10<sup>6</sup> kJ/mol and the maximum force was no greater than 1000 kJ/mol<sup>–1</sup> nm<sup>–1</sup>. Following minimization, an NVT and NPT (i.e. constant number of particles, volume and temperature) equilibration step with LINCS constraint algorithm and PME (Particle Mesh Ewald) coulomb type was run using a timestep of 2 fs for 50,000 steps, yielding 0.1 ns of equilibration. Temperature coupling to 300 K was done separately for protein and water/ions using a modified Berendsen thermostat and a 0.1 ps coupling constant. Isotropic pressure coupling to 1 bar was done using a Parrinello–Rahman barostat with a coupling constant of 2.0 ps and compressibility of 4.5×10<sup>–5</sup> bar<sup>−1</sup>. Finally, dynamic simulation was run with no positional restraints for 20 ns using the same 2 fs timestep from equilibration, after which the system was determined by its root-mean-squared deviation (RMSD) to be reasonably well equilibrated.</p><p>MM/PBSA energies were calculated over the final 5 ns of each simulation using gmx_MMPBSA (<xref ref-type="bibr" rid="bib73">Valdés-Tresanco et al., 2021</xref>), which can be used for calculating binding free energies of non-covalently bound complexes. Postprocessing and RMSD plots were generated using PyMoL (<ext-link ext-link-type="uri" xlink:href="https://pymol.org/2/">https://pymol.org/2/</ext-link>, v.2.5.0) and R packages ggplot2.</p></sec><sec id="s4-27"><title>Cell culture and TPRN-mutant cell construction</title><p>pLV[Exp]-EGFP:T2A:Puro-EF1A (ID: VB220907-1396qay) from VectorBuilder Inc was used in the vector construction. The TPRN His550Gln mutant lentivirus (TPRN-MUT) and its WT lentivirus were constructed. A549 and H1299 cell lines were obtained from Center for Scientific Research, Yunnan University of Chinese Medicine, and separately cultured in RPMI-1640 and DMEM supplemented with 10% fetal bovine serum, and 1% penicillin-streptomycin. The cell culture was maintained in a humidified incubator at 37 °C under 5% CO2. A549 and H1299 cells were then infected with lentivirus.</p></sec><sec id="s4-28"><title>Cell viability assay and colony formation assay</title><p>Cell viability was assessed by CCK8 (cell counting kit) assay. Briefly, cells were seeded in 96-well plates (4×10<sup>3</sup> cells/well) with the indicated treatment. A549 was incubated with CCK8 reagent for 1 hr, while H1299 was incubated with CCK8 reagent for 1.5 hr at 37 °C. The OD value was measured at 450  nm. The results were statistically analyzed using Tukey’s multiple comparisons test with GraphPad Prism software 8.2. For the colony formation assay, A549 and H1299 were separately seeded in a six-well plate (1×10<sup>3</sup> cells/well). Twelve days later, the cells were fixed with 4% paraformaldehyde in PBS for 30 min and then stained with crystal violet for 30  min. The dishes were gently washed with PBS three times.</p></sec><sec id="s4-29"><title>Wound-healing assay</title><p>A549 and H1299 cells were seeded in six-well plates and cultured until 95% confluent. The adherent monolayer cells were scratched using a 200  μl pipette tip and the plate was washed three times. The scratch wounds are marked with dots using labelling pen. The plates were incubated with fresh media containing 2% FBS under 5% CO2 at 37 °C. Images of the scratch wounds were captured using a phase-contrast microscope. Percentage of wound-healing area was calculated using ImageJ as the following formula: (original scratch area - scratch area after healing) (original scratch area)–1×100%, and the results were statistically analyzed using Tukey’s multiple comparisons test with GraphPad Prism software 8.2.</p></sec><sec id="s4-30"><title>Statistics and reproducibility</title><p>Unless specified otherwise, two-sided Fisher’s exact testing was used for p- value calculations between two categorical variables, while two-sided Wilcoxon rank sum testing was used between two continuous variables for all figures. Log-rank tests were used for comparison of survival distributions in Kaplan–Meier plots. For multiple testing corrections, FDR corrections were performed unless specified otherwise.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Supervision, Investigation, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Data curation</p></fn><fn fn-type="con" id="con5"><p>Formal analysis</p></fn><fn fn-type="con" id="con6"><p>Data curation</p></fn><fn fn-type="con" id="con7"><p>Resources, Data curation, Investigation</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis, Funding acquisition</p></fn><fn fn-type="con" id="con9"><p>Resources, Formal analysis, Funding acquisition</p></fn><fn fn-type="con" id="con10"><p>Resources, Funding acquisition, Investigation</p></fn><fn fn-type="con" id="con11"><p>Investigation</p></fn><fn fn-type="con" id="con12"><p>Resources, Data curation, Formal analysis</p></fn><fn fn-type="con" id="con13"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con14"><p>Data curation, Funding acquisition, Investigation</p></fn><fn fn-type="con" id="con15"><p>Resources, Funding acquisition, Investigation</p></fn><fn fn-type="con" id="con16"><p>Resources, Funding acquisition, Investigation</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>The study protocol was reviewed and approved by the ethical committees of Yunnan Cancer Hospital &amp; The Third Affiliated Hospital of Kunming Medical University (KYCS2022067) and conformed to the ethical standards for medical research involving human subjects, as laid out in the 1964 Declaration of Helsinki and its later amendments.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Clinical information for TSLC, TNLC, CNLC, and XWLC cohorts.</title><p>(<bold>a</bold>) Clinical data for TSLC and TNLC cohorts. (<bold>b</bold>) Clinical data for CNLC cohort. (<bold>c</bold>) Clinical data for XWLC cohort.</p></caption><media xlink:href="elife-95453-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Somatic mutation profile in XWLC.</title><p>(<bold>a</bold>) Somatic mutation profile in XWLC. (<bold>b</bold>) Mutation frequency of cancer driver genes XWLC cohort.</p></caption><media xlink:href="elife-95453-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Copy number variation results in XWLC.</title></caption><media xlink:href="elife-95453-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Normalized mRNA expression (CPM values derived from EdgeR) in XWLC.</title></caption><media xlink:href="elife-95453-supp4-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Proteomic expression results normalized by column (patient) median.</title></caption><media xlink:href="elife-95453-supp5-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Quantitative phosphoproteomic data at phosphosite level normalized by column (patient) median.</title></caption><media xlink:href="elife-95453-supp6-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>Estimation of Immune cell infiltration with ssGSEA method.</title></caption><media xlink:href="elife-95453-supp7-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>Radiomics features in XWLC cohort.</title></caption><media xlink:href="elife-95453-supp8-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp9"><label>Supplementary file 9.</label><caption><title>Onco_PPIs identified in four cohorts.</title><p>(a) onco_PPIs in XWLC cohort; (b) onco_PPIs in CNLC cohort; (c) onco_PPIs in TNLCF cohort; (d) onco_PPIs in TSLC cohort.</p></caption><media xlink:href="elife-95453-supp9-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-95453-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Raw sequencing data have been deposited in the Genome Sequence Archive for Human (GSA-Human, <ext-link ext-link-type="uri" xlink:href="https://ngdc.cncb.ac.cn/gsa-human/">https://ngdc.cncb.ac.cn/gsa-human/</ext-link>) under accession codes HRA000124, HRA001481 and HRA001482. Proteomics and phosphoproteomics data have been deposited in the Open Archive for Miscellaneous Data (OMIX, <ext-link ext-link-type="uri" xlink:href="https://ngdc.cncb.ac.cn/omix/">https://ngdc.cncb.ac.cn/omix/</ext-link>) under accession codes OMIX001292. The raw lung CT images used in this paper are available from OMIX under accession codes OMIX002491.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>XWFA</data-title><source>NGDC GSA for Human</source><pub-id pub-id-type="accession" xlink:href="https://ngdc.cncb.ac.cn/gsa-human/browse/HRA000124">HRA000124</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>XWFA_2nd_batch_WES</data-title><source>NGDC GSA for Human</source><pub-id pub-id-type="accession" xlink:href="https://ngdc.cncb.ac.cn/gsa-human/browse/HRA001481">HRA001481</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>XWFA_2nd_batch_RNAseq</data-title><source>NGDC GSA for Human</source><pub-id pub-id-type="accession" xlink:href="https://ngdc.cncb.ac.cn/gsa-human/browse/HRA001482">HRA001482</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset4"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>LCCS proteomics</data-title><source>NGDC OMIX</source><pub-id pub-id-type="accession" xlink:href="https://ngdc.cncb.ac.cn/omix/release/OMIX001292">OMIX001292</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset5"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>lung cancer imaging</data-title><source>NGDC OMIX</source><pub-id pub-id-type="accession" xlink:href="https://ngdc.cncb.ac.cn/omix/release/OMIX002491">OMIX002491</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Kesha Yang from Novogene Co., Ltd., Wenfeng Sun from Scale Biomedicine Technology Co., Ltd. (Beijing, China), and Jingli Li from Beijing Qinglian Biotech Co., Ltd. for their help in sequencing and/or bioinformatics analysis. We also thank the 'Open and Shared Public Science and Technology Service Platform of Traditional Chinese Medicine Science and Technology Resources in Yunnan' for providing experimental platforms and equipment. This work was supported by the National Natural Science Foundation (Nos. 82273501, 82360613, 82160343, 82060519); Yunnan Basic Research Program (Nos. 202101AZ070001-002, 202401AS070070, 202301AY070001-106); Yunnan Young and Middle-aged Academic and Technical Leaders Reserve Talents Project (No. 202005AC160048); Yunnan Provincial Department of Education Science Research Fund Project (2024J0246); 'Famous Doctor' Special Project of Ten Thousand People Plan of Yunnan Province (Nos. CZ0096, YNWR-MY-2020–095); and the Medical Leading Talents Training Program of Yunnan Provincial Health Commission (No. L-2019028).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abd El-Fattah</surname><given-names>EE</given-names></name><name><surname>Abdelhamid</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Benzo[a]pyrene immunogenetics and immune archetype reprogramming of lung</article-title><source>Toxicology</source><volume>463</volume><elocation-id>152994</elocation-id><pub-id pub-id-type="doi">10.1016/j.tox.2021.152994</pub-id><pub-id pub-id-type="pmid">34678320</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Aparicio</surname><given-names>S</given-names></name><name><surname>Behjati</surname><given-names>S</given-names></name><name><surname>Biankin</surname><given-names>AV</given-names></name><name><surname>Bignell</surname><given-names>GR</given-names></name><name><surname>Bolli</surname><given-names>N</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Børresen-Dale</surname><given-names>AL</given-names></name><name><surname>Boyault</surname><given-names>S</given-names></name><name><surname>Burkhardt</surname><given-names>B</given-names></name><name><surname>Butler</surname><given-names>AP</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>Davies</surname><given-names>HR</given-names></name><name><surname>Desmedt</surname><given-names>C</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Eyfjörd</surname><given-names>JE</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name><name><surname>Greaves</surname><given-names>M</given-names></name><name><surname>Hosoda</surname><given-names>F</given-names></name><name><surname>Hutter</surname><given-names>B</given-names></name><name><surname>Ilicic</surname><given-names>T</given-names></name><name><surname>Imbeaud</surname><given-names>S</given-names></name><name><surname>Imielinski</surname><given-names>M</given-names></name><name><surname>Jäger</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>DTW</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Knappskog</surname><given-names>S</given-names></name><name><surname>Kool</surname><given-names>M</given-names></name><name><surname>Lakhani</surname><given-names>SR</given-names></name><name><surname>López-Otín</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Munshi</surname><given-names>NC</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Northcott</surname><given-names>PA</given-names></name><name><surname>Pajic</surname><given-names>M</given-names></name><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><name><surname>Paradiso</surname><given-names>A</given-names></name><name><surname>Pearson</surname><given-names>JV</given-names></name><name><surname>Puente</surname><given-names>XS</given-names></name><name><surname>Raine</surname><given-names>K</given-names></name><name><surname>Ramakrishna</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Richter</surname><given-names>J</given-names></name><name><surname>Rosenstiel</surname><given-names>P</given-names></name><name><surname>Schlesner</surname><given-names>M</given-names></name><name><surname>Schumacher</surname><given-names>TN</given-names></name><name><surname>Span</surname><given-names>PN</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Totoki</surname><given-names>Y</given-names></name><name><surname>Tutt</surname><given-names>ANJ</given-names></name><name><surname>Valdés-Mas</surname><given-names>R</given-names></name><name><surname>van Buuren</surname><given-names>MM</given-names></name><name><surname>van ’t Veer</surname><given-names>L</given-names></name><name><surname>Vincent-Salomon</surname><given-names>A</given-names></name><name><surname>Waddell</surname><given-names>N</given-names></name><name><surname>Yates</surname><given-names>LR</given-names></name><collab>Australian Pancreatic Cancer Genome Initiative</collab><collab>ICGC Breast Cancer Consortium</collab><collab>ICGC MMML-Seq Consortium</collab><collab>ICGC PedBrain</collab><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>McDermott</surname><given-names>U</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Grimmond</surname><given-names>SM</given-names></name><name><surname>Siebert</surname><given-names>R</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Pfister</surname><given-names>SM</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2013">2013a</year><article-title>Signatures of mutational processes in human cancer</article-title><source>Nature</source><volume>500</volume><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/nature12477</pub-id><pub-id pub-id-type="pmid">23945592</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2013">2013b</year><article-title>Deciphering signatures of mutational processes operative in human cancer</article-title><source>Cell Reports</source><volume>3</volume><fpage>246</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2012.12.008</pub-id><pub-id pub-id-type="pmid">23318258</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbie</surname><given-names>DA</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Moody</surname><given-names>SE</given-names></name><name><surname>Dunn</surname><given-names>IF</given-names></name><name><surname>Schinzel</surname><given-names>AC</given-names></name><name><surname>Sandy</surname><given-names>P</given-names></name><name><surname>Meylan</surname><given-names>E</given-names></name><name><surname>Scholl</surname><given-names>C</given-names></name><name><surname>Fröhling</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>EM</given-names></name><name><surname>Sos</surname><given-names>ML</given-names></name><name><surname>Michel</surname><given-names>K</given-names></name><name><surname>Mermel</surname><given-names>C</given-names></name><name><surname>Silver</surname><given-names>SJ</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Reiling</surname><given-names>JH</given-names></name><name><surname>Sheng</surname><given-names>Q</given-names></name><name><surname>Gupta</surname><given-names>PB</given-names></name><name><surname>Wadlow</surname><given-names>RC</given-names></name><name><surname>Le</surname><given-names>H</given-names></name><name><surname>Hoersch</surname><given-names>S</given-names></name><name><surname>Wittner</surname><given-names>BS</given-names></name><name><surname>Ramaswamy</surname><given-names>S</given-names></name><name><surname>Livingston</surname><given-names>DM</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>RK</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1</article-title><source>Nature</source><volume>462</volume><fpage>108</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1038/nature08460</pub-id><pub-id pub-id-type="pmid">19847166</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barone-Adesi</surname><given-names>F</given-names></name><name><surname>Chapman</surname><given-names>RS</given-names></name><name><surname>Silverman</surname><given-names>DT</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Vermeulen</surname><given-names>R</given-names></name><name><surname>Ning</surname><given-names>B</given-names></name><name><surname>Fraumeni</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Rothman</surname><given-names>N</given-names></name><name><surname>Lan</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Risk of lung cancer associated with domestic use of coal in Xuanwei, China: retrospective cohort study</article-title><source>BMJ</source><volume>345</volume><elocation-id>e5414</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.e5414</pub-id><pub-id pub-id-type="pmid">22936785</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>M-J</given-names></name><name><surname>Orchard</surname><given-names>S</given-names></name><name><surname>Magrane</surname><given-names>M</given-names></name><name><surname>Agivetova</surname><given-names>R</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Alpi</surname><given-names>E</given-names></name><name><surname>Bowler-Barnett</surname><given-names>EH</given-names></name><name><surname>Britto</surname><given-names>R</given-names></name><name><surname>Bursteinas</surname><given-names>B</given-names></name><name><surname>Bye-A-Jee</surname><given-names>H</given-names></name><name><surname>Coetzee</surname><given-names>R</given-names></name><name><surname>Cukura</surname><given-names>A</given-names></name><name><surname>Da Silva</surname><given-names>A</given-names></name><name><surname>Denny</surname><given-names>P</given-names></name><name><surname>Dogan</surname><given-names>T</given-names></name><name><surname>Ebenezer</surname><given-names>T</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Castro</surname><given-names>LG</given-names></name><name><surname>Garmiri</surname><given-names>P</given-names></name><name><surname>Georghiou</surname><given-names>G</given-names></name><name><surname>Gonzales</surname><given-names>L</given-names></name><name><surname>Hatton-Ellis</surname><given-names>E</given-names></name><name><surname>Hussein</surname><given-names>A</given-names></name><name><surname>Ignatchenko</surname><given-names>A</given-names></name><name><surname>Insana</surname><given-names>G</given-names></name><name><surname>Ishtiaq</surname><given-names>R</given-names></name><name><surname>Jokinen</surname><given-names>P</given-names></name><name><surname>Joshi</surname><given-names>V</given-names></name><name><surname>Jyothi</surname><given-names>D</given-names></name><name><surname>Lock</surname><given-names>A</given-names></name><name><surname>Lopez</surname><given-names>R</given-names></name><name><surname>Luciani</surname><given-names>A</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Lussi</surname><given-names>Y</given-names></name><name><surname>MacDougall</surname><given-names>A</given-names></name><name><surname>Madeira</surname><given-names>F</given-names></name><name><surname>Mahmoudy</surname><given-names>M</given-names></name><name><surname>Menchi</surname><given-names>M</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Moulang</surname><given-names>K</given-names></name><name><surname>Nightingale</surname><given-names>A</given-names></name><name><surname>Oliveira</surname><given-names>CS</given-names></name><name><surname>Pundir</surname><given-names>S</given-names></name><name><surname>Qi</surname><given-names>G</given-names></name><name><surname>Raj</surname><given-names>S</given-names></name><name><surname>Rice</surname><given-names>D</given-names></name><name><surname>Lopez</surname><given-names>MR</given-names></name><name><surname>Saidi</surname><given-names>R</given-names></name><name><surname>Sampson</surname><given-names>J</given-names></name><name><surname>Sawford</surname><given-names>T</given-names></name><name><surname>Speretta</surname><given-names>E</given-names></name><name><surname>Turner</surname><given-names>E</given-names></name><name><surname>Tyagi</surname><given-names>N</given-names></name><name><surname>Vasudev</surname><given-names>P</given-names></name><name><surname>Volynkin</surname><given-names>V</given-names></name><name><surname>Warner</surname><given-names>K</given-names></name><name><surname>Watkins</surname><given-names>X</given-names></name><name><surname>Zaru</surname><given-names>R</given-names></name><name><surname>Zellner</surname><given-names>H</given-names></name><name><surname>Bridge</surname><given-names>A</given-names></name><name><surname>Poux</surname><given-names>S</given-names></name><name><surname>Redaschi</surname><given-names>N</given-names></name><name><surname>Aimo</surname><given-names>L</given-names></name><name><surname>Argoud-Puy</surname><given-names>G</given-names></name><name><surname>Auchincloss</surname><given-names>A</given-names></name><name><surname>Axelsen</surname><given-names>K</given-names></name><name><surname>Bansal</surname><given-names>P</given-names></name><name><surname>Baratin</surname><given-names>D</given-names></name><name><surname>Blatter</surname><given-names>M-C</given-names></name><name><surname>Bolleman</surname><given-names>J</given-names></name><name><surname>Boutet</surname><given-names>E</given-names></name><name><surname>Breuza</surname><given-names>L</given-names></name><name><surname>Casals-Casas</surname><given-names>C</given-names></name><name><surname>de Castro</surname><given-names>E</given-names></name><name><surname>Echioukh</surname><given-names>KC</given-names></name><name><surname>Coudert</surname><given-names>E</given-names></name><name><surname>Cuche</surname><given-names>B</given-names></name><name><surname>Doche</surname><given-names>M</given-names></name><name><surname>Dornevil</surname><given-names>D</given-names></name><name><surname>Estreicher</surname><given-names>A</given-names></name><name><surname>Famiglietti</surname><given-names>ML</given-names></name><name><surname>Feuermann</surname><given-names>M</given-names></name><name><surname>Gasteiger</surname><given-names>E</given-names></name><name><surname>Gehant</surname><given-names>S</given-names></name><name><surname>Gerritsen</surname><given-names>V</given-names></name><name><surname>Gos</surname><given-names>A</given-names></name><name><surname>Gruaz-Gumowski</surname><given-names>N</given-names></name><name><surname>Hinz</surname><given-names>U</given-names></name><name><surname>Hulo</surname><given-names>C</given-names></name><name><surname>Hyka-Nouspikel</surname><given-names>N</given-names></name><name><surname>Jungo</surname><given-names>F</given-names></name><name><surname>Keller</surname><given-names>G</given-names></name><name><surname>Kerhornou</surname><given-names>A</given-names></name><name><surname>Lara</surname><given-names>V</given-names></name><name><surname>Le Mercier</surname><given-names>P</given-names></name><name><surname>Lieberherr</surname><given-names>D</given-names></name><name><surname>Lombardot</surname><given-names>T</given-names></name><name><surname>Martin</surname><given-names>X</given-names></name><name><surname>Masson</surname><given-names>P</given-names></name><name><surname>Morgat</surname><given-names>A</given-names></name><name><surname>Neto</surname><given-names>TB</given-names></name><name><surname>Paesano</surname><given-names>S</given-names></name><name><surname>Pedruzzi</surname><given-names>I</given-names></name><name><surname>Pilbout</surname><given-names>S</given-names></name><name><surname>Pourcel</surname><given-names>L</given-names></name><name><surname>Pozzato</surname><given-names>M</given-names></name><name><surname>Pruess</surname><given-names>M</given-names></name><name><surname>Rivoire</surname><given-names>C</given-names></name><name><surname>Sigrist</surname><given-names>C</given-names></name><name><surname>Sonesson</surname><given-names>K</given-names></name><name><surname>Stutz</surname><given-names>A</given-names></name><name><surname>Sundaram</surname><given-names>S</given-names></name><name><surname>Tognolli</surname><given-names>M</given-names></name><name><surname>Verbregue</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>CH</given-names></name><name><surname>Arighi</surname><given-names>CN</given-names></name><name><surname>Arminski</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Garavelli</surname><given-names>JS</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Laiho</surname><given-names>K</given-names></name><name><surname>McGarvey</surname><given-names>P</given-names></name><name><surname>Natale</surname><given-names>DA</given-names></name><name><surname>Ross</surname><given-names>K</given-names></name><name><surname>Vinayaka</surname><given-names>CR</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yeh</surname><given-names>L-S</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ruch</surname><given-names>P</given-names></name><name><surname>Teodoro</surname><given-names>D</given-names></name><collab>The UniProt Consortium</collab></person-group><year iso-8601-date="2021">2021</year><article-title>UniProt: the universal protein knowledgebase in 2021</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>D480</fpage><lpage>D489</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa1100</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA</source><volume>68</volume><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cairns</surname><given-names>RA</given-names></name><name><surname>Harris</surname><given-names>IS</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Regulation of cancer cell metabolism</article-title><source>Nature Reviews. Cancer</source><volume>11</volume><fpage>85</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1038/nrc2981</pub-id><pub-id pub-id-type="pmid">21258394</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cancer Genome Atlas Research</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Comprehensive molecular profiling of lung adenocarcinoma</article-title><source>Nature</source><volume>511</volume><fpage>543</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/nature13385</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmeliet</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Angiogenesis in life, disease and medicine</article-title><source>Nature</source><volume>438</volume><fpage>932</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1038/nature04478</pub-id><pub-id pub-id-type="pmid">16355210</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casado</surname><given-names>P</given-names></name><name><surname>Rodriguez-Prados</surname><given-names>J-C</given-names></name><name><surname>Cosulich</surname><given-names>SC</given-names></name><name><surname>Guichard</surname><given-names>S</given-names></name><name><surname>Vanhaesebroeck</surname><given-names>B</given-names></name><name><surname>Joel</surname><given-names>S</given-names></name><name><surname>Cutillas</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>rs6</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2003573</pub-id><pub-id pub-id-type="pmid">23532336</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakravarty</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Phillips</surname><given-names>SM</given-names></name><name><surname>Kundra</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Rudolph</surname><given-names>JE</given-names></name><name><surname>Yaeger</surname><given-names>R</given-names></name><name><surname>Soumerai</surname><given-names>T</given-names></name><name><surname>Nissan</surname><given-names>MH</given-names></name><name><surname>Chang</surname><given-names>MT</given-names></name><name><surname>Chandarlapaty</surname><given-names>S</given-names></name><name><surname>Traina</surname><given-names>TA</given-names></name><name><surname>Paik</surname><given-names>PK</given-names></name><name><surname>Ho</surname><given-names>AL</given-names></name><name><surname>Hantash</surname><given-names>FM</given-names></name><name><surname>Grupe</surname><given-names>A</given-names></name><name><surname>Baxi</surname><given-names>SS</given-names></name><name><surname>Callahan</surname><given-names>MK</given-names></name><name><surname>Snyder</surname><given-names>A</given-names></name><name><surname>Chi</surname><given-names>P</given-names></name><name><surname>Danila</surname><given-names>D</given-names></name><name><surname>Gounder</surname><given-names>M</given-names></name><name><surname>Harding</surname><given-names>JJ</given-names></name><name><surname>Hellmann</surname><given-names>MD</given-names></name><name><surname>Iyer</surname><given-names>G</given-names></name><name><surname>Janjigian</surname><given-names>Y</given-names></name><name><surname>Kaley</surname><given-names>T</given-names></name><name><surname>Levine</surname><given-names>DA</given-names></name><name><surname>Lowery</surname><given-names>M</given-names></name><name><surname>Omuro</surname><given-names>A</given-names></name><name><surname>Postow</surname><given-names>MA</given-names></name><name><surname>Rathkopf</surname><given-names>D</given-names></name><name><surname>Shoushtari</surname><given-names>AN</given-names></name><name><surname>Shukla</surname><given-names>N</given-names></name><name><surname>Voss</surname><given-names>M</given-names></name><name><surname>Paraiso</surname><given-names>E</given-names></name><name><surname>Zehir</surname><given-names>A</given-names></name><name><surname>Berger</surname><given-names>MF</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Saltz</surname><given-names>LB</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Hyman</surname><given-names>DM</given-names></name><name><surname>Baselga</surname><given-names>J</given-names></name><name><surname>Sabbatini</surname><given-names>P</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>OncoKB: A precision oncology knowledge base</article-title><source>JCO Precision Oncology</source><volume>2017</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1200/PO.17.00011</pub-id><pub-id pub-id-type="pmid">28890946</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>RS</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Blair</surname><given-names>AE</given-names></name><name><surname>Lan</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Improvement in household stoves and risk of chronic obstructive pulmonary disease in Xuanwei, China: retrospective cohort study</article-title><source>BMJ</source><volume>331</volume><elocation-id>1050</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.38628.676088.55</pub-id><pub-id pub-id-type="pmid">16234255</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charoentong</surname><given-names>P</given-names></name><name><surname>Finotello</surname><given-names>F</given-names></name><name><surname>Angelova</surname><given-names>M</given-names></name><name><surname>Mayer</surname><given-names>C</given-names></name><name><surname>Efremova</surname><given-names>M</given-names></name><name><surname>Rieder</surname><given-names>D</given-names></name><name><surname>Hackl</surname><given-names>H</given-names></name><name><surname>Trajanoski</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade</article-title><source>Cell Reports</source><volume>18</volume><fpage>248</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.12.019</pub-id><pub-id pub-id-type="pmid">28052254</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Roumeliotis</surname><given-names>TI</given-names></name><name><surname>Chang</surname><given-names>YH</given-names></name><name><surname>Chen</surname><given-names>CT</given-names></name><name><surname>Han</surname><given-names>CL</given-names></name><name><surname>Lin</surname><given-names>MH</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>Chang</surname><given-names>GC</given-names></name><name><surname>Chang</surname><given-names>YL</given-names></name><name><surname>Wu</surname><given-names>CT</given-names></name><name><surname>Lin</surname><given-names>MW</given-names></name><name><surname>Hsieh</surname><given-names>MS</given-names></name><name><surname>Wang</surname><given-names>YT</given-names></name><name><surname>Chen</surname><given-names>YR</given-names></name><name><surname>Jonassen</surname><given-names>I</given-names></name><name><surname>Ghavidel</surname><given-names>FZ</given-names></name><name><surname>Lin</surname><given-names>ZS</given-names></name><name><surname>Lin</surname><given-names>KT</given-names></name><name><surname>Chen</surname><given-names>CW</given-names></name><name><surname>Sheu</surname><given-names>PY</given-names></name><name><surname>Hung</surname><given-names>CT</given-names></name><name><surname>Huang</surname><given-names>KC</given-names></name><name><surname>Yang</surname><given-names>HC</given-names></name><name><surname>Lin</surname><given-names>PY</given-names></name><name><surname>Yen</surname><given-names>TC</given-names></name><name><surname>Lin</surname><given-names>YW</given-names></name><name><surname>Wang</surname><given-names>JH</given-names></name><name><surname>Raghav</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>YS</given-names></name><name><surname>Wu</surname><given-names>PS</given-names></name><name><surname>Lai</surname><given-names>CT</given-names></name><name><surname>Weng</surname><given-names>SH</given-names></name><name><surname>Su</surname><given-names>KY</given-names></name><name><surname>Chang</surname><given-names>WH</given-names></name><name><surname>Tsai</surname><given-names>PY</given-names></name><name><surname>Robles</surname><given-names>AI</given-names></name><name><surname>Rodriguez</surname><given-names>H</given-names></name><name><surname>Hsiao</surname><given-names>YJ</given-names></name><name><surname>Chang</surname><given-names>WH</given-names></name><name><surname>Sung</surname><given-names>TY</given-names></name><name><surname>Chen</surname><given-names>JS</given-names></name><name><surname>Yu</surname><given-names>SL</given-names></name><name><surname>Choudhary</surname><given-names>JS</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Yang</surname><given-names>PC</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Proteogenomics of non-smoking lung cancer in east asia delineates molecular signatures of pathogenesis and progression</article-title><source>Cell</source><volume>182</volume><fpage>226</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.012</pub-id><pub-id pub-id-type="pmid">32649875</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Teo</surname><given-names>ASM</given-names></name><name><surname>Amer</surname><given-names>LB</given-names></name><name><surname>Sherbaf</surname><given-names>FG</given-names></name><name><surname>Tan</surname><given-names>CQ</given-names></name><name><surname>Alvarez</surname><given-names>JJS</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Lim</surname><given-names>JQ</given-names></name><name><surname>Takano</surname><given-names>A</given-names></name><name><surname>Nahar</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>YY</given-names></name><name><surname>Phua</surname><given-names>CZJ</given-names></name><name><surname>Chua</surname><given-names>KP</given-names></name><name><surname>Suteja</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Chang</surname><given-names>MM</given-names></name><name><surname>Koh</surname><given-names>TPT</given-names></name><name><surname>Ong</surname><given-names>B-H</given-names></name><name><surname>Anantham</surname><given-names>D</given-names></name><name><surname>Hsu</surname><given-names>AAL</given-names></name><name><surname>Gogna</surname><given-names>A</given-names></name><name><surname>Too</surname><given-names>CW</given-names></name><name><surname>Aung</surname><given-names>ZW</given-names></name><name><surname>Lee</surname><given-names>YF</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Lim</surname><given-names>TKH</given-names></name><name><surname>Wilm</surname><given-names>A</given-names></name><name><surname>Choi</surname><given-names>PS</given-names></name><name><surname>Ng</surname><given-names>PY</given-names></name><name><surname>Toh</surname><given-names>CK</given-names></name><name><surname>Lim</surname><given-names>W-T</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Lim</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Tam</surname><given-names>WL</given-names></name><name><surname>Skanderup</surname><given-names>AJ</given-names></name><name><surname>Yeong</surname><given-names>JPS</given-names></name><name><surname>Tan</surname><given-names>E-H</given-names></name><name><surname>Creasy</surname><given-names>CL</given-names></name><name><surname>Tan</surname><given-names>DSW</given-names></name><name><surname>Hillmer</surname><given-names>AM</given-names></name><name><surname>Zhai</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Genomic landscape of lung adenocarcinoma in East Asians</article-title><source>Nature Genetics</source><volume>52</volume><fpage>177</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/s41588-019-0569-6</pub-id><pub-id pub-id-type="pmid">32015526</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Martin</surname><given-names>WR</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Hao</surname><given-names>T</given-names></name><name><surname>Yue</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Castrillon</surname><given-names>JA</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Lathia</surname><given-names>JD</given-names></name><name><surname>Keri</surname><given-names>RA</given-names></name><name><surname>Lightstone</surname><given-names>FC</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name><name><surname>Rabadan</surname><given-names>R</given-names></name><name><surname>Hill</surname><given-names>DE</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Vidal</surname><given-names>M</given-names></name><name><surname>Loscalzo</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Comprehensive characterization of protein-protein interactions perturbed by disease mutations</article-title><source>Nature Genetics</source><volume>53</volume><fpage>342</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1038/s41588-020-00774-y</pub-id><pub-id pub-id-type="pmid">33558758</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiu</surname><given-names>C-H</given-names></name><name><surname>Yang</surname><given-names>C-T</given-names></name><name><surname>Shih</surname><given-names>J-Y</given-names></name><name><surname>Huang</surname><given-names>M-S</given-names></name><name><surname>Su</surname><given-names>W-C</given-names></name><name><surname>Lai</surname><given-names>R-S</given-names></name><name><surname>Wang</surname><given-names>C-C</given-names></name><name><surname>Hsiao</surname><given-names>S-H</given-names></name><name><surname>Lin</surname><given-names>Y-C</given-names></name><name><surname>Ho</surname><given-names>C-L</given-names></name><name><surname>Hsia</surname><given-names>T-C</given-names></name><name><surname>Wu</surname><given-names>M-F</given-names></name><name><surname>Lai</surname><given-names>C-L</given-names></name><name><surname>Lee</surname><given-names>K-Y</given-names></name><name><surname>Lin</surname><given-names>C-B</given-names></name><name><surname>Yu-Wung Yeh</surname><given-names>D</given-names></name><name><surname>Chuang</surname><given-names>C-Y</given-names></name><name><surname>Chang</surname><given-names>F-K</given-names></name><name><surname>Tsai</surname><given-names>C-M</given-names></name><name><surname>Perng</surname><given-names>R-P</given-names></name><name><surname>Chih-Hsin Yang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations</article-title><source>Journal of Thoracic Oncology</source><volume>10</volume><fpage>793</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1097/JTO.0000000000000504</pub-id><pub-id pub-id-type="pmid">25668120</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Lim</surname><given-names>SH</given-names></name><name><surname>An</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Park</surname><given-names>KU</given-names></name><name><surname>Kang</surname><given-names>EJ</given-names></name><name><surname>Choi</surname><given-names>YH</given-names></name><name><surname>Ahn</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>MH</given-names></name><name><surname>Sun</surname><given-names>J-M</given-names></name><name><surname>Lee</surname><given-names>S-H</given-names></name><name><surname>Ahn</surname><given-names>JS</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Ahn</surname><given-names>M-J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09)</article-title><source>Journal of Clinical Oncology</source><volume>38</volume><fpage>488</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.00931</pub-id><pub-id pub-id-type="pmid">31825714</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>J-Y</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>Y-J</given-names></name><name><surname>Jung</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>J-E</given-names></name><name><surname>Lee</surname><given-names>SG</given-names></name><name><surname>Kim</surname><given-names>JT</given-names></name><name><surname>Oh</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>CJ</given-names></name><name><surname>Yoon</surname><given-names>Y-D</given-names></name><name><surname>Yoo</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>J-M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Cellular defense mechanisms against benzo[a]pyrene in testicular Leydig cells: implications of p53, aryl-hydrocarbon receptor, and cytochrome P450 1A1 status</article-title><source>Endocrinology</source><volume>148</volume><fpage>6134</fpage><lpage>6144</lpage><pub-id pub-id-type="doi">10.1210/en.2007-0006</pub-id><pub-id pub-id-type="pmid">17884947</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cogliano</surname><given-names>VJ</given-names></name><name><surname>Baan</surname><given-names>R</given-names></name><name><surname>Straif</surname><given-names>K</given-names></name><name><surname>Grosse</surname><given-names>Y</given-names></name><name><surname>Lauby-Secretan</surname><given-names>B</given-names></name><name><surname>El Ghissassi</surname><given-names>F</given-names></name><name><surname>Bouvard</surname><given-names>V</given-names></name><name><surname>Benbrahim-Tallaa</surname><given-names>L</given-names></name><name><surname>Guha</surname><given-names>N</given-names></name><name><surname>Freeman</surname><given-names>C</given-names></name><name><surname>Galichet</surname><given-names>L</given-names></name><name><surname>Wild</surname><given-names>CP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Preventable exposures associated with human cancers</article-title><source>Journal of the National Cancer Institute</source><volume>103</volume><fpage>1827</fpage><lpage>1839</lpage><pub-id pub-id-type="doi">10.1093/jnci/djr483</pub-id><pub-id pub-id-type="pmid">22158127</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cellular metabolism and disease: what do metabolic outliers teach us?</article-title><source>Cell</source><volume>148</volume><fpage>1132</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.032</pub-id><pub-id pub-id-type="pmid">22424225</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ettinger</surname><given-names>DS</given-names></name><name><surname>Wood</surname><given-names>DE</given-names></name><name><surname>Aisner</surname><given-names>DL</given-names></name><name><surname>Akerley</surname><given-names>W</given-names></name><name><surname>Bauman</surname><given-names>JR</given-names></name><name><surname>Bharat</surname><given-names>A</given-names></name><name><surname>Bruno</surname><given-names>DS</given-names></name><name><surname>Chang</surname><given-names>JY</given-names></name><name><surname>Chirieac</surname><given-names>LR</given-names></name><name><surname>D’Amico</surname><given-names>TA</given-names></name><name><surname>DeCamp</surname><given-names>M</given-names></name><name><surname>Dilling</surname><given-names>TJ</given-names></name><name><surname>Dowell</surname><given-names>J</given-names></name><name><surname>Gettinger</surname><given-names>S</given-names></name><name><surname>Grotz</surname><given-names>TE</given-names></name><name><surname>Gubens</surname><given-names>MA</given-names></name><name><surname>Hegde</surname><given-names>A</given-names></name><name><surname>Lackner</surname><given-names>RP</given-names></name><name><surname>Lanuti</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Loo</surname><given-names>BW</given-names></name><name><surname>Lovly</surname><given-names>CM</given-names></name><name><surname>Maldonado</surname><given-names>F</given-names></name><name><surname>Massarelli</surname><given-names>E</given-names></name><name><surname>Morgensztern</surname><given-names>D</given-names></name><name><surname>Ng</surname><given-names>T</given-names></name><name><surname>Otterson</surname><given-names>GA</given-names></name><name><surname>Pacheco</surname><given-names>JM</given-names></name><name><surname>Patel</surname><given-names>SP</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Riess</surname><given-names>J</given-names></name><name><surname>Schild</surname><given-names>SE</given-names></name><name><surname>Shapiro</surname><given-names>TA</given-names></name><name><surname>Singh</surname><given-names>AP</given-names></name><name><surname>Stevenson</surname><given-names>J</given-names></name><name><surname>Tam</surname><given-names>A</given-names></name><name><surname>Tanvetyanon</surname><given-names>T</given-names></name><name><surname>Yanagawa</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>SC</given-names></name><name><surname>Yau</surname><given-names>E</given-names></name><name><surname>Gregory</surname><given-names>K</given-names></name><name><surname>Hughes</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology</article-title><source>Journal of the National Comprehensive Cancer Network</source><volume>20</volume><fpage>497</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2022.0025</pub-id><pub-id pub-id-type="pmid">35545176</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fajersztajn</surname><given-names>L</given-names></name><name><surname>Veras</surname><given-names>M</given-names></name><name><surname>Barrozo</surname><given-names>LV</given-names></name><name><surname>Saldiva</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Air pollution: a potentially modifiable risk factor for lung cancer</article-title><source>Nature Reviews. Cancer</source><volume>13</volume><fpage>674</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1038/nrc3572</pub-id><pub-id pub-id-type="pmid">23924644</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedorov</surname><given-names>A</given-names></name><name><surname>Beichel</surname><given-names>R</given-names></name><name><surname>Kalpathy-Cramer</surname><given-names>J</given-names></name><name><surname>Finet</surname><given-names>J</given-names></name><name><surname>Fillion-Robin</surname><given-names>J-C</given-names></name><name><surname>Pujol</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>C</given-names></name><name><surname>Jennings</surname><given-names>D</given-names></name><name><surname>Fennessy</surname><given-names>F</given-names></name><name><surname>Sonka</surname><given-names>M</given-names></name><name><surname>Buatti</surname><given-names>J</given-names></name><name><surname>Aylward</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>JV</given-names></name><name><surname>Pieper</surname><given-names>S</given-names></name><name><surname>Kikinis</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>3D slicer as an image computing platform for the quantitative imaging network</article-title><source>Magnetic Resonance Imaging</source><volume>30</volume><fpage>1323</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1016/j.mri.2012.05.001</pub-id><pub-id pub-id-type="pmid">22770690</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrar</surname><given-names>T</given-names></name><name><surname>Chamousset</surname><given-names>D</given-names></name><name><surname>De Wever</surname><given-names>V</given-names></name><name><surname>Nimick</surname><given-names>M</given-names></name><name><surname>Andersen</surname><given-names>J</given-names></name><name><surname>Trinkle-Mulcahy</surname><given-names>L</given-names></name><name><surname>Moorhead</surname><given-names>GBG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Taperin (c9orf75), a mutated gene in nonsyndromic deafness, encodes a vertebrate specific, nuclear localized protein phosphatase one alpha (PP1α) docking protein</article-title><source>Biology Open</source><volume>1</volume><fpage>128</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1242/bio.2011049</pub-id><pub-id pub-id-type="pmid">23213405</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Floc’h</surname><given-names>N</given-names></name><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Bickerton</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Orme</surname><given-names>J</given-names></name><name><surname>Urosevic</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>MJ</given-names></name><name><surname>Cross</surname><given-names>DAE</given-names></name><name><surname>Cho</surname><given-names>BC</given-names></name><name><surname>Smith</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Osimertinib, an irreversible next-generation EGFR tyrosine kinase inhibitor, exerts antitumor activity in various preclinical NSCLC models harboring the uncommon EGFR mutations G719X or L861Q or S768I</article-title><source>Molecular Cancer Therapeutics</source><volume>19</volume><fpage>2298</fpage><lpage>2307</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-20-0103</pub-id><pub-id pub-id-type="pmid">32943544</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>J</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regularization paths for generalized linear models via coordinate descent</article-title><source>Journal of Statistical Software</source><volume>33</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">20808728</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gehring</surname><given-names>JS</given-names></name><name><surname>Fischer</surname><given-names>B</given-names></name><name><surname>Lawrence</surname><given-names>M</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>SomaticSignatures: inferring mutational signatures from single-nucleotide variants</article-title><source>Bioinformatics</source><volume>31</volume><fpage>3673</fpage><lpage>3675</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btv408</pub-id><pub-id pub-id-type="pmid">26163694</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Satpathy</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name><name><surname>Vasaikar</surname><given-names>SV</given-names></name><name><surname>Krug</surname><given-names>K</given-names></name><name><surname>Petralia</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>WW</given-names></name><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Krek</surname><given-names>A</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Hong</surname><given-names>R</given-names></name><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Blumenberg</surname><given-names>L</given-names></name><name><surname>Savage</surname><given-names>SR</given-names></name><name><surname>Wendl</surname><given-names>MC</given-names></name><name><surname>Wen</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Tang</surname><given-names>LC</given-names></name><name><surname>MacMullan</surname><given-names>MA</given-names></name><name><surname>Avanessian</surname><given-names>SC</given-names></name><name><surname>Kane</surname><given-names>MH</given-names></name><name><surname>Newton</surname><given-names>CJ</given-names></name><name><surname>Cornwell</surname><given-names>M</given-names></name><name><surname>Kothadia</surname><given-names>RB</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Yoo</surname><given-names>S</given-names></name><name><surname>Mannan</surname><given-names>R</given-names></name><name><surname>Vats</surname><given-names>P</given-names></name><name><surname>Kumar-Sinha</surname><given-names>C</given-names></name><name><surname>Kawaler</surname><given-names>EA</given-names></name><name><surname>Omelchenko</surname><given-names>T</given-names></name><name><surname>Colaprico</surname><given-names>A</given-names></name><name><surname>Geffen</surname><given-names>Y</given-names></name><name><surname>Maruvka</surname><given-names>YE</given-names></name><name><surname>da Veiga Leprevost</surname><given-names>F</given-names></name><name><surname>Wiznerowicz</surname><given-names>M</given-names></name><name><surname>Gümüş</surname><given-names>ZH</given-names></name><name><surname>Veluswamy</surname><given-names>RR</given-names></name><name><surname>Hostetter</surname><given-names>G</given-names></name><name><surname>Heiman</surname><given-names>DI</given-names></name><name><surname>Wyczalkowski</surname><given-names>MA</given-names></name><name><surname>Hiltke</surname><given-names>T</given-names></name><name><surname>Mesri</surname><given-names>M</given-names></name><name><surname>Kinsinger</surname><given-names>CR</given-names></name><name><surname>Boja</surname><given-names>ES</given-names></name><name><surname>Omenn</surname><given-names>GS</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>Rodriguez</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>QK</given-names></name><name><surname>Jewell</surname><given-names>SD</given-names></name><name><surname>Thiagarajan</surname><given-names>M</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Fenyö</surname><given-names>D</given-names></name><name><surname>Ruggles</surname><given-names>KV</given-names></name><name><surname>Cieslik</surname><given-names>MP</given-names></name><name><surname>Robles</surname><given-names>AI</given-names></name><name><surname>Clauser</surname><given-names>KR</given-names></name><name><surname>Govindan</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Nesvizhskii</surname><given-names>AI</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Mani</surname><given-names>DR</given-names></name><name><surname>Carr</surname><given-names>SA</given-names></name><name><surname>Webster</surname><given-names>A</given-names></name><name><surname>Francis</surname><given-names>A</given-names></name><name><surname>Charamut</surname><given-names>A</given-names></name><name><surname>Paulovich</surname><given-names>AG</given-names></name><name><surname>Perou</surname><given-names>AM</given-names></name><name><surname>Godwin</surname><given-names>AK</given-names></name><name><surname>Karnuta</surname><given-names>A</given-names></name><name><surname>Marrero-Oliveras</surname><given-names>A</given-names></name><name><surname>Hindenach</surname><given-names>B</given-names></name><name><surname>Pruetz</surname><given-names>B</given-names></name><name><surname>Kubisa</surname><given-names>B</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Birger</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>CD</given-names></name><name><surname>Valley</surname><given-names>DR</given-names></name><name><surname>Rohrer</surname><given-names>DC</given-names></name><name><surname>Zhou</surname><given-names>DC</given-names></name><name><surname>Chan</surname><given-names>DW</given-names></name><name><surname>Chesla</surname><given-names>D</given-names></name><name><surname>Clark</surname><given-names>DJ</given-names></name><name><surname>Rykunov</surname><given-names>D</given-names></name><name><surname>Tan</surname><given-names>D</given-names></name><name><surname>Ponomareva</surname><given-names>EV</given-names></name><name><surname>Duffy</surname><given-names>E</given-names></name><name><surname>Burks</surname><given-names>EJ</given-names></name><name><surname>Schadt</surname><given-names>EE</given-names></name><name><surname>Bergstrom</surname><given-names>EJ</given-names></name><name><surname>Fedorov</surname><given-names>ES</given-names></name><name><surname>Malc</surname><given-names>E</given-names></name><name><surname>Wilson</surname><given-names>GD</given-names></name><name><surname>Chen</surname><given-names>HQ</given-names></name><name><surname>Krzystek</surname><given-names>HM</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Culpepper</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Day</surname><given-names>J</given-names></name><name><surname>Suh</surname><given-names>J</given-names></name><name><surname>Whiteaker</surname><given-names>JR</given-names></name><name><surname>Eschbacher</surname><given-names>J</given-names></name><name><surname>McGee</surname><given-names>J</given-names></name><name><surname>Ketchum</surname><given-names>KA</given-names></name><name><surname>Rodland</surname><given-names>KD</given-names></name><name><surname>Robinson</surname><given-names>K</given-names></name><name><surname>Hoadley</surname><given-names>KA</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Um</surname><given-names>KS</given-names></name><name><surname>Elburn</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>LB</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Hannick</surname><given-names>L</given-names></name><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Sokoll</surname><given-names>LJ</given-names></name><name><surname>Wojtyś</surname><given-names>M</given-names></name><name><surname>Domagalski</surname><given-names>MJ</given-names></name><name><surname>Gritsenko</surname><given-names>MA</given-names></name><name><surname>Beasley</surname><given-names>MB</given-names></name><name><surname>Monroe</surname><given-names>ME</given-names></name><name><surname>Ellis</surname><given-names>MJ</given-names></name><name><surname>Dyer</surname><given-names>M</given-names></name><name><surname>Burke</surname><given-names>MC</given-names></name><name><surname>Borucki</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>MH</given-names></name><name><surname>Roehrl</surname><given-names>MH</given-names></name><name><surname>Birrer</surname><given-names>MJ</given-names></name><name><surname>Noble</surname><given-names>M</given-names></name><name><surname>Schnaubelt</surname><given-names>M</given-names></name><name><surname>Vernon</surname><given-names>M</given-names></name><name><surname>Chaikin</surname><given-names>M</given-names></name><name><surname>Krotevich</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Selvan</surname><given-names>ME</given-names></name><name><surname>Roche</surname><given-names>N</given-names></name><name><surname>Edwards</surname><given-names>NJ</given-names></name><name><surname>Vatanian</surname><given-names>N</given-names></name><name><surname>Potapova</surname><given-names>O</given-names></name><name><surname>Grady</surname><given-names>P</given-names></name><name><surname>McGarvey</surname><given-names>PB</given-names></name><name><surname>Mieczkowski</surname><given-names>P</given-names></name><name><surname>Hariharan</surname><given-names>P</given-names></name><name><surname>Madan</surname><given-names>R</given-names></name><name><surname>Thangudu</surname><given-names>RR</given-names></name><name><surname>Smith</surname><given-names>RD</given-names></name><name><surname>Welsh</surname><given-names>RJ</given-names></name><name><surname>Zelt</surname><given-names>R</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Matteotti</surname><given-names>R</given-names></name><name><surname>Mareedu</surname><given-names>S</given-names></name><name><surname>Payne</surname><given-names>SH</given-names></name><name><surname>Cottingham</surname><given-names>S</given-names></name><name><surname>Markey</surname><given-names>SP</given-names></name><name><surname>Chugh</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Tsang</surname><given-names>S</given-names></name><name><surname>Cai</surname><given-names>S</given-names></name><name><surname>Boca</surname><given-names>SM</given-names></name><name><surname>Carter</surname><given-names>S</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>De Young</surname><given-names>S</given-names></name><name><surname>Stein</surname><given-names>SE</given-names></name><name><surname>Shankar</surname><given-names>S</given-names></name><name><surname>Krubit</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Skelly</surname><given-names>T</given-names></name><name><surname>Bauer</surname><given-names>T</given-names></name><name><surname>Velvulou</surname><given-names>U</given-names></name><name><surname>Ozbek</surname><given-names>U</given-names></name><name><surname>Petyuk</surname><given-names>VA</given-names></name><name><surname>Sovenko</surname><given-names>V</given-names></name><name><surname>Bocik</surname><given-names>WE</given-names></name><name><surname>Maggio</surname><given-names>WW</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma</article-title><source>Cell</source><volume>182</volume><fpage>200</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.013</pub-id><pub-id pub-id-type="pmid">32649874</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govindan</surname><given-names>R</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Griffith</surname><given-names>M</given-names></name><name><surname>Subramanian</surname><given-names>J</given-names></name><name><surname>Dees</surname><given-names>ND</given-names></name><name><surname>Kanchi</surname><given-names>KL</given-names></name><name><surname>Maher</surname><given-names>CA</given-names></name><name><surname>Fulton</surname><given-names>R</given-names></name><name><surname>Fulton</surname><given-names>L</given-names></name><name><surname>Wallis</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Walker</surname><given-names>J</given-names></name><name><surname>McDonald</surname><given-names>S</given-names></name><name><surname>Bose</surname><given-names>R</given-names></name><name><surname>Ornitz</surname><given-names>D</given-names></name><name><surname>Xiong</surname><given-names>D</given-names></name><name><surname>You</surname><given-names>M</given-names></name><name><surname>Dooling</surname><given-names>DJ</given-names></name><name><surname>Watson</surname><given-names>M</given-names></name><name><surname>Mardis</surname><given-names>ER</given-names></name><name><surname>Wilson</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Genomic landscape of non-small cell lung cancer in smokers and never-smokers</article-title><source>Cell</source><volume>150</volume><fpage>1121</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.08.024</pub-id><pub-id pub-id-type="pmid">22980976</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gridley</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Notch signaling in vascular development and physiology</article-title><source>Development</source><volume>134</volume><fpage>2709</fpage><lpage>2718</lpage><pub-id pub-id-type="doi">10.1242/dev.004184</pub-id><pub-id pub-id-type="pmid">17611219</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guex</surname><given-names>N</given-names></name><name><surname>Peitsch</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>SWISS-MODEL and the SWISS-PdbViewer: an environment for comparative protein modeling</article-title><source>Electrophoresis</source><volume>18</volume><fpage>2714</fpage><lpage>2723</lpage><pub-id pub-id-type="doi">10.1002/elps.1150181505</pub-id><pub-id pub-id-type="pmid">9504803</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Miao</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Functional evaluation of missense variations in the human MAD1L1 and MAD2L1 genes and their impact on susceptibility to lung cancer</article-title><source>Journal of Medical Genetics</source><volume>47</volume><fpage>616</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1136/jmg.2009.074252</pub-id><pub-id pub-id-type="pmid">20516147</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>S-W</given-names></name><name><surname>Kim</surname><given-names>T-Y</given-names></name><name><surname>Hwang</surname><given-names>PG</given-names></name><name><surname>Jeong</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>IS</given-names></name><name><surname>Oh</surname><given-names>D-Y</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>D-W</given-names></name><name><surname>Chung</surname><given-names>DH</given-names></name><name><surname>Im</surname><given-names>S-A</given-names></name><name><surname>Kim</surname><given-names>YT</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Heo</surname><given-names>DS</given-names></name><name><surname>Bang</surname><given-names>Y-J</given-names></name><name><surname>Kim</surname><given-names>NK</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib</article-title><source>Journal of Clinical Oncology</source><volume>23</volume><fpage>2493</fpage><lpage>2501</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.01.388</pub-id><pub-id pub-id-type="pmid">15710947</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harada</surname><given-names>T</given-names></name><name><surname>Futamura</surname><given-names>S</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Sawada</surname><given-names>R</given-names></name><name><surname>Okuda</surname><given-names>T</given-names></name><name><surname>Kagawa</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>P2.03-13 acquired resistance to afatinib in non-small cell lung cancer with EGFR G719X mutation</article-title><source>Journal of Thoracic Oncology</source><volume>14</volume><elocation-id>S687</elocation-id><pub-id pub-id-type="doi">10.1016/j.jtho.2019.08.1460</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hidaka</surname><given-names>T</given-names></name><name><surname>Fujimura</surname><given-names>T</given-names></name><name><surname>Aiba</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Aryl hydrocarbon receptor modulates carcinogenesis and maintenance of skin cancers</article-title><source>Frontiers in Medicine</source><volume>6</volume><elocation-id>194</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2019.00194</pub-id><pub-id pub-id-type="pmid">31552251</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>W</given-names></name><name><surname>Lim</surname><given-names>EL</given-names></name><name><surname>Weeden</surname><given-names>CE</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Augustine</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Kuan</surname><given-names>FC</given-names></name><name><surname>Marongiu</surname><given-names>F</given-names></name><name><surname>Evans</surname><given-names>EJ</given-names></name><name><surname>Moore</surname><given-names>DA</given-names></name><name><surname>Rodrigues</surname><given-names>FS</given-names></name><name><surname>Pich</surname><given-names>O</given-names></name><name><surname>Bakker</surname><given-names>B</given-names></name><name><surname>Cha</surname><given-names>H</given-names></name><name><surname>Myers</surname><given-names>R</given-names></name><name><surname>van Maldegem</surname><given-names>F</given-names></name><name><surname>Boumelha</surname><given-names>J</given-names></name><name><surname>Veeriah</surname><given-names>S</given-names></name><name><surname>Rowan</surname><given-names>A</given-names></name><name><surname>Naceur-Lombardelli</surname><given-names>C</given-names></name><name><surname>Karasaki</surname><given-names>T</given-names></name><name><surname>Sivakumar</surname><given-names>M</given-names></name><name><surname>De</surname><given-names>S</given-names></name><name><surname>Caswell</surname><given-names>DR</given-names></name><name><surname>Nagano</surname><given-names>A</given-names></name><name><surname>Black</surname><given-names>JRM</given-names></name><name><surname>Martínez-Ruiz</surname><given-names>C</given-names></name><name><surname>Ryu</surname><given-names>MH</given-names></name><name><surname>Huff</surname><given-names>RD</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Favé</surname><given-names>MJ</given-names></name><name><surname>Magness</surname><given-names>A</given-names></name><name><surname>Suárez-Bonnet</surname><given-names>A</given-names></name><name><surname>Priestnall</surname><given-names>SL</given-names></name><name><surname>Lüchtenborg</surname><given-names>M</given-names></name><name><surname>Lavelle</surname><given-names>K</given-names></name><name><surname>Pethick</surname><given-names>J</given-names></name><name><surname>Hardy</surname><given-names>S</given-names></name><name><surname>McRonald</surname><given-names>FE</given-names></name><name><surname>Lin</surname><given-names>MH</given-names></name><name><surname>Troccoli</surname><given-names>CI</given-names></name><name><surname>Ghosh</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>YE</given-names></name><name><surname>Merrick</surname><given-names>DT</given-names></name><name><surname>Keith</surname><given-names>RL</given-names></name><name><surname>Al Bakir</surname><given-names>M</given-names></name><name><surname>Bailey</surname><given-names>C</given-names></name><name><surname>Hill</surname><given-names>MS</given-names></name><name><surname>Saal</surname><given-names>LH</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>George</surname><given-names>AM</given-names></name><name><surname>Abbosh</surname><given-names>C</given-names></name><name><surname>Kanu</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>McGranahan</surname><given-names>N</given-names></name><name><surname>Berg</surname><given-names>CD</given-names></name><name><surname>Sasieni</surname><given-names>P</given-names></name><name><surname>Houlston</surname><given-names>R</given-names></name><name><surname>Turnbull</surname><given-names>C</given-names></name><name><surname>Lam</surname><given-names>S</given-names></name><name><surname>Awadalla</surname><given-names>P</given-names></name><name><surname>Grönroos</surname><given-names>E</given-names></name><name><surname>Downward</surname><given-names>J</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Carlsten</surname><given-names>C</given-names></name><name><surname>Malanchi</surname><given-names>I</given-names></name><name><surname>Hackshaw</surname><given-names>A</given-names></name><name><surname>Litchfield</surname><given-names>K</given-names></name><collab>TRACERx Consortium</collab><name><surname>DeGregori</surname><given-names>J</given-names></name><name><surname>Jamal-Hanjani</surname><given-names>M</given-names></name><name><surname>Swanton</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Lung adenocarcinoma promotion by air pollutants</article-title><source>Nature</source><volume>616</volume><fpage>159</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-05874-3</pub-id><pub-id pub-id-type="pmid">37020004</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosgood</surname><given-names>HD</given-names><suffix>III</suffix></name><name><surname>Pao</surname><given-names>W</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Pan</surname><given-names>YH</given-names></name><name><surname>Kuchinsky</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>KD</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Vermeulen</surname><given-names>R</given-names></name><name><surname>Simko</surname><given-names>J</given-names></name><name><surname>Lan</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning</article-title><source>Respiratory Medicine</source><volume>107</volume><fpage>1755</fpage><lpage>1762</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2013.08.018</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>DW</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title><source>Nature Protocols</source><volume>4</volume><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1038/nprot.2008.211</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>IARC Working Group on the Evaluation of Carcinogenic Risks to Humans</collab></person-group><year iso-8601-date="2010">2010</year><article-title>Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures</article-title><source>IARC Monographs on the Evaluation of Carcinogenic Risks to Humans</source><volume>92</volume><fpage>1</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">21141735</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janning</surname><given-names>M</given-names></name><name><surname>Süptitz</surname><given-names>J</given-names></name><name><surname>Albers-Leischner</surname><given-names>C</given-names></name><name><surname>Delpy</surname><given-names>P</given-names></name><name><surname>Tufman</surname><given-names>A</given-names></name><name><surname>Velthaus-Rusik</surname><given-names>JL</given-names></name><name><surname>Reck</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>A</given-names></name><name><surname>Kauffmann-Guerrero</surname><given-names>D</given-names></name><name><surname>Bonzheim</surname><given-names>I</given-names></name><name><surname>Brändlein</surname><given-names>S</given-names></name><name><surname>Hummel</surname><given-names>HD</given-names></name><name><surname>Wiesweg</surname><given-names>M</given-names></name><name><surname>Schildhaus</surname><given-names>HU</given-names></name><name><surname>Stratmann</surname><given-names>JA</given-names></name><name><surname>Sebastian</surname><given-names>M</given-names></name><name><surname>Alt</surname><given-names>J</given-names></name><name><surname>Buth</surname><given-names>J</given-names></name><name><surname>Esposito</surname><given-names>I</given-names></name><name><surname>Berger</surname><given-names>J</given-names></name><name><surname>Tögel</surname><given-names>L</given-names></name><name><surname>Saalfeld</surname><given-names>FC</given-names></name><name><surname>Wermke</surname><given-names>M</given-names></name><name><surname>Merkelbach-Bruse</surname><given-names>S</given-names></name><name><surname>Hillmer</surname><given-names>AM</given-names></name><name><surname>Klauschen</surname><given-names>F</given-names></name><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Buettner</surname><given-names>R</given-names></name><name><surname>Wolf</surname><given-names>J</given-names></name><name><surname>Loges</surname><given-names>S</given-names></name><collab>National Network Genomic Medicine Lung Cancer (nNGM)</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Treatment outcome of atypical EGFR mutations in the German national network genomic medicine lung cancer (nNGM)</article-title><source>Annals of Oncology</source><volume>33</volume><fpage>602</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.02.225</pub-id><pub-id pub-id-type="pmid">35263633</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachuk</surname><given-names>C</given-names></name><name><surname>Stephen</surname><given-names>K</given-names></name><name><surname>Doucette</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Comparison of sodium dodecyl sulfate depletion techniques for proteome analysis by mass spectrometry</article-title><source>Journal of Chromatography. A</source><volume>1418</volume><fpage>158</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.chroma.2015.09.042</pub-id><pub-id pub-id-type="pmid">26422304</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Chapman</surname><given-names>RS</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Hosgood</surname><given-names>HD</given-names></name><name><surname>Liu</surname><given-names>LZ</given-names></name><name><surname>Lai</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Silverman</surname><given-names>DT</given-names></name><name><surname>Vermeulen</surname><given-names>R</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Bassig</surname><given-names>B</given-names></name><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name><name><surname>Lan</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Smoky coal, tobacco smoking, and lung cancer risk in Xuanwei, China</article-title><source>Lung Cancer</source><volume>84</volume><fpage>31</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2014.01.004</pub-id><pub-id pub-id-type="pmid">24506909</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucab</surname><given-names>JE</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Morganella</surname><given-names>S</given-names></name><name><surname>Joel</surname><given-names>M</given-names></name><name><surname>Nanda</surname><given-names>AS</given-names></name><name><surname>Nagy</surname><given-names>E</given-names></name><name><surname>Gomez</surname><given-names>C</given-names></name><name><surname>Degasperi</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>R</given-names></name><name><surname>Jackson</surname><given-names>SP</given-names></name><name><surname>Arlt</surname><given-names>VM</given-names></name><name><surname>Phillips</surname><given-names>DH</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A compendium of mutational signatures of environmental agents</article-title><source>Cell</source><volume>177</volume><fpage>821</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.03.001</pub-id><pub-id pub-id-type="pmid">30982602</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunishige</surname><given-names>M</given-names></name><name><surname>Ichihara</surname><given-names>S</given-names></name><name><surname>Kadota</surname><given-names>N</given-names></name><name><surname>Okano</surname><given-names>Y</given-names></name><name><surname>Machida</surname><given-names>H</given-names></name><name><surname>Hatakeyama</surname><given-names>N</given-names></name><name><surname>Naruse</surname><given-names>K</given-names></name><name><surname>Shinohara</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib</article-title><source>Thoracic Cancer</source><volume>14</volume><fpage>423</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1111/1759-7714.14775</pub-id><pub-id pub-id-type="pmid">36519636</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lan</surname><given-names>Q</given-names></name><name><surname>Chapman</surname><given-names>RS</given-names></name><name><surname>Schreinemachers</surname><given-names>DM</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Household stove improvement and risk of lung cancer in Xuanwei, China</article-title><source>Journal of the National Cancer Institute</source><volume>94</volume><fpage>826</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1093/jnci/94.11.826</pub-id><pub-id pub-id-type="pmid">12048270</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberzon</surname><given-names>A</given-names></name><name><surname>Birger</surname><given-names>C</given-names></name><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Ghandi</surname><given-names>M</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The molecular signatures database (MSigDB) hallmark gene set collection</article-title><source>Cell Systems</source><volume>1</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2015.12.004</pub-id><pub-id pub-id-type="pmid">26771021</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Ning</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>SC</given-names></name><name><surname>Huss</surname><given-names>A</given-names></name><name><surname>Vermeulen</surname><given-names>R</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Lung cancer mortality among women in Xuan Wei, China: a comparison of spatial clustering detection methods</article-title><source>Asia-Pacific Journal of Public Health</source><volume>27</volume><fpage>392</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1177/1010539512444778</pub-id><pub-id pub-id-type="pmid">22548776</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangal</surname><given-names>D</given-names></name><name><surname>Vudathala</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>J-H</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Penning</surname><given-names>TM</given-names></name><name><surname>Blair</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Analysis of 7,8-dihydro-8-oxo-2’-deoxyguanosine in cellular DNA during oxidative stress</article-title><source>Chemical Research in Toxicology</source><volume>22</volume><fpage>788</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1021/tx800343c</pub-id><pub-id pub-id-type="pmid">19309085</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massarelli</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>FM</given-names></name><name><surname>Erickson</surname><given-names>HS</given-names></name><name><surname>Wistuba</surname><given-names>II</given-names></name><name><surname>Papadimitrakopoulou</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance</article-title><source>Lung Cancer</source><volume>80</volume><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2013.01.018</pub-id><pub-id pub-id-type="pmid">23485129</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertins</surname><given-names>P</given-names></name><name><surname>Tang</surname><given-names>LC</given-names></name><name><surname>Krug</surname><given-names>K</given-names></name><name><surname>Clark</surname><given-names>DJ</given-names></name><name><surname>Gritsenko</surname><given-names>MA</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Clauser</surname><given-names>KR</given-names></name><name><surname>Clauss</surname><given-names>TR</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Petyuk</surname><given-names>VA</given-names></name><name><surname>Thomas</surname><given-names>SN</given-names></name><name><surname>Mani</surname><given-names>DR</given-names></name><name><surname>Mundt</surname><given-names>F</given-names></name><name><surname>Moore</surname><given-names>RJ</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Schnaubelt</surname><given-names>M</given-names></name><name><surname>Keshishian</surname><given-names>H</given-names></name><name><surname>Monroe</surname><given-names>ME</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Udeshi</surname><given-names>ND</given-names></name><name><surname>Mani</surname><given-names>D</given-names></name><name><surname>Davies</surname><given-names>SR</given-names></name><name><surname>Townsend</surname><given-names>RR</given-names></name><name><surname>Chan</surname><given-names>DW</given-names></name><name><surname>Smith</surname><given-names>RD</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Carr</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry</article-title><source>Nature Protocols</source><volume>13</volume><fpage>1632</fpage><lpage>1661</lpage><pub-id pub-id-type="doi">10.1038/s41596-018-0006-9</pub-id><pub-id pub-id-type="pmid">29988108</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>MJ</given-names></name><name><surname>Beltrán</surname><given-names>JF</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name><name><surname>Fragoza</surname><given-names>R</given-names></name><name><surname>Rumack</surname><given-names>A</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Interactome INSIDER: a structural interactome browser for genomic studies</article-title><source>Nature Methods</source><volume>15</volume><fpage>107</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4540</pub-id><pub-id pub-id-type="pmid">29355848</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mumford</surname><given-names>JL</given-names></name><name><surname>He</surname><given-names>XZ</given-names></name><name><surname>Chapman</surname><given-names>RS</given-names></name><name><surname>Cao</surname><given-names>SR</given-names></name><name><surname>Harris</surname><given-names>DB</given-names></name><name><surname>Li</surname><given-names>XM</given-names></name><name><surname>Xian</surname><given-names>YL</given-names></name><name><surname>Jiang</surname><given-names>WZ</given-names></name><name><surname>Xu</surname><given-names>CW</given-names></name><name><surname>Chuang</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Lung cancer and indoor air pollution in Xuan Wei, China</article-title><source>Science</source><volume>235</volume><fpage>217</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1126/science.3798109</pub-id><pub-id pub-id-type="pmid">3798109</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Páll</surname><given-names>S</given-names></name><name><surname>Zhmurov</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>P</given-names></name><name><surname>Abraham</surname><given-names>M</given-names></name><name><surname>Lundborg</surname><given-names>M</given-names></name><name><surname>Gray</surname><given-names>A</given-names></name><name><surname>Hess</surname><given-names>B</given-names></name><name><surname>Lindahl</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Heterogeneous parallelization and acceleration of molecular dynamics simulations in GROMACS</article-title><source>The Journal of Chemical Physics</source><volume>153</volume><elocation-id>134110</elocation-id><pub-id pub-id-type="doi">10.1063/5.0018516</pub-id><pub-id pub-id-type="pmid">33032406</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Pisani</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Global cancer statistics, 2002</article-title><source>CA</source><volume>55</volume><fpage>74</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.3322/canjclin.55.2.74</pub-id><pub-id pub-id-type="pmid">15761078</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petit</surname><given-names>P</given-names></name><name><surname>Maître</surname><given-names>A</given-names></name><name><surname>Persoons</surname><given-names>R</given-names></name><name><surname>Bicout</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lung cancer risk assessment for workers exposed to polycyclic aromatic hydrocarbons in various industries</article-title><source>Environment International</source><volume>124</volume><fpage>109</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.envint.2018.12.058</pub-id><pub-id pub-id-type="pmid">30641254</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>BG</given-names></name><name><surname>Wiehe</surname><given-names>K</given-names></name><name><surname>Hwang</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>B-H</given-names></name><name><surname>Vreven</surname><given-names>T</given-names></name><name><surname>Weng</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>ZDOCK server: interactive docking prediction of protein–protein complexes and symmetric multimers</article-title><source>Bioinformatics</source><volume>30</volume><fpage>1771</fpage><lpage>1773</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu097</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitulescu</surname><given-names>ME</given-names></name><name><surname>Schmidt</surname><given-names>I</given-names></name><name><surname>Giaimo</surname><given-names>BD</given-names></name><name><surname>Antoine</surname><given-names>T</given-names></name><name><surname>Berkenfeld</surname><given-names>F</given-names></name><name><surname>Ferrante</surname><given-names>F</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Ehling</surname><given-names>M</given-names></name><name><surname>Biljes</surname><given-names>D</given-names></name><name><surname>Rocha</surname><given-names>SF</given-names></name><name><surname>Langen</surname><given-names>UH</given-names></name><name><surname>Stehling</surname><given-names>M</given-names></name><name><surname>Nagasawa</surname><given-names>T</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Borggrefe</surname><given-names>T</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dll4 and Notch signalling couples sprouting angiogenesis and artery formation</article-title><source>Nature Cell Biology</source><volume>19</volume><fpage>915</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1038/ncb3555</pub-id><pub-id pub-id-type="pmid">28714968</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinlan</surname><given-names>AR</given-names></name><name><surname>Hall</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title><source>Bioinformatics</source><volume>26</volume><fpage>841</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq033</pub-id><pub-id pub-id-type="pmid">20110278</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robin</surname><given-names>X</given-names></name><name><surname>Turck</surname><given-names>N</given-names></name><name><surname>Hainard</surname><given-names>A</given-names></name><name><surname>Tiberti</surname><given-names>N</given-names></name><name><surname>Lisacek</surname><given-names>F</given-names></name><name><surname>Sanchez</surname><given-names>J-C</given-names></name><name><surname>Müller</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>pROC: an open-source package for R and S+ to analyze and compare ROC curves</article-title><source>BMC Bioinformatics</source><volume>12</volume><elocation-id>77</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-77</pub-id><pub-id pub-id-type="pmid">21414208</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahni</surname><given-names>N</given-names></name><name><surname>Yi</surname><given-names>S</given-names></name><name><surname>Taipale</surname><given-names>M</given-names></name><name><surname>Fuxman Bass</surname><given-names>JI</given-names></name><name><surname>Coulombe-Huntington</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Weile</surname><given-names>J</given-names></name><name><surname>Karras</surname><given-names>GI</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Kovács</surname><given-names>IA</given-names></name><name><surname>Kamburov</surname><given-names>A</given-names></name><name><surname>Krykbaeva</surname><given-names>I</given-names></name><name><surname>Lam</surname><given-names>MH</given-names></name><name><surname>Tucker</surname><given-names>G</given-names></name><name><surname>Khurana</surname><given-names>V</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>Y-Y</given-names></name><name><surname>Yachie</surname><given-names>N</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Palagi</surname><given-names>A</given-names></name><name><surname>San-Miguel</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Balcha</surname><given-names>D</given-names></name><name><surname>Dricot</surname><given-names>A</given-names></name><name><surname>Jordan</surname><given-names>DM</given-names></name><name><surname>Walsh</surname><given-names>JM</given-names></name><name><surname>Shah</surname><given-names>AA</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Stoyanova</surname><given-names>AK</given-names></name><name><surname>Leighton</surname><given-names>A</given-names></name><name><surname>Calderwood</surname><given-names>MA</given-names></name><name><surname>Jacob</surname><given-names>Y</given-names></name><name><surname>Cusick</surname><given-names>ME</given-names></name><name><surname>Salehi-Ashtiani</surname><given-names>K</given-names></name><name><surname>Whitesell</surname><given-names>LJ</given-names></name><name><surname>Sunyaev</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>B</given-names></name><name><surname>Barabási</surname><given-names>A-L</given-names></name><name><surname>Charloteaux</surname><given-names>B</given-names></name><name><surname>Hill</surname><given-names>DE</given-names></name><name><surname>Hao</surname><given-names>T</given-names></name><name><surname>Roth</surname><given-names>FP</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Walhout</surname><given-names>AJM</given-names></name><name><surname>Lindquist</surname><given-names>S</given-names></name><name><surname>Vidal</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Widespread macromolecular interaction perturbations in human genetic disorders</article-title><source>Cell</source><volume>161</volume><fpage>647</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.04.013</pub-id><pub-id pub-id-type="pmid">25910212</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saravanakumar</surname><given-names>K</given-names></name><name><surname>Sivasantosh</surname><given-names>S</given-names></name><name><surname>Sathiyaseelan</surname><given-names>A</given-names></name><name><surname>Sankaranarayanan</surname><given-names>A</given-names></name><name><surname>Naveen</surname><given-names>KV</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Jamla</surname><given-names>M</given-names></name><name><surname>Vijayasarathy</surname><given-names>S</given-names></name><name><surname>Vishnu Priya</surname><given-names>V</given-names></name><name><surname>MubarakAli</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Impact of benzo[a]pyrene with other pollutants induce the molecular alternation in the biological system: Existence, detection, and remediation methods</article-title><source>Environmental Pollution</source><volume>304</volume><elocation-id>119207</elocation-id><pub-id pub-id-type="doi">10.1016/j.envpol.2022.119207</pub-id><pub-id pub-id-type="pmid">35351595</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>P</given-names></name><name><surname>Markiel</surname><given-names>A</given-names></name><name><surname>Ozier</surname><given-names>O</given-names></name><name><surname>Baliga</surname><given-names>NS</given-names></name><name><surname>Wang</surname><given-names>JT</given-names></name><name><surname>Ramage</surname><given-names>D</given-names></name><name><surname>Amin</surname><given-names>N</given-names></name><name><surname>Schwikowski</surname><given-names>B</given-names></name><name><surname>Ideker</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title><source>Genome Research</source><volume>13</volume><fpage>2498</fpage><lpage>2504</lpage><pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id><pub-id pub-id-type="pmid">14597658</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Godschalk</surname><given-names>RWL</given-names></name><name><surname>van Schooten</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inflammation and the chemical carcinogen benzo[a]pyrene: Partners in crime</article-title><source>Mutation Research. Reviews in Mutation Research</source><volume>774</volume><fpage>12</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.mrrev.2017.08.003</pub-id><pub-id pub-id-type="pmid">29173495</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sironi</surname><given-names>L</given-names></name><name><surname>Mapelli</surname><given-names>M</given-names></name><name><surname>Knapp</surname><given-names>S</given-names></name><name><surname>De Antoni</surname><given-names>A</given-names></name><name><surname>Jeang</surname><given-names>K-T</given-names></name><name><surname>Musacchio</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Crystal structure of the tetrameric Mad1-Mad2 core complex: implications of a “safety belt” binding mechanism for the spindle checkpoint</article-title><source>The EMBO Journal</source><volume>21</volume><fpage>2496</fpage><lpage>2506</lpage><pub-id pub-id-type="doi">10.1093/emboj/21.10.2496</pub-id><pub-id pub-id-type="pmid">12006501</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamborero</surname><given-names>D</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>A</given-names></name><name><surname>Lopez-Bigas</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes</article-title><source>Bioinformatics</source><volume>29</volume><fpage>2238</fpage><lpage>2244</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt395</pub-id><pub-id pub-id-type="pmid">23884480</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tate</surname><given-names>JG</given-names></name><name><surname>Bamford</surname><given-names>S</given-names></name><name><surname>Jubb</surname><given-names>HC</given-names></name><name><surname>Sondka</surname><given-names>Z</given-names></name><name><surname>Beare</surname><given-names>DM</given-names></name><name><surname>Bindal</surname><given-names>N</given-names></name><name><surname>Boutselakis</surname><given-names>H</given-names></name><name><surname>Cole</surname><given-names>CG</given-names></name><name><surname>Creatore</surname><given-names>C</given-names></name><name><surname>Dawson</surname><given-names>E</given-names></name><name><surname>Fish</surname><given-names>P</given-names></name><name><surname>Harsha</surname><given-names>B</given-names></name><name><surname>Hathaway</surname><given-names>C</given-names></name><name><surname>Jupe</surname><given-names>SC</given-names></name><name><surname>Kok</surname><given-names>CY</given-names></name><name><surname>Noble</surname><given-names>K</given-names></name><name><surname>Ponting</surname><given-names>L</given-names></name><name><surname>Ramshaw</surname><given-names>CC</given-names></name><name><surname>Rye</surname><given-names>CE</given-names></name><name><surname>Speedy</surname><given-names>HE</given-names></name><name><surname>Stefancsik</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>SL</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ward</surname><given-names>S</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Forbes</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>COSMIC: the catalogue of somatic mutations in cancer</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D941</fpage><lpage>D947</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1015</pub-id><pub-id pub-id-type="pmid">30371878</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukasaki</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>CW</given-names></name><name><surname>Greenspun</surname><given-names>E</given-names></name><name><surname>Eshaghian</surname><given-names>S</given-names></name><name><surname>Kawabata</surname><given-names>H</given-names></name><name><surname>Fujimoto</surname><given-names>T</given-names></name><name><surname>Tomonaga</surname><given-names>M</given-names></name><name><surname>Sawyers</surname><given-names>C</given-names></name><name><surname>Said</surname><given-names>JW</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Mutations in the mitotic check point gene, MAD1L1, in human cancers</article-title><source>Oncogene</source><volume>20</volume><fpage>3301</fpage><lpage>3305</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1204421</pub-id><pub-id pub-id-type="pmid">11423979</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations</article-title><source>CA: A Cancer Journal for Clinicians</source><volume>01</volume><elocation-id>21632</elocation-id><pub-id pub-id-type="doi">10.3322/caac.21632</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valdés-Tresanco</surname><given-names>MS</given-names></name><name><surname>Valdés-Tresanco</surname><given-names>ME</given-names></name><name><surname>Valiente</surname><given-names>PA</given-names></name><name><surname>Moreno</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS</article-title><source>Journal of Chemical Theory and Computation</source><volume>17</volume><fpage>6281</fpage><lpage>6291</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.1c00645</pub-id><pub-id pub-id-type="pmid">34586825</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Understanding the Warburg effect: the metabolic requirements of cell proliferation</article-title><source>Science</source><volume>324</volume><fpage>1029</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1126/science.1160809</pub-id><pub-id pub-id-type="pmid">19460998</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Griethuysen</surname><given-names>JJM</given-names></name><name><surname>Fedorov</surname><given-names>A</given-names></name><name><surname>Parmar</surname><given-names>C</given-names></name><name><surname>Hosny</surname><given-names>A</given-names></name><name><surname>Aucoin</surname><given-names>N</given-names></name><name><surname>Narayan</surname><given-names>V</given-names></name><name><surname>Beets-Tan</surname><given-names>RGH</given-names></name><name><surname>Fillion-Robin</surname><given-names>J-C</given-names></name><name><surname>Pieper</surname><given-names>S</given-names></name><name><surname>Aerts</surname><given-names>HJWL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Computational radiomics system to decode the radiographic phenotype</article-title><source>Cancer Research</source><volume>77</volume><fpage>e104</fpage><lpage>e107</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0339</pub-id><pub-id pub-id-type="pmid">29092951</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varadi</surname><given-names>M</given-names></name><name><surname>Anyango</surname><given-names>S</given-names></name><name><surname>Deshpande</surname><given-names>M</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Natassia</surname><given-names>C</given-names></name><name><surname>Yordanova</surname><given-names>G</given-names></name><name><surname>Yuan</surname><given-names>D</given-names></name><name><surname>Stroe</surname><given-names>O</given-names></name><name><surname>Wood</surname><given-names>G</given-names></name><name><surname>Laydon</surname><given-names>A</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Petersen</surname><given-names>S</given-names></name><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Clancy</surname><given-names>E</given-names></name><name><surname>Green</surname><given-names>R</given-names></name><name><surname>Vora</surname><given-names>A</given-names></name><name><surname>Lutfi</surname><given-names>M</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Cowie</surname><given-names>A</given-names></name><name><surname>Hobbs</surname><given-names>N</given-names></name><name><surname>Kohli</surname><given-names>P</given-names></name><name><surname>Kleywegt</surname><given-names>G</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Hassabis</surname><given-names>D</given-names></name><name><surname>Velankar</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models</article-title><source>Nucleic Acids Research</source><volume>50</volume><fpage>D439</fpage><lpage>D444</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab1061</pub-id><pub-id pub-id-type="pmid">34791371</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeulen</surname><given-names>R</given-names></name><name><surname>Downward</surname><given-names>GS</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Portengen</surname><given-names>L</given-names></name><name><surname>Bassig</surname><given-names>BA</given-names></name><name><surname>Hammond</surname><given-names>SK</given-names></name><name><surname>Wong</surname><given-names>JYY</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Reiss</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Seow</surname><given-names>WJ</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Ji</surname><given-names>B-T</given-names></name><name><surname>Silverman</surname><given-names>D</given-names></name><name><surname>Chanock</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name><name><surname>Lan</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Constituents of household air pollution and risk of lung cancer among never-smoking women in Xuanwei and Fuyuan, China</article-title><source>Environmental Health Perspectives</source><volume>127</volume><elocation-id>97001</elocation-id><pub-id pub-id-type="doi">10.1289/EHP4913</pub-id><pub-id pub-id-type="pmid">31487206</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Whole genome sequencing analysis of lung adenocarcinoma in Xuanwei, China</article-title><source>Thoracic Cancer</source><volume>8</volume><fpage>88</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1111/1759-7714.12411</pub-id><pub-id pub-id-type="pmid">28083984</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Skibbe</surname><given-names>JR</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Ferchen</surname><given-names>K</given-names></name><name><surname>Su</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Weng</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Qin</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>1853</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-01913-y</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Duan</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>Q-H</given-names></name><name><surname>Gong</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Integrated analysis of DNA methylation profiling and gene expression profiling identifies novel markers in lung cancer in Xuanwei, China</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0203155</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0203155</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Immunomodulatory effect of eriocitrin in experimental animals with Benzo(a)Pyrene-induced Lung Carcinogenesis</article-title><source>Journal of Environmental Pathology, Toxicology and Oncology</source><volume>39</volume><fpage>137</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1615/JEnvironPatholToxicolOncol.2020031953</pub-id><pub-id pub-id-type="pmid">32749123</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Minegishi</surname><given-names>Y</given-names></name><name><surname>Yoshizawa</surname><given-names>H</given-names></name><name><surname>Maemondo</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Sugawara</surname><given-names>S</given-names></name><name><surname>Isobe</surname><given-names>H</given-names></name><name><surname>Harada</surname><given-names>M</given-names></name><name><surname>Ishii</surname><given-names>Y</given-names></name><name><surname>Gemma</surname><given-names>A</given-names></name><name><surname>Hagiwara</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q</article-title><source>Journal of Thoracic Oncology</source><volume>9</volume><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1097/JTO.0000000000000048</pub-id><pub-id pub-id-type="pmid">24419415</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Widziewicz</surname><given-names>K</given-names></name><name><surname>Rogula-Kozłowska</surname><given-names>W</given-names></name><name><surname>Majewski</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Lung cancer risk associated with exposure to Benzo(A)Pyrene in Polish Agglomerations, Cities, and Other Areas</article-title><source>International Journal of Environmental Research</source><volume>11</volume><fpage>685</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1007/s41742-017-0061-z</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkerson</surname><given-names>MD</given-names></name><name><surname>Hayes</surname><given-names>DN</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking</article-title><source>Bioinformatics</source><volume>26</volume><fpage>1572</fpage><lpage>1573</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq170</pub-id><pub-id pub-id-type="pmid">20427518</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiredja</surname><given-names>DD</given-names></name><name><surname>Koyuturk</surname><given-names>M</given-names></name><name><surname>Chance</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The KSEA App: a web-based tool for kinase activity inference from quantitative phosphoproteomics</article-title><source>Bioinformatics</source><volume>33</volume><fpage>3489</fpage><lpage>3491</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btx415</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiśniewski</surname><given-names>JR</given-names></name><name><surname>Zougman</surname><given-names>A</given-names></name><name><surname>Nagaraj</surname><given-names>N</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Universal sample preparation method for proteome analysis</article-title><source>Nature Methods</source><volume>6</volume><fpage>359</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1322</pub-id><pub-id pub-id-type="pmid">19377485</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>JYY</given-names></name><name><surname>Downward</surname><given-names>GS</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Portengen</surname><given-names>L</given-names></name><name><surname>Seow</surname><given-names>WJ</given-names></name><name><surname>Silverman</surname><given-names>DT</given-names></name><name><surname>Bassig</surname><given-names>BA</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>B-T</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Vermeulen</surname><given-names>R</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name><name><surname>Lan</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lung cancer risk by geologic coal deposits: A case-control study of female never-smokers from Xuanwei and Fuyuan, China</article-title><source>International Journal of Cancer</source><volume>144</volume><fpage>2918</fpage><lpage>2927</lpage><pub-id pub-id-type="doi">10.1002/ijc.32034</pub-id><pub-id pub-id-type="pmid">30511435</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>JY</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhai</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Ying</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Integrative proteomic characterization of human lung adenocarcinoma</article-title><source>Cell</source><volume>182</volume><fpage>245</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.043</pub-id><pub-id pub-id-type="pmid">32649877</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>C-J</given-names></name><name><surname>Tomchick</surname><given-names>DR</given-names></name><name><surname>Machius</surname><given-names>M</given-names></name><name><surname>Rizo</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Insights into mad2 regulation in the spindle checkpoint revealed by the crystal structure of the symmetric mad2 dimer</article-title><source>PLOS Biology</source><volume>6</volume><elocation-id>e50</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.0060050</pub-id><pub-id pub-id-type="pmid">18318601</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JCH</given-names></name><name><surname>Sequist</surname><given-names>LV</given-names></name><name><surname>Geater</surname><given-names>SL</given-names></name><name><surname>Tsai</surname><given-names>CM</given-names></name><name><surname>Mok</surname><given-names>TSK</given-names></name><name><surname>Schuler</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>CJ</given-names></name><name><surname>Ou</surname><given-names>SHI</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Massey</surname><given-names>D</given-names></name><name><surname>Zazulina</surname><given-names>V</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6</article-title><source>The Lancet. Oncology</source><volume>16</volume><fpage>830</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00026-1</pub-id><pub-id pub-id-type="pmid">26051236</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>N</given-names></name><name><surname>Ou</surname><given-names>Q</given-names></name><name><surname>Xiang</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Bao</surname><given-names>H</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Shao</surname><given-names>YW</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Investigating novel resistance mechanisms to third-generation egfr tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients</article-title><source>Clinical Cancer Research</source><volume>24</volume><fpage>3097</fpage><lpage>3107</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-2310</pub-id><pub-id pub-id-type="pmid">29506987</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>JC-H</given-names></name><name><surname>Schuler</surname><given-names>M</given-names></name><name><surname>Popat</surname><given-names>S</given-names></name><name><surname>Miura</surname><given-names>S</given-names></name><name><surname>Heeke</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Märten</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Afatinib for the Treatment of NSCLC Harboring uncommon EGFR mutations: a database of 693 cases</article-title><source>Journal of Thoracic Oncology</source><volume>15</volume><fpage>803</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2019.12.126</pub-id><pub-id pub-id-type="pmid">31931137</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Payne</surname><given-names>SH</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>McDermott</surname><given-names>JE</given-names></name><name><surname>Zhou</surname><given-names>J-Y</given-names></name><name><surname>Petyuk</surname><given-names>VA</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Ray</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Cha</surname><given-names>SW</given-names></name><name><surname>Aiyetan</surname><given-names>P</given-names></name><name><surname>Woo</surname><given-names>S</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Gritsenko</surname><given-names>MA</given-names></name><name><surname>Clauss</surname><given-names>TR</given-names></name><name><surname>Choi</surname><given-names>C</given-names></name><name><surname>Monroe</surname><given-names>ME</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Nie</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Moore</surname><given-names>RJ</given-names></name><name><surname>Yu</surname><given-names>K-H</given-names></name><name><surname>Tabb</surname><given-names>DL</given-names></name><name><surname>Fenyö</surname><given-names>D</given-names></name><name><surname>Bafna</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Rodriguez</surname><given-names>H</given-names></name><name><surname>Boja</surname><given-names>ES</given-names></name><name><surname>Hiltke</surname><given-names>T</given-names></name><name><surname>Rivers</surname><given-names>RC</given-names></name><name><surname>Sokoll</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Shih</surname><given-names>I-M</given-names></name><name><surname>Cope</surname><given-names>L</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Snyder</surname><given-names>MP</given-names></name><name><surname>Levine</surname><given-names>DA</given-names></name><name><surname>Smith</surname><given-names>RD</given-names></name><name><surname>Chan</surname><given-names>DW</given-names></name><name><surname>Rodland</surname><given-names>KD</given-names></name><collab>CPTAC Investigators</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Integrated Proteogenomic characterization of human high-grade serous ovarian cancer</article-title><source>Cell</source><volume>166</volume><fpage>755</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.05.069</pub-id><pub-id pub-id-type="pmid">27372738</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X-C</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>G-G</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Qu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Moy</surname><given-names>C</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Albertyn</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Platero</surname><given-names>S</given-names></name><name><surname>Lorenzi</surname><given-names>MV</given-names></name><name><surname>Zudaire</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Y-L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1772</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09762-1</pub-id><pub-id pub-id-type="pmid">30992440</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Joubert</surname><given-names>P</given-names></name><name><surname>Ansari-Pour</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Hoang</surname><given-names>PH</given-names></name><name><surname>Lokanga</surname><given-names>R</given-names></name><name><surname>Moye</surname><given-names>AL</given-names></name><name><surname>Rosenbaum</surname><given-names>J</given-names></name><name><surname>Gonzalez-Perez</surname><given-names>A</given-names></name><name><surname>Martínez-Jiménez</surname><given-names>F</given-names></name><name><surname>Castro</surname><given-names>A</given-names></name><name><surname>Muscarella</surname><given-names>LA</given-names></name><name><surname>Hofman</surname><given-names>P</given-names></name><name><surname>Consonni</surname><given-names>D</given-names></name><name><surname>Pesatori</surname><given-names>AC</given-names></name><name><surname>Kebede</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Gould Rothberg</surname><given-names>BE</given-names></name><name><surname>Peneva</surname><given-names>I</given-names></name><name><surname>Schabath</surname><given-names>MB</given-names></name><name><surname>Poeta</surname><given-names>ML</given-names></name><name><surname>Costantini</surname><given-names>M</given-names></name><name><surname>Hirsch</surname><given-names>D</given-names></name><name><surname>Heselmeyer-Haddad</surname><given-names>K</given-names></name><name><surname>Hutchinson</surname><given-names>A</given-names></name><name><surname>Olanich</surname><given-names>M</given-names></name><name><surname>Lawrence</surname><given-names>SM</given-names></name><name><surname>Lenz</surname><given-names>P</given-names></name><name><surname>Duggan</surname><given-names>M</given-names></name><name><surname>Bhawsar</surname><given-names>PMS</given-names></name><name><surname>Sang</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Mendoza</surname><given-names>L</given-names></name><name><surname>Saini</surname><given-names>N</given-names></name><name><surname>Klimczak</surname><given-names>LJ</given-names></name><name><surname>Islam</surname><given-names>SMA</given-names></name><name><surname>Otlu</surname><given-names>B</given-names></name><name><surname>Khandekar</surname><given-names>A</given-names></name><name><surname>Cole</surname><given-names>N</given-names></name><name><surname>Stewart</surname><given-names>DR</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>KM</given-names></name><name><surname>Caporaso</surname><given-names>NE</given-names></name><name><surname>Wilson</surname><given-names>SH</given-names></name><name><surname>Pommier</surname><given-names>Y</given-names></name><name><surname>Lan</surname><given-names>Q</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name><name><surname>Almeida</surname><given-names>JS</given-names></name><name><surname>Carter</surname><given-names>H</given-names></name><name><surname>Ried</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>CF</given-names></name><name><surname>Lopez-Bigas</surname><given-names>N</given-names></name><name><surname>Garcia-Closas</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Bossé</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Gordenin</surname><given-names>DA</given-names></name><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Landi</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Genomic and evolutionary classification of lung cancer in never smokers</article-title><source>Nature Genetics</source><volume>53</volume><fpage>1348</fpage><lpage>1359</lpage><pub-id pub-id-type="doi">10.1038/s41588-021-00920-0</pub-id><pub-id pub-id-type="pmid">34493867</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Jiao</surname><given-names>B</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Genomic evidence of lung carcinogenesis associated with coal smoke in Xuanwei area, China</article-title><source>National Science Review</source><volume>8</volume><elocation-id>nwab152</elocation-id><pub-id pub-id-type="doi">10.1093/nsr/nwab152</pub-id><pub-id pub-id-type="pmid">34987843</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>James</surname><given-names>LP</given-names></name><name><surname>Moskowitz</surname><given-names>CS</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Ginsberg</surname><given-names>MS</given-names></name><name><surname>Lefkowitz</surname><given-names>RA</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Schwartz</surname><given-names>LH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer</article-title><source>Radiology</source><volume>252</volume><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1148/radiol.2522081593</pub-id><pub-id pub-id-type="pmid">19561260</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Lou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Miao</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MAD1L1 Arg558His and MAD2L1 Leu84Met interaction with smoking increase the risk of colorectal cancer</article-title><source>Scientific Reports</source><volume>5</volume><elocation-id>12202</elocation-id><pub-id pub-id-type="doi">10.1038/srep12202</pub-id><pub-id pub-id-type="pmid">26183163</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Pache</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Khodabakhshi</surname><given-names>AH</given-names></name><name><surname>Tanaseichuk</surname><given-names>O</given-names></name><name><surname>Benner</surname><given-names>C</given-names></name><name><surname>Chanda</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metascape provides a biologist-oriented resource for the analysis of systems-level datasets</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1523</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09234-6</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95453.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sobol</surname><given-names>Robert W</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Brown University</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Incomplete</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Useful</kwd></kwd-group></front-stub><body><p>This <bold>useful</bold> manuscript presents an interesting multi-modal omics analysis of lung adenocarcinoma patients with distinct clinical clusters, mutation hotspots, and potential risk factors identified in cases linked to air pollution. The findings show potential for clinical and therapeutic impact. Some of the conclusions remain <bold>incomplete</bold> as they are based on correlative or suggestive findings, and would benefit from further functional investigation and validating approaches.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95453.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This is a well-written and detailed manuscript showing important results on the molecular profile of 4 different cohorts of female patients with lung cancer.</p><p>Strengths:</p><p>The authors used several different methods to identify potential novel targets for therapeutic interventions.</p><p>Weaknesses:</p><p>Statistical test results need to be provided in comparisons between cohorts. This was addressed by the authors in the revisions.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95453.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>New comments are added after authors responses to my initial comments.</p><p>Summary:</p><p>Zhang et al. performed a proteogenomic analysis of lung adenocarcinoma (LUAD) in 169 female never-smokers from the Xuanwei area (XWLC) in China. These analyses reveal that XWLC is a distinct subtype of LUAD and that BaP is a major risk factor associated with EGFR G719X mutations found in the XWLC cohort. Four subtypes of XWLC were classified with unique features based on multi-omics data clustering.</p><p>Strengths:</p><p>The authors made great efforts in performing several large-scale proteogenomic analyses and characterizing molecular features of XWLCs. Datasets from this study will be a valuable resource to further explore the etiology and therapeutic strategies of air-pollution-associated lung cancers, particularly for XWLC.</p><p>Weaknesses:</p><p>[...]</p><p>(2) Importantly, while providing the large datasets, validating key findings is minimally performed, and surprisingly there is no interrogation of XWLC drug response/efficacy based on their findings, which makes this manuscript descriptive and incomplete rather than conclusive. For example, testing the efficacy of XWLC response to afatinib combined with other drugs targeting activated kinases in EGFR G719X mutated XWLC tumors would be one way to validate their datasets and new therapeutic options.</p><p>Response: We appreciate your suggestion. In reference to testing the efficacy of XWLC response to afatinib combined with drugs targeting kinases, we have planned to establish PDX and organoid models to validate the effectiveness of our therapeutic approach. Due to the extended timeframe required, we intend to present these results in a subsequent study.</p><p>Comments: All conclusions in the manuscript made by authors are based on interpretations of large-scale multi-omics data, which should be properly validated by other approaches and methods. Without validation, these are all speculations and any conclusions without supporting evidence are not acceptable. This reviewer suggested an example of validation experiment, and Reviewer #3 also pointed out several data that need to be validated. However, authors do not agree to perform any of these validation experiments without reasonable justification.</p><p>(3) The authors found MAD1 and TPRN are novel therapeutic targets in XWLC. Are these two genes more frequently mutated in one subtype than the other 3 XWLC subtypes? How these mutations could be targeted in patients?</p><p>Response: Thank you for your question. We have investigated the TPRN and MAD1 mutations in our dataset, identifying five TPRN mutations and eight MAD1 mutations. Among the TPRN mutations, XWLC_0046 and XWLC_0017 belong to the MCII subtype, XWLC_0012 belongs to the MCI subtype, and the subtype of the other three samples is undetermined, resulting in mutation frequencies of 1/16, 2/24, 0/15, and 0/13, respectively. Similarly, for the MAD1 mutations, XWLC_0115, XWLC_0021, and XWLC_0047 belong to the MCII subtype, XWLC_0055 containing two mutations belongs to the MCI subtype, and the subtype of the other three samples is undetermined, resulting in mutation frequencies of 1/16, 3/24, 0/15, and 0/13 across subtypes, respectively. Fisher's test did not reveal significant differences between the subtypes. For targeting novel therapeutic targets such as MAD1 and TPRN, we propose a multi-step approach. Firstly, we advocate for conducting functional in vivo and in vitro experiments to verify their roles during cancer progression. Secondly, we suggest conducting small molecule drug screening based on the pharmacophore of these proteins, which may lead to the identification of potential therapeutic drugs. Lastly, we recommend testing the efficacy of these drugs to further validate their potential as effective treatments.</p><p>Comments: Please properly incorporate the above explanation into the main text.</p><p>(4) In Figures 2a and b: while Figure 2a shows distinct genomic mutations among each LC cohort, Figure 2b shows similarity in affected oncogenic pathways (cell cycle, Hippo, NOTCH, PI3K, RTK-RAS, and WNT) between XWLC and TNLC/CNLC. Considering that different genomic mutations could converge into common pathways and biological processes, wouldn't these results indicate commonalities among XWLC, TNLC, and CNLC? How about other oncogenic pathways not shown in Figure 2b?</p><p>Response: Thank you for your question. Based on the data presented in Fig. 2a, which encompasses all genomic mutations, it appears that the mutation landscape of XWLC bears the closest resemblance to TSLC (Fig. 2a). However, when considering oncogenic pathways (Fig. 2b) and genes (Fig. 2c), there is a notable disparity between the two cohorts. These findings suggest that while XWLC and TSLC exhibit similarities in terms of genomic mutations, they possess distinct characteristics in terms of oncogenic pathways and genes.</p><p>Regarding the oncogenic signaling pathways, we referred to ten well-established pathways identified from TCGA cohorts. These members of oncogenic pathways are likely to serve as cancer drivers (functional contributors) or therapeutic targets, as highlighted by Sanchez-Vega et al. in 2018(Sanchez-Vega et al., 2018).</p><p>Comments: It is unclear to this reviewer how authors defined &quot;distinct characteristics&quot; in terms of oncogenic pathways and genes. Would 10-20% differences in &quot;Fraction of samples affected&quot; in Fig2b be sufficient to claim significance? How could authors be sure whether mutations in genes involved in each oncogenic pathway are activating or inactivating mutations (rather than benign, thus non-affecting mutations)?</p><p>[...]</p><p>(6) Supplementary Table 11 shows a number of mutations at the interface and length of interface between a given protein-protein interaction pair. Such that, it does not provide what mutation(s) in a given PPI interface is found in each LC cohort. For example, it fails to provide whether MAD1 R558H and TPRN H550Q mutations are found significantly in each LC cohort.</p><p>Response: We appreciate your careful review. In Supplementary Table 11, we have provided significant onco_PPI data for each LC cohort, focusing on enriched mutations at the interface of two proteins. Our emphasis lies on onco_PPI rather than individual mutations, as any mutation occurring at the interface could potentially influence the function of the protein complex. Thus, our Supplementary Table 11 exclusively displays the onco_PPI rather than mutations. MAD1 R558H and TPRN H550Q were identified through onco_PPI analysis, and subsequent extensive literature research led us to focus specifically on these mutations.</p><p>Comments: Are authors referring to Table S9 (Onco_PPIs identified in four cohorts) instead of Supplementary Table 11? There is no Table 11 among submitted files. In Table S9, the Column N (length of protein product of gene1) does not make sense: MYO1C (8152), TP53 (3924), EGFR (12961). These should not be the number of amino acids residues of each protein. Then, what do these numbers mean?</p><p>(7) Figure 7c and d are simulation data not from an actual binding assay. The authors should perform a biochemical binding assay with proteins or show that the mutation significantly alters the interaction to support the conclusion.</p><p>Response: We appreciate your suggestion. The relevant experiments are currently in progress, and we anticipate presenting the corresponding data in a subsequent study.</p><p>Comments: The suggested experiment is to support the simulated data. Again, without supporting experimental results, authors could not make a conclusion simply based on simulated data. Where else could the supporting experimental results be presented?</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.95453.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Honglei</given-names></name><role specific-use="author">Author</role><aff><institution>Yunnan University of Chinese Medicine</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Chao</given-names></name><role specific-use="author">Author</role><aff><institution>Third Affiliated Hospital of Kunming Medical University</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Shuting</given-names></name><role specific-use="author">Author</role><aff><institution>Third Affiliated Hospital of Kunming Medical University</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Qing</given-names></name><role specific-use="author">Author</role><aff><institution>Qujing First People's Hospital</institution><addr-line><named-content content-type="city">Qujing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Xu</given-names></name><role specific-use="author">Author</role><aff><institution>Yunnan University of Chinese Medicine</institution><addr-line><named-content content-type="city">Kuming</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Huawei</given-names></name><role specific-use="author">Author</role><aff><institution>the Second People's Hospital of Yunnan Province</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Li</given-names></name><role specific-use="author">Author</role><aff><institution>Qujing First People's Hospital</institution><addr-line><named-content content-type="city">Qujing</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Chao</given-names></name><role specific-use="author">Author</role><aff><institution>Third Affiliated Hospital of Kunming Medical University</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lu</given-names></name><role specific-use="author">Author</role><aff><institution>Third Affiliated Hospital of Kunming Medical University</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Hou</surname><given-names>Fei</given-names></name><role specific-use="author">Author</role><aff><institution>Third Affiliated Hospital of Kunming Medical University</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Minjun</given-names></name><role specific-use="author">Author</role><aff><institution>Community Health Service Center in Fengning Street Wuhua District</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Zhiyong</given-names></name><role specific-use="author">Author</role><aff><institution>Third Affiliated Hospital of Kunming Medical University</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Heng</given-names></name><role specific-use="author">Author</role><aff><institution>Third Affiliated Hospital of Kunming Medical University</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yong</given-names></name><role specific-use="author">Author</role><aff><institution>West China Hospital of Sichuan University</institution><addr-line><named-content content-type="city">Chengdu</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Su</surname><given-names>Xiaosan</given-names></name><role specific-use="author">Author</role><aff><institution>Yunnan University of Chinese Medicine</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Gaofeng</given-names></name><role specific-use="author">Author</role><aff><institution>Third Affiliated Hospital of Kunming Medical University</institution><addr-line><named-content content-type="city">Kunming</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>This is a well-written and detailed manuscript showing important results on the molecular profile of 4 different cohorts of female patients with lung cancer.</p><p>The authors conducted comprehensive multi-omic profiling of air-pollution-associated LUAD to study the roles of the air pollutant BaP. Utilizing multi-omic clustering and mutation-informed interface analysis, potential novel therapeutic strategies were identified.</p><p>Strengths:</p><p>The authors used several different methods to identify potential novel targets for therapeutic interventions.</p><p>Weaknesses:</p><p>Statistical test results need to be provided in comparisons between cohorts.</p></disp-quote><p>We appreciate your recognition and valuable suggestions.. We have revised statistical test results in the panels including: Fig. 3b, e and g.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>Zhang et al. performed a proteogenomic analysis of lung adenocarcinoma (LUAD) in 169 female never-smokers from the Xuanwei area (XWLC) in China. These analyses reveal that XWLC is a distinct subtype of LUAD and that BaP is a major risk factor associated with EGFR G719X mutations found in the XWLC cohort. Four subtypes of XWLC were classified with unique features based on multi-omics data clustering.</p><p>Strengths:</p><p>The authors made great efforts in performing several large-scale proteogenomic analyses and characterizing molecular features of XWLCs. Datasets from this study will be a valuable resource to further explore the etiology and therapeutic strategies of air-pollution-associated lung cancers, particularly for XWLC.</p><p>Weaknesses:</p><p>(1) While analyzing and interpreting the datasets, however, this reviewer thinks that authors should provide more detailed procedures of (i) data processing, (ii) justification for choosing methods of various analyses, and (iii) justification of focusing on a few target gene/proteins in the datasets for further validation in the main text.</p></disp-quote><p>We appreciate your valuable feedback. In response to the suggestions for enhancing the manuscript's clarity, we have provided more detailed procedures in the main text and methods sections.</p><disp-quote content-type="editor-comment"><p>(2) Importantly, while providing the large datasets, validating key findings is minimally performed, and surprisingly there is no interrogation of XWLC drug response/efficacy based on their findings, which makes this manuscript descriptive and incomplete rather than conclusive. For example, testing the efficacy of XWLC response to afatinib combined with other drugs targeting activated kinases in EGFR G719X mutated XWLC tumors would be one way to validate their datasets and new therapeutic options.</p></disp-quote><p>We appreciate your suggestion. In reference to testing the efficacy of XWLC response to afatinib combined with drugs targeting kinases, we have planned to establish PDX and organoid models to validate the effectiveness of our therapeutic approach. Due to the extended timeframe required, we intend to present these results in a subsequent study.</p><disp-quote content-type="editor-comment"><p>(3) The authors found MAD1 and TPRN are novel therapeutic targets in XWLC. Are these two genes more frequently mutated in one subtype than the other 3 XWLC subtypes? How these mutations could be targeted in patients?</p></disp-quote><p>Thank you for your question. We have investigated the TPRN and MAD1 mutations in our dataset, identifying five TPRN mutations and eight MAD1 mutations. Among the TPRN mutations, XWLC_0046 and XWLC_0017 belong to the MCII subtype, XWLC_0012 belongs to the MCI subtype, and the subtype of the other three samples is undetermined, resulting in mutation frequencies of 1/16, 2/24, 0/15, and 0/13, respectively. Similarly, for the MAD1 mutations, XWLC_0115, XWLC_0021, and XWLC_0047 belong to the MCII subtype, XWLC_0055 containing two mutations belongs to the MCI subtype, and the subtype of the other three samples is undetermined, resulting in mutation frequencies of 1/16, 3/24, 0/15, and 0/13 across subtypes, respectively. Fisher’s test did not reveal significant differences between the subtypes.</p><p>For targeting novel therapeutic targets such as MAD1 and TPRN, we propose a multi-step approach. Firstly, we advocate for conducting functional in <italic>vivo</italic> and in <italic>vitro</italic> experiments to verify their roles during cancer progression. Secondly, we suggest conducting small molecule drug screening based on the pharmacophore of these proteins, which may lead to the identification of potential therapeutic drugs. Lastly, we recommend testing the efficacy of these drugs to further validate their potential as effective treatments.</p><disp-quote content-type="editor-comment"><p>(4) In Figures 2a and b: while Figure 2a shows distinct genomic mutations among each LC cohort, Figure 2b shows similarity in affected oncogenic pathways (cell cycle, Hippo, NOTCH, PI3K, RTK-RAS, and WNT) between XWLC and TNLC/CNLC. Considering that different genomic mutations could converge into common pathways and biological processes, wouldn't these results indicate commonalities among XWLC, TNLC, and CNLC? How about other oncogenic pathways not shown in Figure 2b?</p></disp-quote><p>Thank you for your question. Based on the data presented in Fig. 2a, which encompasses all genomic mutations, it appears that the mutation landscape of XWLC bears the closest resemblance to TSLC (Fig. 2a). However, when considering oncogenic pathways (Fig. 2b) and genes (Fig. 2c), there is a notable disparity between the two cohorts. These findings suggest that while XWLC and TSLC exhibit similarities in terms of genomic mutations, they possess distinct characteristics in terms of oncogenic pathways and genes.</p><p>Regarding the oncogenic signaling pathways, we referred to ten well-established pathways identified from TCGA cohorts. These members of oncogenic pathways are likely to serve as cancer drivers (functional contributors) or therapeutic targets, as highlighted by Sanchez-Vega et al. in 2018(Sanchez-Vega et al., 2018).</p><disp-quote content-type="editor-comment"><p>(5) In Figure 2c, how and why were the four genes (EGFR, TP53, RBM10, KRAS) selected? What about other genes? In this regard, given tumor genome sequencing was done, it would be more informative to provide the oncoprints of XWLC, TSLC, TNLC, and CNLC for complete genomic alteration comparison.</p></disp-quote><p>Thank you for your question and good suggestion. Building upon our previous study (Zhang et al., 2021), we found that EGFR, TP53, RBM10, and KRAS were the top mutated genes in Xuanwei lung cancer cohorts. Furthermore, we have included the mutation frequency of cancer driver genes (Bailey et al., 2018) across XWLC, TSLC, TNLC, and CNLC in Supplementary Table 2b.</p><disp-quote content-type="editor-comment"><p>(6) Supplementary Table 11 shows a number of mutations at the interface and length of interface between a given protein-protein interaction pair. Such that, it does not provide what mutation(s) in a given PPI interface is found in each LC cohort. For example, it fails to provide whether MAD1 R558H and TPRN H550Q mutations are found significantly in each LC cohort.</p></disp-quote><p>We appreciate your careful review. In Supplementary Table 11, we have provided significant onco_PPI data for each LC cohort, focusing on enriched mutations at the interface of two proteins. Our emphasis lies on onco_PPI rather than individual mutations, as any mutation occurring at the interface could potentially influence the function of the protein complex. Thus, our Supplementary Table 11 exclusively displays the onco_PPI rather than mutations. MAD1 R558H and TPRN H550Q were identified through onco_PPI analysis, and subsequent extensive literature research led us to focus specifically on these mutations.</p><disp-quote content-type="editor-comment"><p>(7) Figure 7c and d are simulation data not from an actual binding assay. The authors should perform a biochemical binding assay with proteins or show that the mutation significantly alters the interaction to support the conclusion.</p></disp-quote><p>We appreciate your suggestion. The relevant experiments are currently in progress, and we anticipate presenting the corresponding data in a subsequent study.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public Review):</bold></p><p>Summary:</p><p>The manuscript from Zhang et al. utilizes a multi-omics approach to analyze lung adenocarcinoma cases in female never smokers from the Xuanwei area (XWLC cohort) compared with cases associated with smoking or other endogenous factors to identify mutational signatures and proteome changes in lung cancers associated with air pollution. Mutational signature analysis revealed a mutation hotspot, EGFR-G719X, potentially associated with BaP exposure, in 20% of the XWLC cohort. This correlated with predicted MAPK pathway activations and worse outcomes relative to other EGFR mutations. Multi-omics clustering, including RNA-seq, proteomics, and phosphoproteomics identified 4 clusters with the XWLC cohort, with additional feature analysis pathway activation, genetic differences, and radiomic features to investigate clinical diagnostic and therapeutic strategy potential for each subgroup. The study, which nicely combines multi-modal omics, presents potentially important findings, that could inform clinicians with enhanced diagnosis and therapeutic strategies for more personalized or targeted treatments in lung adenocarcinoma associated with air pollution. The authors successfully identify four distinct clusters with the XWLC cohort, with distinct diagnostic characteristics and potential targets. However, many validating experiments must be performed, and data supporting BaP exposure linkage to XWLC subtypes is suggestive but incomplete to conclusively support this claim. Thus, while the manuscript presents important findings with the potential for significant clinical impact, the data presented are incomplete in supporting some of the claims and would benefit from validation experiments.</p><p>Strengths:</p><p>Integration of omics data from multimodalities is a tremendous strength of the manuscript, allowing for cross-modal comparison/validation of results, functional pathway analysis, and a wealth of data to identify clinically relevant case clusters at the transcriptomic, translational, and post-translational levels. The inclusion of phosphoproteomics is an additional strength, as many pathways are functional and therefore biologically relevant actions center around activation of proteins and effectors via kinase and phosphatase activity without necessarily altering the expression of the genes or proteins.</p><p>Clustering analysis provides clinically relevant information with strong therapeutic potential both from a diagnostic and treatment perspective. This is bolstered by the individual microbiota, radiographic, wound healing, outcomes, and other functional analyses to further characterize these distinct subtypes.</p><p>Visually the figures are well-designed and presented and for the most part easy to follow. Summary figures/histograms of proteogenomic data, and specifically highlighted genes/proteins are well presented.</p><p>Molecular dynamics simulations and 3D binding analysis are nice additions.</p><p>While I don't necessarily agree with the authors' interpretation of the microbiota data, the experiment and results are very interesting, and clustering information can be gleaned from this data.</p><p>Weaknesses:</p><p>(1) Statistical methods for assessing significance may not always be appropriate.</p></disp-quote><p>We appreciate your suggestion. We have revised statistical test results in the panels including: Fig. 3b,e and g.</p><disp-quote content-type="editor-comment"><p>(2) Necessary validating experiments are lacking for some of the major conclusions of the paper.</p></disp-quote><p>Thank you for raising this point. However, we respectfully choose not to comment on this matter at present.</p><disp-quote content-type="editor-comment"><p>(3) Many of the conclusions are based on correlative or suggestive results, and the data is not always substantive to support them.</p></disp-quote><p>Thank you for raising this point. However, we respectfully choose not to comment on this matter at present.</p><disp-quote content-type="editor-comment"><p>(4) Experimental design is not always appropriate, sometimes lacking necessary controls or large disparity in sample sizes.</p></disp-quote><p>Thank you for raising this point. However, we respectfully choose not to comment on this matter at present.</p><disp-quote content-type="editor-comment"><p>(5) Conclusions are sometimes overstated without validating measures, such as in BaP exposure association with the identified hotspot, kinase activation analysis, or the EMT function.</p></disp-quote><p>Thank you for raising this point. However, we respectfully choose not to comment on this matter at present.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>(1) Please provide a justification for why only females were included in the study. I am concerned that the results obtained in this study can not be generalized as only females were included.</p></disp-quote><p>We appreciate your suggestion. Lung cancer in never smokers (LCINS) accounts for approximately 25% of lung cancer cases (15% of lung cancer in men and 53% in women) (Parkin et al., 2005). Currently, the etiology and mechanisms of LCINS are not clear. Globally, LCINS shows remarkable gender and geographic variations, occurring more frequently among Asian women (Bray et al., 2018). Indoor coal burning for heating and cooking has been implicated as a risk factor for Chinese women, as they spend more time indoors (Mumford et al., 1987). Among men, the proportion of never smokers is lower, with less regional variation, and lung cancer in males is frequently caused by smoking. Thus, to better reveal the etiology and molecular mechanisms of LCINS, we collected data exclusively from female LCINS patients in the Xuanwei area, excluding potential confounding factors such as hormonal or smoking status. Our study specifically aims to uncover the etiology and mechanisms of LCINS in female patients, with future research planned to verify whether our conclusions can be generalized to LCINS in male patients.</p><disp-quote content-type="editor-comment"><p>(2) &quot;Therefore, the XWLC and TSLC cohorts are more explicitly influenced by environmental carcinogens, while the TNLC and CNLC cohorts may be more affected by age or endogenous risk factors.&quot; This statement in the results (starting line 142) does not have adequate support from the results. First, the average age in the 4 cohorts does not seem to be very different to me based on Figure 1b. if they are different, please provide statistical test results. Please make sure this statement is supported by other results, otherwise, I would recommend excluding it from the manuscript.</p></disp-quote><p>We appreciate your suggestion. To gain biological insights, we frequently associate mutational signatures with factors such as age, defective DNA mismatch repair, or environmental exposures. These remain associations rather than causation. Thus, we agree with the suggestion to weaken the conclusion as follows:</p><p>“Generally, exposure to tobacco smoking carcinogens (COSMIC signature 4) and chemicals such as BaP (Kucab signatures 49 and 20) were identified as the most significant contributing factors in both the XWLC and TSLC cohorts (Fig. 1f and 1g). In contrast, defective DNA mismatch repair (COSMIC signature ID: SBS6) was identified as the major contributor in both the TNLC and CNLC cohorts (Fig. 1h and 1i), with no potential chemicals identified based on signature similarities. Therefore, the XWLC and TSLC cohorts appear to be more explicitly associated with environmental carcinogens, while the TNLC and CNLC cohorts may be more associated with defective DNA mismatch repair processes.”</p><disp-quote content-type="editor-comment"><p>(3) Please provide statistical test results in this subsection &quot;The EGFR-G719X mutation, which is a hotspot associated with BaP exposure, possesses distinctive biological features &quot; (Line 203) showing that the number of G719X is significantly different in XWLC.</p></disp-quote><p>We appreciate your suggestion. Two-sided Fisher’s test was used to calculate p-values, which are labeled in Figure 3b.</p><disp-quote content-type="editor-comment"><p>(4) &quot;Analysis of overall survival and progression-free interval (PFI) revealed that patients with the G719X mutation had worse outcomes compared to other EGFR mutation subtypes &quot; This statement (starting Line 232) should be supported by literature data.</p></disp-quote><p>We appreciate your suggestion.</p><p>In the Watanabe <italic>et al.</italic> post-hoc analysis, patients with the G719 mutation had significantly shorter OS with gefitinib compared to patients with the common mutations (Watanabe et al., 2014). We revised the sentences as following:</p><p>“Analysis of overall survival and progression-free interval (PFI) revealed that patients with the G719X mutation had worse outcomes compared to other EGFR mutation subtypes (Fig. 3j and 3k) which was consistent with a previous study(Watanabe et al., 2014).”</p><disp-quote content-type="editor-comment"><p>(5) I would suggest changing this statement to a &quot;suggestion&quot; as there is no experimental support for this, and mentioning that this requires further experimental validation with the suggested drugs &quot;Therefore, a promising approach to overcome resistance in tumors with this mutation could involve combining afatinib, which targets activated EGFR, with FDA-approved drugs that specifically target the activated kinases associated with G719X. &quot; (Line 260).</p></disp-quote><p>We appreciate your suggestion. We change the sentences as following:</p><p>&quot;Therefore, we propose a potential approach to overcoming resistance in tumors with this mutation, which could involve combining afatinib, targeting activated EGFR, with FDA-approved drugs that specifically target the activated kinases associated with G719X. &quot;</p><disp-quote content-type="editor-comment"><p>(6) It is not clear to me how PPIs were integrated with missense. Please clarify the method.</p></disp-quote><p>We appreciate your suggestion. To identify interactions enriched with missense mutations, we constructed mutation-associated protein–protein interactomes (PPIs). Initially, we downloaded protein-protein interactomes from Interactome INSIDER (v.2018.2) (Meyer et al., 2018). Subsequently, we identified interfaces carrying missense mutations by mapping mutation sites to PPI interface genomic coordinates using bedtools (v2.25.0)(Quinlan and Hall, 2010). Finally, we defined oncoPPI as those PPIs significantly enriched in interface mutations in either of the two protein-binding partners across individuals. For more details, please refer to the methods sections “Building mutation-associated protein–protein interactomes” and “Significance test of PPI interface mutations.”</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Regarding the tumor microbiota composition, it is not clear what the significance of these results would be. Are the specific microbiota associated with MC-IV more pathogenic than other species found in other subtypes? What are the unique features of these MC-IV microbiota? If these are difficult to address, this section could be removed from the manuscript.</p></disp-quote><p>We appreciate your suggestion. This section is removed from the manuscript.</p><disp-quote content-type="editor-comment"><p>Regarding the radiomic data section (Figure 6d and Extended Figure 6d), more description about the eight and five features (that are different between MC-II and others) would be helpful to better understand the importance and significance of these data.</p></disp-quote><p>We appreciate your suggestion. We have added the description as following: “Features such as median and mean reflect average gray level intensity and Idmn and Gray Level Non-Uniformity measure the variability of gray-level intensity values in the image, with a higher value indicating greater heterogeneity in intensity values. These results suggest a denser and more heterogeneous image in the MC-II subtype.”</p><disp-quote content-type="editor-comment"><p>Other minor comments:</p><p>(1) If EGFR G719X is a known hotspot mutation associated with BaP, please cite previous literature.</p></disp-quote><p>We appreciate your suggestion. Upon careful retrieval using &quot;G719X&quot; and &quot;BaP&quot; as keywords, we did not find previous literature discussing G719X as a known hotspot mutation associated with BaP.</p><disp-quote content-type="editor-comment"><p>(2) In Figure 1d, it should be clearly written in the legend that tumor (T) and normal (N) tissue were analyzed.</p></disp-quote><p>We appreciate your suggestion. We have clarified the figure legend of Figure 1d.</p><disp-quote content-type="editor-comment"><p>(3) In Figure 1m, it is not obvious that EGFR pY1173 and pY1068 are more abundant in the Bap+S9 sample. Total EGFR bands are very faint. These western blots should be repeated and quantified.</p></disp-quote><p>We appreciate your suggestion. We have removed Fig. 1m. After identifying the antibody with satisfactory performance, we will provide the revised results.</p><disp-quote content-type="editor-comment"><p>(4) In Figure 2d, aren't the EGFR E746__A750del mutations more frequently found in CNLC, TSLC, and TNLC? (which is opposite to what the authors wrote in the text).</p></disp-quote><p>We appreciate your suggestion. This mistake has been corrected.</p><disp-quote content-type="editor-comment"><p>(5) In Figure 7f-i and Ext Figure 8, Does &quot;CK&quot; mean empty vector control? Then, it would be changed to &quot;EV&quot;.</p></disp-quote><p>We appreciate your suggestion. This mistake has been corrected.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>Methods:</p><p>While previous work was referenced, a description of proteomics methods should still include: instrumentation, acquisition method, all software packages used, method for protein identification, method for protein quantification, how FDR was maintained for identification/quantification, definition of differentially expressed proteins, whether multiple testing correction was performed and if so what method.</p></disp-quote><p>We appreciate your suggestion. We revised the description of label-free mass spectrometry methods accordingly.</p><disp-quote content-type="editor-comment"><p>The paper would greatly benefit from brief methodological explanations throughout, as all methods are currently exclusively found in the supplementary information. This severely hampers the readability of the manuscript.</p></disp-quote><p>Thank you for raising this point. However, we respectfully choose not to comment on this matter at present.</p><disp-quote content-type="editor-comment"><p>Suggestions Throughout</p><p>The paper would greatly benefit from proofreading/editing</p><p>Line 157-158/Figure 1J for CYP1A1 displays protein concentrations while Figure 1K for AhR shows mRNA. Why this discrepancy? It would be preferable to show both mRNA and protein levels for both CYP1A1 and AhR. Also, there is a large discrepancy in the &quot;n&quot; between the normal and tumor groups, which makes the statistical comparison challenging. The AhR data is therefore unconvincing, and additional protein data is suggested. Thus the claim of significantly elevated AhR and CYP1A1 levels in tumors is not sufficiently supported and requires further investigation, both mRNA and protein, and with similarly sized sample groups.</p></disp-quote><p>We appreciate your suggestion. We have thoroughly edited the revised manuscript, with all changes marked accordingly. Compared to mRNA level assessment, protein abundance is a better indicator of gene expression. Therefore, we reanalyzed the protein level of AhR for comparison and found no significant differences (Figure 1k). Additionally, the samples sequenced by mRNA-seq were not entirely consistent with those sequenced by label-free proteomics. The samples analyzed by different methods are shown in Figure 1d.</p><disp-quote content-type="editor-comment"><p>Line 159 Figure 1I There is no control for the data serum data presented here. What are the serum levels for individuals not residing in the Xuanwei? It is unclear whether this represents elevated BPDE serum levels without appropriate controls. Thus nothing insightful can be derived from this data.</p></disp-quote><p>We appreciate your suggestion. We have deleted the results concerning BPDE serum detection in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Line 164 The statement &quot;sites such as Y1173 and Y1068 of EGFR were more phosphorylated in BaP treated cells&quot; is not sufficiently supported by the presented data and cannot be made. Figure 1M has no quantitation, no indication of &quot;n&quot; or whether this represents a single experiment or one validated with repeating. The western blot is also cropped with no indication of molecular weight or antibody specificity. This data is NOT convincing. The antibody signal is very weak, and not convincing with cropped blots. An updated figure, with an uncropped blot, and quantitation with multiple n's and statistical comparison is required. I am not sure the Wilcoxon rank sum test is appropriate to test significance in j-l. The null hypothesis should not be equal medians but equal means based on the experimental design.</p></disp-quote><p>We appreciate your suggestion. We have removed Fig. 1m. After identifying the antibody with satisfactory performance, we will provide the revised results.</p><disp-quote content-type="editor-comment"><p>Line 181 phrase &quot;significant differences&quot; should not be used unless making a claim about statistical significance.</p></disp-quote><p>We appreciate your suggestion. We change “significant differences” to “noticeable differences”.</p><disp-quote content-type="editor-comment"><p>Line 197: &quot;The blood serum assay provided support...&quot; As noted above this claim is not sufficiently supported by the presented data and requires more complete investigation.</p></disp-quote><p>We appreciate your suggestion. This conclusion has been deleted in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Line 219: Requires proofreading/editing.</p></disp-quote><p>We appreciate your suggestion. We have thoroughly edited the revised manuscript, with all changes marked accordingly.</p><disp-quote content-type="editor-comment"><p>Line 220: appears to have a typo and should read GGGC&gt;GTGC</p></disp-quote><p>We appreciate your suggestion. This mistake has been corrected in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Line 223/224 Figure 3e-h. Again there is a large disparity between the n's of each group. Despite the WT having the highest frequency in the XWLC study population, it has only n=5 when comparing the protein and phosphosite for MAPKs. There is also no explanation for what the graph symbols indicate, what statistical test was performed to determine the statistical significance of the presented differences, and between which specific groups that significance exists. Thus, it is challenging to ascertain whether there are relevant differences in the MAPK signaling components.</p></disp-quote><p>We appreciate your suggestion. We added the description of “N, number of tumor samples containing corresponding EGFR mutation” to the figure legend. p-values were calculated with a two-tailed Wilcoxon rank sum test, and p&lt;0.05 was labeled on Figures 3e-i.</p><disp-quote content-type="editor-comment"><p>Figure 3I Good figure. However, it would be beneficial to provide validation with Western Blotting for a few of these substrates using pospho-specific antibodies. It is suggested that this experiment be added.</p></disp-quote><p>We appreciate your suggestion. Figure 3I showed the comparison of patients’ ages among subtypes. I guess you mean Figure 3g and Figure 3h. The relevant experiments are currently underway, and we will provide the corresponding data in the next revised version.</p><disp-quote content-type="editor-comment"><p>Figure 4b. Very compelling figure.</p></disp-quote><p>We appreciate your suggestion.</p><disp-quote content-type="editor-comment"><p>Line 276: The AhR and CYP1A1 data presented earlier was not convincing, and CYP1A1 and AhR cannot be responsibly used as indicators of BaP activity based on potential. This is not an appropriate application.</p></disp-quote><p>We appreciate your suggestion. CYP1A1 and AhR are two key regulators involved in BaP metabolism and signaling transduction, respectively. However, after examining the protein expression of AhR between tumor and normal tissues, we found no significant differences (Fig. 1k) and CYP1A1 has been proven to be highly expressed in tumor samples (Fig. 1j). Thus, we mainly examined the expression of CYP1A1 among the four subgroups. We changed our description as follows:</p><p>“As CYP1A1 is a key regulator involved in BaP metabolism and has been proven to be highly expressed in tumor samples (Fig. 1j), we next examined the expression of CYP1A1 among the four subgroups to evaluate their associations with air pollution.”</p><disp-quote content-type="editor-comment"><p>Figure 4d. Here it is AhR protein used rather than mRNA measured earlier. What is the explanation for this change?</p></disp-quote><p>We appreciate your suggestion. As there was no significant differences of the protein expression of AhR between tumor and normal tissues (Fig. 1k), we deleted the expression comparison of AhR among subtypes.</p><disp-quote content-type="editor-comment"><p>Line 281 &quot;Moderately elevated expression level of AhR&quot; is not supported by the presented data and should be removed.</p></disp-quote><p>We appreciate your suggestion. We have deleted the result of comparison of AhR among subtypes.</p><disp-quote content-type="editor-comment"><p>Figure 4: There is no indication or explanation of how the protein abundance is being measured. Is this from the proteomics (MS) approaches, by ELISA or by Western? If it is simply by MS then validation by another method is preferable. The data presented in Figure 4 do not adequately support the claim that MC-II subtype is more strongly associated with BaP exposure. What statistical test is used in 4F? Why is the n in the MC-II group, which is the highlighted group of interest nearly double the other groups?</p></disp-quote><p>We appreciate your suggestion. Fig. 4e is derived from the proteomics data. The two-tailed Wilcoxon rank sum test was used to calculate p-values in panels c and e.</p><disp-quote content-type="editor-comment"><p>Figure 4g: At least one or two of these should be validated by Western Blot or targeted MS.</p></disp-quote><p>We appreciate your suggestion. The relevant experiments are currently underway, and we will provide the corresponding data in the next revised version.</p><disp-quote content-type="editor-comment"><p>Figure 5a: Assuming these were also measured via proteomic analysis, how do their expression patterns compare across the different omics modes?</p></disp-quote><p>Thank you for your suggestion. Figure 5 integrates transcriptomics (19182 genes), proteomics (9152 genes), and phosphoproteomics (5733 genes) data. In general, we utilized transcriptomics data to identify unique or distinct pathways among subgroups. Furthermore, proteomics and phosphoproteomics data were employed to validate key gene expressions, as they encompass fewer genes compared to transcriptomics data.</p><p>For instance, in Fig. 5a-d, we observed higher expression levels of mesenchymal markers such as VIM, FN1, TWIST2, SNAI2, ZEB1, ZEB2, and others in the MC-IV subtype using transcriptomics data (Fig. 5a). Additionally, we calculated epithelial-mesenchymal transition (EMT) scores using the ssGSEA enrichment method based on protein levels and conducted GSEA analysis using transcriptomics data (Fig. 5b). Furthermore, using proteomics data, we evaluated Fibronectin (FN1), an EMT marker that promotes the dissociation, migration, and invasion of epithelial cells, at the protein level (Fig. 5c), and β-Catenin, a key regulator in initiating EMT, also at the protein level (Fig. 5d). Overall, our findings indicate that the MC-IV subtype exhibits an enhanced EMT capability, which may contribute to the high malignancy observed in this subtype.</p><disp-quote content-type="editor-comment"><p>Line 314: Not compared with MCI, which appeared to be much lower at the mRNA level. Is there an explanation for this difference?</p></disp-quote><p>We appreciate your suggestion. FN1 expression is lowest in MCI at the protein level (Fig. 5c). However, at the transcriptome level, FN1 expression is lowest in the MCIII subtype (Fig. 5a). You may wonder why these results are inconsistent. Discrepancies between mRNA and protein expression levels are common, and previous study showed that about 20% genes had a statistically significant correlation between protein and mRNA expression in lung adenocarcinomas (Chen et al., 2002). Post-transcriptional mechanisms, including protein translation, post-translational modification, and degradation, may influence the level of a protein present in a given cell or tissue. In this situation, we focused on identifying distinct biological pathways in each subgroup, supported by multi-omics data.</p><disp-quote content-type="editor-comment"><p>Line 321: MC-IV *potentially* possesses an enhanced EMT capability. This statement cannot be conclusively made.</p></disp-quote><p>We appreciate your suggestion. We changed our description as: “Collectively, our findings demonstrate that the MC-IV subtype is associated with enhanced EMT capability, which may contribute to the high malignancy observed in this subtype.”</p><disp-quote content-type="editor-comment"><p>Lines 325 and 327 indicated dysregulation of cell cycle processes and activation of CDK1 and CDK2 pathways based on KSEA analysis which is closely linked to cell cycle regulation as two separate pieces of evidence. However, these are both drawn from the phosphoproteomics, and likely indicate conclusions drawn from the same phosphosite data. Said another way, if phosphosite data indicates differences in kinases linked to cell cycle regulation then you would also expect phosphosite data to indicate dysregulation of cell cycle.</p></disp-quote><p>We appreciate your suggestion. You mentioned that Fig. 4f and Fig. 5e redundantly prove that the CDK1 and CDK2 pathways are dysregulated. However, KSEA analysis in Fig. 4f estimates changes in kinase activity based on the collective phosphorylation changes of its identified substrates (Wiredja et al., 2017). In contrast, Fig. 5e directly evaluates the abundance of protein and phosphosite levels of CDK1 and CDK2 across subtypes. These analyses mutually confirm each other rather than being redundant.</p><disp-quote content-type="editor-comment"><p>Line 413/Figure 6b: While there may be a trend displayed by the figure, it is not convincing enough to state that MC-IV shows a conclusively distinguishable bacterial composition. Too much variability exists within groups MC-II and MC-III. However, it does show that MC-IV and MC-II have consistent composition within their groups, and that is interesting.</p></disp-quote><p>We appreciate your suggestion. We have deleted the analysis of bacterial composition across subtypes.</p><disp-quote content-type="editor-comment"><p>Figure 6: Overall very nice figure, with intriguing diagnostic potential. See the above note on 6a-b interpretation.</p></disp-quote><p>We appreciate your suggestion. We have deleted the analysis of bacterial composition across subtypes, including Fig. 6a-6c.</p><disp-quote content-type="editor-comment"><p>Figure 7c-f better labeling of the panels will aid reader comprehension.</p></disp-quote><p>We appreciate your suggestion. Necessary labeling has been added to Fig. 7c-f to enhance comprehension.</p><disp-quote content-type="editor-comment"><p>Figure 7 panel order is confusing, switching from right to left to vertical. Rearranging to either left to right or vertical would help orient readers.</p></disp-quote><p>We appreciate your suggestion. We have adjusted the order of Fig. 7 and extended Fig. 8 panel.</p><disp-quote content-type="editor-comment"><p>Figure 7 legend i: should read Cell colony* assay</p></disp-quote><p>We appreciate your suggestion. We have corrected this mistake in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>The Discussion is very brief. While it includes a discussion of the potential impact of the study, it does not include an analysis of the caveats/drawbacks of the study. A more thorough discussion of other studies focusing on the impacts of BaP exposure is also suggested as this was a highlighted point by the authors.</p></disp-quote><p>We appreciate your suggestion. we have added discussion about the associations between BaP exposure and lung cancer and also talked about the shortcomings of our study as followings:</p><p>“Mechanistically, Qing Wang showed that BaP induces lung carcinogenesis, characterized by increased inflammatory cytokines, and cell proliferative markers, while decreasing antioxidant levels, and apoptotic protein expression(Wang et al., 2020). In our study, we used clinical samples and linked the mutational signatures of XWLC to the chemical compound BaP, which advanced the etiology and mechanism of air-pollution-induced lung cancer. In our study, several limitations must be acknowledged. Firstly, although our multi-omics approach provided a comprehensive analysis of the subtypes and their unique biological pathways, the sample size for each subtype was relatively small. This limitation may affect the robustness of the clustering results and the identified subtype-specific pathways. Larger cohort studies are necessary to confirm these findings and refine the subtype classifications. Secondly, although our study advanced the understanding of air-pollution-induced lung cancer by using clinical samples, the reliance on epidemiological data in previous studies introduces potential confounding factors. Our findings should be interpreted with caution, and further mechanistic studies are warranted to establish causal relationships more definitively. Thirdly, our in silico analysis suggested potential approach to drug resistence in G719X mutations. However, these predictions need to be validated through extensive in vitro and in vivo experiments. The reliance on computational models without experimental confirmation may limit the clinical applicability of these findings.”</p><p>References:</p><p>Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B.<italic>, et al.</italic> (2018). Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell <italic>173</italic>, 371-385 e318.</p><p>Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin <italic>68</italic>, 394-424.</p><p>Chen, G., Gharib, T. G., Huang, C. C., Taylor, J. M., Misek, D. E., Kardia, S. L., Giordano, T. J., Iannettoni, M. D., Orringer, M. B., Hanash, S. M., and Beer, D. G. (2002). Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics <italic>1</italic>, 304-313.</p><p>Meyer, M. J., Beltran, J. F., Liang, S., Fragoza, R., Rumack, A., Liang, J., Wei, X., and Yu, H. (2018). Interactome INSIDER: a structural interactome browser for genomic studies. Nat Methods <italic>15</italic>, 107-114.</p><p>Mumford, J. L., He, X. Z., Chapman, R. S., Cao, S. R., Harris, D. B., Li, X. M., Xian, Y. L., Jiang, W. Z., Xu, C. W., Chuang, J. C., and et al. (1987). Lung cancer and indoor air pollution in Xuan Wei, China. Science <italic>235</italic>, 217-220.</p><p>Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA Cancer J Clin <italic>55</italic>, 74-108.</p><p>Quinlan, A. R., and Hall, I. M. (2010). BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics <italic>26</italic>, 841-842.</p><p>Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S.<italic>, et al.</italic> (2018). Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell <italic>173</italic>, 321-337 e310.</p><p>Wang, Q., Zhang, L., Huang, M., Zheng, Y., and Zheng, K. (2020). Immunomodulatory Effect of Eriocitrin in Experimental Animals with Benzo(a)Pyrene-induced Lung Carcinogenesis. J Environ Pathol Toxicol Oncol <italic>39</italic>, 137-147.</p><p>Watanabe, S., Minegishi, Y., Yoshizawa, H., Maemondo, M., Inoue, A., Sugawara, S., Isobe, H., Harada, M., Ishii, Y., Gemma, A.<italic>, et al.</italic> (2014). Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol <italic>9</italic>, 189-194.</p><p>Wiredja, D. D., Koyuturk, M., and Chance, M. R. (2017). The KSEA App: a web-based tool for kinase activity inference from quantitative phosphoproteomics. Bioinformatics <italic>33</italic>, 3489-3491.</p><p>Zhang, H., Liu, C., Li, L., Feng, X., Wang, Q., Li, J., Xu, S., Wang, S., Yang, Q., Shen, Z.<italic>, et al.</italic> (2021). Genomic evidence of lung carcinogenesis associated with coal smoke in Xuanwei area, China. Natl Sci Rev <italic>8</italic>, nwab152.</p></body></sub-article></article>